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GENERAL INTRODUCTION
In recent years, many new anticancer drugs have been developed and numerous others are in 
the pipeline. Most drugs belong to the category of the so-called ‘targeted drugs’: compounds 
aimed at tumor-specifi  c targets. In order to be eff  ective, it is mandatory that the target is 
present at time of treatment with these agents. Selection of the appropriate targeted drug for 
solid tumors in the individual patient remains diffi   cult. Th   ere are however already a number of 
established biomarkers available. Th   e best examples are Estrogen Receptor (ER), Progesterone 
Receptor (PR) and Human Epidermal Growth Factor Receptor 2 (HER2/neu, further referred 
to as ‘HER2’) expression in breast cancer, c-KIT mutations in Gastrointestinal Stromal tumors 
(GIST) and Epidermal Growth Factor Receptor 1 (EGFR1) mutations in non-small-cell lung 
carcinoma (NSCLC) and colorectal cancer. 
In addition to the presence of the tumor target, it is necessary that suffi   cient drug penetrates 
into the tumor. Large, intact monoclonal antibodies (mAbs) penetrate slowly but constant into 
solid tumor tissue, ultimately resulting in high tumor accumulation. Small pharmaceuticals 
such as the recombinant human tumor necrosis factor (TNF)-related apoptosis inducing 
ligand (TRAIL), however penetrate swift  ly into tumor tissue, but are rapidly cleared by the 
kidneys, resulting in limited tumor uptake. 
Currently tumor tissue is oft  en required for the biomarker assays. Whole body non-invasive 
scintigraphy of all tumor lesions could be a strategy to determine eligibility of patients for 
targeted therapy, determine biodistribution of the drug and help predict therapy response. 
Sui table radi op harmaceu ti cals, h o w ev er , ha v e to meet the cri teria o f g ood selectivi ty an d 
specifi  city and be capable of detecting small tumor lesions, including non-accessible distant 
metastases in a single scan. 
Two important targets for current and new anticancer drugs, the HER2 member of the ErbB 
tyrosine kinase receptor family and the extrinsic apoptotic pathway are explored in this thesis.10
Th   e ErbB tyrosine kinase receptor family consists of four receptors: HER1-4. Th   ese receptors are 
composed of an extracellular binding domain, a transmembrane segment and an intracellular 
protein tyrosine kinase domain. Members of the HER family have growth stimulating activity, 
and play an important role in the regulation of cell growth, survival (e.g. through inhibition 
of apoptosis), diff  erentiation and have been detected in a wide range of human cancers. 
Overexpression and amplifi  cation of HER2 is associated with oncogenic transformation in 
tumors. In case of breast cancer, there is a worse prognosis and a more aggressive behavior of 
the tumor in the clinical setting when no HER2 directed therapy is used. Current available 
therapy consists of the humanized anti-HER2 monoclonal antibody trastuzumab or the EGFR1 
and HER2 dual tyrosine kinase inhibitor lapatinib. Th   e HER2 tumor status can show a time-
dependent change following therapy and may be diff  erent across tumor lesions within a single 
patient. As a consequence, patients with a tumor that turned HER2 positive would be entitled 
to receive trastuzumab treatment which is currently withheld, while those with a tumor that 
lost HER2 (over)expression should no longer receive trastuzumab. Additional biopsies during 
the course of the disease to analyze the HER2 status, could support such a decision. However 
doctors and patients are frequently reluctant to use invasive techniques, particularly for lesions 
that are not easily accessible. Whole body non-invasive HER2 scintigraphy could be a strategy 
to determine the HER2 expression of all lesions, including non-accessible distant metastases 
with high selectivity and specifi  city in a single scan and thus overcome these problems.
Aim and objectives of the thesis
Th  e aim of this thesis is to explore the preclinical and clinical use of newly developed 
radiopharmaceuticals targeting the HER2 and the TRAIL death receptors for patient selection 
and to evaluate therapy.
Outline of the thesis
Chapter 2 presents a literature overview of the diff  erent radiopharmaceuticals that are available 
for HER2 imaging. Th   e potential role of immunoscintigraphy in improving diagnostic imaging, 
guiding monoclonal antibody (mAb)-based therapy and supporting the development of mAb-
based drugs is described. Several radiopharmaceuticals are compared and the possibilities and 
limitations of preclinical and clinical HER2 imaging are being discussed. 
Chapter 3 and 4 are dedicated to zirconium-89 (89Zr) radiolabeled trastuzumab. Th   e goal of 
these chapters was to develop and evaluate a new HER2 immunoPET radiopharmaceutical, 
suitable for clinical use in order to select patients eligible for trastuzumab therapy and to evaluate 
and guide trastuzumab therapy. In chapter 3 89Zr-trastuzumab is developed and preclinically 
tested. In vitro binding and stability properties of 89Zr-trastuzumab were established. In human 
HER2-positive or -negative tumor xenograft  -bearing mice, the minimal dose of trastuzumab 
required for optimal small-animal PET imaging and biodistribution was determined and 
compared with our previously clinically applied indium-111 (111In) radiolabeled trastuzumab. 
Chapter 4 describes the fi  rst in man study with 89Zr-trastuzumab in HER2-positive metastatic 
breast cancer patients. Th   is feasibility study was performed to determine optimal conditions 
of  89Zr-trastuzumab antibody dose and timing for HER2 imaging. Patients received 89Zr-
trastuzumab at 3 diff  erent protein doses of trastuzumab and underwent PET-scans at an early 
and at a later time point. 1  GENERAL INTRODUCTION 11
PET-scans were visually examined to determine the 89Z r - t r a s t u z u m a b  u p t ak e  i n  v a r i o u s  
organs. In addition, the 89Zr-trastuzumab uptake in metastatic lesions and normal tissue was 
quantifi  ed as the relative uptake value (RUVmean).
Adjacent to the blockage of the growth factor receptor, which makes the tumor cells more 
vulnerable to chemotherapy induced cell death, apoptosis can be directly induced by proteins 
that activate the extrinsic cellular pathway. Apoptosis or regulated cell death can be induced 
through two separate pathways: the intrinsic (mitochondrial) or the extrinsic (death receptor) 
pathway. Th  e intrinsic pathway is activated upon extracellular binding of death receptor 
ligands to their cognate receptors (TRAIL-Receptor 1 (R1) and TRAIL-Receptor 2 (R2)), 
setting an apoptosis cascade in motion, ultimately resulting in tumor cell death. Among the 
death receptor ligands are tumor necrosis alpha (TNF-α), Fas ligand (FasL) and naturally 
occurring TRAIL. Recombinant human (rh) TRAIL, death receptor targeting antibodies are 
currently explored with acceptable toxicity in the (pre)clinic. 
Chapter 5 and 6 are dedicated to the death receptor family. Th  e goal was to develop and 
evaluate clinical grade radiopharmaceuticals for imaging of the TRAIL-R1 and TRAIL-R2 
receptor. Imaging with radiolabeled rhTRAIL and TRAIL-antibodies might give insight into 
the biodistribution of anti-tumor proteins and help to predict therapy response.
Chapter 5 describes the development of radiolabeled rhTRAIL and the TRAIL-R1 monoclonal 
antibody mapatumumab, suitable for clinical use. Th  e TRAIL-R1 and TRAIL-R2 targeting 
radiopharmaceuticals were characterized, their in vitro stability and death receptor targeting 
capacities were determined, and in vivo biodistribution was studied in nude mice bearing 
human xenograft  s with diff  erent expression of TRAIL-R1 and TRAIL-R2.
In chapter 6 111In-mapatumumab is applied in patients with solid malignancies eligible for 
treatment with gemcitabine and cisplatin. Patients received 111In-mapatumumab in cycle 1 
and cycle 3. Planar whole body imaging and single-photon emission computed tomography 
(SPECT) was performed. SPECT images were fused with CT. TRAIL-R1 tumor expression 
was assessed immunohistochemically. Pharmacokinetic analysis of 111In-mapatumumab was 
performed in both cycles.
Finally, new promising anti-cancer proteins are constantly being developed. Mammalian cells 
remain the best choice for antibody and complex protein production, due to their proper protein 
folding, but despite the use of effi   cient expression vector systems to optimize production, there 
is an ever increasing demand on the high and effi   cient production of clinical grade (genetically 
modifi  ed) proteins. 
In the laboratory, research and development of new proteins takes place in microtiter plates 
and T-fl  asks on a very small scale. Although this is generally suffi   cient for in vitro evaluation 
of the protein, preclinical and early clinical evaluation of these proteins is oft  en hampered 
by the inability to produce suffi   cient amounts of the protein. In case of innovative proteins 
(like fusion proteins), there is even more need for large amounts of mammalian cells, since 
the production can be magnitudes lower than that of antibodies. An example of such a fusion 
protein is the innovative scFv425:sTRAIL. ScFv425:sTRAIL combines EGFR1-signaling 
inhibition with target cell-restricted apoptosis induction using a TRAIL fusion protein with 
engineered specifi  city for EGFR1. ScFv425:sTRAIL, comprises the EGFR1-blocking single 
chain antibody fragment scFv425 genetically fused to soluble TRAIL (sTRAIL). Th  e use of 12
high surface growth matrices that can hold large quantities of cells might be a possibility to 
fi  ll the gap between the initial small-scale lab production and the fi  rst upscaling of the protein 
production under well controlled conditions and at an acceptable workload.
Th  e goal of Chapter 7 was to explore whether high surface disks could be used to upscale 
the production of scFv425:s TRAIL in mammalian cells. Th  e production of the genetically 
fused protein scFv425:sTRAIL in a batch fed system on high surface disks was compared 
with the previous production in T-fl  asks and the in vitro properties of the fusion protein are 
characterized. 
In Chapter 8 a summary of the thesis is provided with a general discussion and future 
perspectives. In Chapter 9 the thesis is summarized in Dutch.1  GENERAL INTRODUCTION 132
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IMMUNOSCINTIGRAPHY AS POTENTIAL 
TOOL IN THE CLINICAL EVALUATION OF 
HER2/NEU TARGETED THERAPY
Abstract
Many new targeted anticancer drugs have been developed. In order for these drugs to be 
eff  ective, the tumor target has to be present during treatment. Currently there are only a few 
biomarkers available to help the physician select the appropriate targeted drug for the patient 
and oft  en tumor tissue is required for biomarker assays. Immunoscintigraphy might be able 
to improve diagnostic imaging, to guide antibody based therapy and to support early antibody 
development. Many diff  erent radiopharmaceuticals have been developed and used to visualize 
all kind of diff  erent targets especially in oncology. Intact radiolabeled antibodies generally 
show high tumor uptake but low tumor-to-blood ratios, particularly at early time points. 
Radiolabeled antibody fragments and proteins show widely diff  ering values for tumor uptake 
and tumor-to-blood contrast. 
One of the promising targets for visualization might be HER2/neu ( further referred to as 
‘HER2’). HER2 scans may prove useful for tumor staging, guiding of targeted therapy and 
measuring target occupancy in early drug development. Immunoscintigraphic clinical 
studies performed with intact antibodies indicate that HER2 imaging is feasible. Additional 
research will be performed to prove its value and make this technique applicable on a larger 
scale. 
Th   e aim of this review is to describe the types of radiopharmaceuticals that are available, and the 
potential role of immunoscintigraphy in improving diagnostic imaging, guiding monoclonal 
antibody (mAb)-based therapy and supporting the development of mAb-based drugs using the 
HER2 target as an example. 16
Introduction
In recent years, many new anticancer drugs have been developed and numerous others are 
in the pipeline. Most of these belong to the category of the so-called ‘targeted drugs’: compounds 
aimed at tumor-specifi  c targets. In order for such drugs to be eff  ective, it is mandatory that the 
target is present at time of treatment. Currently there are only a few biomarkers available to 
help the physician select the appropriate targeted drug for solid tumors in the individual 
patient. Th   e best examples are Estrogen Receptor (ER), Progesterone Receptor (PR) and 
Human Epidermal Growth Factor Receptor 2 (HER2/neu) expression in breast cancer, 
c-KIT mutations in Gastrointestinal Stromal tumors (GIST) and Epidermal Growth Factor 
Receptor 1 (EGFR1) mutations in non-small-cell lung carcinoma (NSCLC). Oft  en tumor 
tissue is required for biomarker assays. In an ongoing search for new methods that can assist 
in predicting therapy response, non-invasive molecular imaging with immunoscintigraphy, 
providing a whole body image, is a potentially interesting approach.
Th   e aim of this review is to describe the types of radio-pharmaceuticals that are available, 
and the potential role of immunoscintigraphy in improving diagnostic imaging, guiding 
monoclonal antibody (mAb)-based therapy and supporting the development of mAb-based 
drugs.
Th   e article is focused on HER2/neu (further referred to as ‘HER2’), since this antigen can be 
strongly overexpressed in tumor cells as compared to normal cells, and substantial knowledge 
is already available on HER2 imaging. In addition, a therapeutic monoclonal antibody is 
available, so molecular imaging of HER2 might infl  uence clinical decisions in the (near) 
future.
Th   e Human Epidermal Growth Factor Receptor 2
HER2 belongs to the ErbB tyrosine kinase receptor family, which consists of four receptors: 
HER1-4. Th  ese  receptors are composed of an extracellular binding domain, a transmembrane 
segment and an intracellular protein tyrosine kinase domain (fi  gure 1) [1]. Members of the 
HER family have growth stimulating activity, and play an important role in the regulation 
of cell growth, survival and diff  erentiation. HER2 is genetically encoded by the HER2 proto-
oncogene (HER2/neu or c-erbB-2).
In normal cells, two copies of the HER2/neu gene are present. HER2-overexpression (an 
increased number of receptors on the cell surface ) and/ or amplifi  cation (an increased 
number of copies of the HER2/neu gene per cell, resulting in HER2 overexpression) have 
been detected in a wide range of human cancers, including breast (incidence 20-30%), 
colon, lung, and ovarian cancers [2,3]. HER2 overexpression and amplifi  cation in tumors 
are associated with oncogenic transformation and in case of breast cancer, with a worse 
prognosis when no HER directed therapy is used and a more aggressive behavior of the tumor 
in the clinical setting [4-8].2  IMMUNOSCINTIGRAPHY AS POTENTIAL TOOL IN THE CLINICAL EVALUATION OF 
HER2/NEU TARGETED THERAPY
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Figure 1. Schema   c representa   on of transmembrane HER/2neu and EGFR and inhibi   on of the 
receptor by trastuzumab.
Relevance of the Determination of HER2/neu and Available Techniques
HER2 is now known to be a relevant target for therapy in breast cancer in the metastatic as 
well as in the adjuvant setting [9]. Th   e registered monoclonal antibody (mAb) trastuzumab 
(Herceptin) and the dual EGFR1 and HER2/neu tyrosine kinase inhibitor lapatinib (Tykerb) 
have been developed to target HER2.
A wide variety of techniques has been used for the ass e s s m e n t  o f  HE R2  e xp r e s s i o n :  
detection of gene amplifi  cation (Southern blotting, polymerase chain reaction (PCR), 
fl  uorescence in-situ hybridization (FISH) and chromogenic in-situ hybridization (CISH)), 
transcription (Northern blotting), receptor overexpression (immunohistochemistry, IHC) 
and enzyme-linked immunosorbent assay (ELISA) [10]. At this moment, IHC and FISH are 
the standard techniques. IHC is widely available and simple, but evaluation of staining can be 
subjective. FISH provides a more objective scoring, but is more expensive [11]. Both FISH 
and CISH provide accurate HER2 gene amplifi  cation results, but only FISH has been FDA 
approved [12]. A combination of IHC and FISH is recommended for borderline (IHC 
2+) positive lesions [13,14]. Although the HER2 status provides important information about 
the molecular composition of the tumor, it is generally solely determined at diagnosis and 
only in the primary tumor. Th  e HER2 tumor status may show a time-dependent change 
following therapy and it may be diff  erent across tumor lesions within a single patient. Since 
most studies have been performed in small groups of patients, it is not clear at this moment 
to what extent and in which patients conversion takes place. Th   e results of these studies do, 
however, indicate that conversion is something that has to be reckoned with.18
Rasbridge et al. showed that neoadjuvant anthracycline chemotherapy altered HER2 
expression levels in the primary tumor compared to pre-treatment expression levels in 6 out 
of 15 (40%) patients [15]. In a larger study, biopsies from primary tumors and corresponding 
metastases of 58 breast cancer patients were assessed for HER2 status using IHC and FISH. 
Discordance in HER2 overexpression between primary and distant metastatic sites was found 
in 14% of the patients [16]. In a study in 45 patients with initially HER2 negative primary 
tumors, 27% of the metastases was HER2 positive [17]. In a study of isolated circulating 
tumor cells, it was shown that 12 out of 24 patients (50%) with a HER2 negative primary 
tumor displayed HER2 positive circulating tumor cells, as assessed by IHC and FISH [18].
In contrast, up to 25% of the patients with a HER2 positive primary tumor can have 
metastases with a lower or absent HER2 expression [19]. In other small studies, there was a 
58-93% correlation between HER2 positive primary tumors and the HER2 status of metastases 
[17].
Th   ese data indicate that chemotherapy or hormonal treatment can lead to the acquisition 
or loss of HER2 expression in metastatic breast cancer. As a consequence, patients with 
a tumor that turned HER2 positive would be entitled to receive trastuzumab treatment 
which is currently withheld, while those with a tumor that lost HER2 expression should no 
longer receive trastuzumab. A new biopsy to analyze the HER2 status during the course 
of the disease could support such a decision. However doctors and patients are frequently 
reluctant to use invasive techniques, particularly for lesions that are not easily accessible 
[20]. Whole body non-invasive HER2 scintigraphy could be a strategy to determine the 
HER2 expression of all lesions, including non-accessible distant metastases in a single scan 
and thus overcome these problems. Currently, numerous radiopharmaceuticals for use in 
Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography 
(SPECT) have been developed for the non-invasive imaging of HER2. Many of these have 
been evaluated in animals and some even in humans.
Building-Blocks for Immunoscintigraphy
Antibodies have excellent specifi   city, so most radiopharmaceuticals that have been 
developed for non-invasive imaging of HER2 are based upon proteins instead of chemical 
structures. Th   ese proteins come in diff  erent shapes and sizes, but can roughly be divided 
into two diff  erent groups namely the intact immunoglobulin G (IgG) Abs and the smaller 
(Ab derived) proteins. Th  e  diff  erent structures are shown schematically in fi  gure 2.
Antibodies are highly specifi  c targeting agents, which play an important role in the defense 
of the human organism against pathogenic organisms and toxins. Th   e most important class 
of Abs is the IgG: Y-shaped molecules, composed of heavy (50 kDa) and light polypeptide 
chains (25 kDa). Two heavy chains and two light chains are linked together by disulfi  de 
bonds to form one IgG molecule. Th  e  amino-terminal variable domains of the heavy and 
light chains are responsible for antigen binding. Because IgG-Abs are bivalent, their affi   nity 
and retention time to surface receptors are increased as compared to monovalent Abs [21].2  IMMUNOSCINTIGRAPHY AS POTENTIAL TOOL IN THE CLINICAL EVALUATION OF 
HER2/NEU TARGETED THERAPY
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Figure 2. Schema   c representa   on of an intact Ab, Fab and F(ab’)2 fragments, a minibody, diabody, aﬃ   body 
and mono- and divalent single chain variable Ab fragments [scFv)2] with their approximate molecular 
weight.
Fragment antigen binding (Fab) fragments (50 kDa) consist of one of the two identical arms 
of the antibody molecule, and therefore contain the complete light chain and part of the 
heavy chain, with a single antigen-binding site. Th  ese  molecules are obtained by enzymatic 
cleavage of the Fc receptor with papain. Cleavage with pepsin results in divalent antibody 
fragments (F(ab’)2, 100 kDa) in which both antigen-binding sites are retained [21].
Minibodies, single chain Fragment variables (ScFvs), diabodies and affi   bodies, on the 
contrary, are not obtained by enzymatic procedures, but derived by genetic engineering. 
Minibodies (80 kDa) are developed by fusion of ScFvs to the constant Ig domain of a human 
IgG1 [22-24].
Th   e ScFv (28 kDa) is a truncated Fab, comprising only the variable domain of a heavy chain 
linked by a stretch of synthetic peptide to a variable domain of a light chain. ScFvs have been 
engineered into 56 kDa dimeric ScFv conjugates, in order to improve tumor retention.
Diabodies (55 kDa) are noncovalent ScFv dimers that mimic the divalent binding properties 
of native IgG antibodies. Th   ey are constructed by shortening the peptide linker between 
the heavy and light chain variable domain of ScFv molecules, resulting in a stable protein 
with high antigen binding affi   nity and a favorable pharmacokinetic profi  le [22].
Mono- and divalent affi   bodies are very small, high affi   nity proteins with a molecular weight 
of only 7 or 15 kDa. Affi   body molecules present a new class of proteins, which utilizes a 
scaff  old based on the 58-residue three-helix bundle Z domain derived from staphylococcal 
protein A. Affi   body proteins are selected as binders to target proteins by phage display of 
combinatorial libraries in which typically 13 side-chains on the surface of helices 1 and 2 in 
the Z domain have been randomized [22, 25, 26]. Aft  er phage display, the obtained clones are 
selected, expressed in Escherichia coli and then analyzed for antigen binding [27].20
Factors Infl  uenzing Pharmacokinetic and Biodistribution Characteristics of 
Antibodies and Fragments
Molecular Size and Shape
Intact Abs display a long serum half-life (>10 days), except for murine antibodies. Intact 
Abs are predominantly excreted through hepatic clearance, due to their large molecular 
weight (150 kDa), which is well above the kidney threshold of approximately 50 kDa [22, 28].
Another factor that adds to the long half-life of human antibodies is their interaction with 
the neonatal Fc receptor. Upon internalization, the neonatal Fc receptor acts as a salvage 
receptor, rescuing them from degradation. Proteins below the renal threshold size will, in 
contrast to intact Abs, rapidly (minutes to hours) be excreted by the kidneys [28].
In vivo imaging studies have shown that molecular weight is an important determinant 
in the biodistribution of Abs and proteins. Large, intact Abs penetrate slowly but constant 
into solid tumor tissue, because there is little serum clearance, ultimately resulting in high 
tumor accumulation. Small proteins, on the contrary, swift  ly penetrate into tumor tissue, 
but because they are cleared much more rapidly, the resulting tumor uptake is limited [28]. 
Ultimately good tumor imaging is a combination of tumor uptake and tumor selectivity, 
which determines the tumor-to-background contrast.
Abs of non-human antigen can be highly immunogenic and already aft  er the fi  rst gift   
HAMAs (Human anti-mouse mAbs), HARA (Human anti-rat mAbs), HACAs (human 
anti-chimer mAbs) or HAHAs (human anti-human mAbs) can be generated by the 
immune system. Th  ese circulating mAbs can form complexes with the foreign Ab and 
dramatically increase liver and spleen clearance. In addition, there is always the (theoretical) 
risk of developing an anaphylactic reaction when (foreign) antibodies are administered [29].
Th  ese hurdles were almost completely overcome by the g e n e r a t i o n  o f  c h i m e r i c  a n d  
humanized mAbs that contain human Fc domains and retain targeting specifi  city. For the 
generation of these mAbs, either the entire murine variable regions (chimer) or the murine 
complementarity-determining regions (humanized mAb) is graft  ed into the human IgG 
framework [30].
Valency, Affi   nity and Avidity
Other factors infl  uencing tumor uptake are valency, affi  nity and avidity. Monovalent and 
low affi   nity binding proteins display poor tumor retention, resulting in low tumor-uptake. 
Although an increase of affi   nity may lead to increased tumor uptake, tumor uptake of 
extremely high affi   nity molecules can be limited by the barrier-eff  ect [31]. A phenomenon 
in which very high affi   nity interactions between proteins and tumor antigens may impair 
effi   cient tumor penetration of the proteins and thus diminish eff  ective in vivo targeting.
Avidity is the combined synergistic strength of the different individual bounds between 
antibody and antigen rather than the sum of bounds.
Th  eoretically, the ideal tumor-targeting agent would be, antigen specifi  c, tumor selective, 
intermediate-sized, multivalent and have a high affi   nity/avidity, resulting in a rapid tissue 
penetration, high target retention and rapid blood clearance [32].2  IMMUNOSCINTIGRAPHY AS POTENTIAL TOOL IN THE CLINICAL EVALUATION OF 
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At the moment various radionuclides for SPET and PECT imaging have been 
used for the detection of HER2. SPECT and PET have their own unique advantages and 
di s a d v an ta g e s .  S P E CT  i s  l e s s  e xp e n s i v e  th an  P E T ,  m o r e  widely available and there is 
worldwide more experience. PET has a higher spatial resolution, and can provide more 
accurate quantitative data and has a lower signal-to-noise ratio than SPECT. Interestingly 
PET and SPECT scans can be fused with CT and MRI , thus yielding images that contain 
anatomic as well as functional information [33].
Radiopharmaceutical Aspects
Most of the current clinical and preclinical HER2 immunoscintigraphic studies have 
been performed with SPECT because these isotopes have a longer history of clinical use than 
positron emitters. However, an increasing number of recently published preclinical studies 
are performed with PET isotopes.
F o r  a d e q u a t e  vi s u aliza ti o n  wi th  s l o w l y  a c c um ul a tin g  mAbs, the use of isotopes with 
long half-lifes (like 111In, 89Zr or 124I) is a necessity. Small proteins, on the contrary, can be 
radiolabeled with shorter living isotopes (e.g.  68Ga, 64Cu, 99mTc,  123I and 18F), due to their 
swift   tumor uptake and fast excretion. In order to minimize bone marrow, thyroid, liver or 
kidney toxicity, the half-life of the isotope should generally not exceed the half-life of protein 
distribution [34].
Abs and proteins can be labeled in two ways: either directly or by use of a chelator. Under 
mild oxidative conditions, iodine radiohalogens are covalently bound to the protein tyrosine 
residues. Radiometals can only be labeled indirectly to the protein lysine or tyrosine residues 
by means of a bifunctional chelator , such as diethylene triamine pentaacetic acid (DTP A), 
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetra-acetic acid (DOTA) or desferal. Even though 
DTPA and DOTA have been successfully used in radiolabeling, the introduction of the 
p-isothiocyanatobenzyl-derivatives (e.g. CHX-A’’-DTPA and SCN-Bn-DTPA or SCN-
Bn-DOTA)  has clearly improved labeling characteristics [35]. P-isothio-cyanatobenzyl-
derivatives are chemically stable chelators, which ensure stability of the metal-ligand 
complex and generally conserve the integrity of the protein during labeling [36]. Modifi  ed 
desferal has been successfully applied in the labeling of Abs with the PET isotope 89Zr [37].
Internalization
Another important parameter infl  uencing the tumor accumulation of a radio-pharmaceutical 
is internalization. Upon cell surface receptor binding, Abs or fragments can be internalized 
by the tumor cell and subsequently degraded. Residualizing labels (including all chelated 
radioisotopes) are trapped in the cell upon internalization, due to their lipophilicity. Non-
residualizing radiopharmaceuticals (e.g. covalently bound radiohalogens), on the contrary, 
are degraded and the radioactive isotope is released in the extracellular compartment. 
Th   e latter results in a decrease in intracellular tumor uptake and a lower signal-to-noise ratio 
[38]. Th  e use of residualizing radiopharmaceuticals can almost double intratumoral Ab 
uptake. It is therefore not surprising, that the majority of studies have been conducted with 
residualizing labels. Since internalization and degradation are time-consuming processes, 22
it is to be expected that residualizing labels will not improve the tumor accumulation of 
small radiopharmaceuticals that are very rapidly cleared from the circulation.
Preclinical HER2/ Imaging
Intact Antibodies
Th  e  fi  rst HER2 immunoscintigraphic preclinical studies have been performed with intact 
Abs and ScFvs. Most Ab studies have been done with radiolabeled trastuzumab and its 
murine predecessor (4D5) or the rat Ab ICR-12.
Of the wide variety of radioisotopes that has been used to radiolabel intact Abs, 111In, iodine 
(124I, 125I and 131I) and 99mTc are mostly used (table 1).
Saga et al. published the fi  rst HER2 imaging study in mice in 1991. Th   is study was performed 
with 125I and 111In radiolabeled murine IgM monoclonal Ab (SV2-61r). Th  e  Ab  was generated 
against human HER2 transfected NIH-3T3 (SV11) cells. With this radiopharmaceutical, 
specifi  c, HER2 expression-dependent tumor uptake was demonstrated in a biodistribution 
and immunoscintigraphy study [39]. Th   e authors observed a diff  erence between residualizing 
and non-residualizing labels. 125I labeled SV2-61r decreased rapidly, whereas 111In-labeled 
SV2-6Ir remained in the tumor, resulting in higher tumor-to-blood (T/B) ratios. At an early 
time point, the tumor uptake of both radiopharmaceuticals was almost identical (11.0 for 
125I-SV2-61r versus 12.8 percent injected dose of radioactivity per gram tissue (% ID/g) for 
111In-SV2-61r). At 48 h aft  er injection, however, there was a substantial diff  erence in tumor 
uptake (5.7 versus 15.1% ID/g) and T/B ratios (1.1 versus 5.5) due to radiopharmaceutical 
catabolism and excretion of 125I-tyrosine in the tumor environment [39].
One year later, the fi  rst HER2 radiopharmaceutical was developed for PET (124I-ICR12). With 
this rat mAb, which was generated using the BT 474 breast carcinoma cell line as an antigen 
source, reasonable uptake (12% ID/g at 120 h) was demonstrated in athymic mice bearing 
human HER2 overexpressing breast carcinoma xenograft  s [40]. ICR12 tumor uptake was 
shown to be HER2 specifi  c: 125I labeled control rat Ab tumor uptake was 6 fold lower 
[40]. By using residualizing radiopharmaceuticals, tumor uptake was further increased to 
20% ID/g [41,42]. Another study with 131I-ICR12 indicated that Ab clearance is protein-dose 
dependent. Total tumor uptake was not infl  uenced by the total protein dose, but the T/B 
ratio decreased with increasingly total protein dose (2.2, 1.8 and 0.9% ID/g for 25,50 and 100 
μg ICR12 respectively) [43].
In the same year, de Santes and Slamon published their study with 131I-4D5. Th  is  murine 
mAb, which is the predecessor of trastuzumab, was directed against the extracellular 
juxtamembrane region of HER2 transfected NIH 3T3 cells [44,45]. Th   e study demonstrated 
specifi  c tumor localization, although the %ID of radioactivity/g tumor declined sharply 
from 25% at 24 h to 5% at 120 h post-injection due to intratumoral catabolism of 131I-4D5 [46].
In athymic mice bearing HER2 transfected MCF7 xenograft  s, 111In-4D5 showed high and 
specifi  c tumor localization and a T/B ratio greater than 2 at 48 h post-injection. Compared 
to 125I-labeled 4D5 in NIH3T3 xenograft  s [46], 111In-4D5 tumor uptake was superior (30% 
versus 17% ID/g at 48 h) [47]. Similar results were shown with 111In-trastuzumab (35 and 
31% ID/g at 48 h), but this study indicated that the T/B ratio can be dependent upon the 2  IMMUNOSCINTIGRAPHY AS POTENTIAL TOOL IN THE CLINICAL EVALUATION OF 
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tumor cell line xenograft  ed: 111In-trastuzumab in the human colon carcinoma xenograft   
(LS-174T) displayed a high T/B ratio of 18.6, whereas the same radiopharmaceutical in a 
human pancreatic carcinoma xenograft   (SHAW) showed a T/B ratio of only 4.2 at 168 h post 
injection [48].
A comparative 111In/90Y biodistribution study demonstrated a very high maximal 111In-
trastuzumab tumor uptake of 67% ID/g at 72 h (T/B-ratio: 5.1) and while 111In-trastuzumab 
proved to be a suitable surrogate for yttrium (Y)-radiolabeled trastuzumab in many organs, 
it did not parallel the uptake of 86Y-trastuzumab in the bone, and thus may not accurately pre-
dict the level of Y accumulation in the bone for clinical radioimmunotherapy applications. 
Appropriate matched pair isotopes for imaging and therapy might therefore be required to 
predict accurate dosimetry [49]. We showed that the diff  erence in 111In-DTPA-trastuzumab 
tumor uptake in HER2-positive and HER2-negative lesions was most pronounced 3 days 
aft  er injection (15.3 versus 3.2% ID/g). Th   is GMP-grade radiopharmaceutical was later used 
in clinical HER2 scintigraphy [50].
Recently we have also developed the residualizing HER2/neu immunoPET radiopharmaceutical 
89Zr-trastuzumab,  suitable for clinical use. 89Zr-trastuzumab uptake was specifi  c  and 
maximized at day 6 (33.4% ID/g in the xenograft  ed human SKOV3 HER2 positive tumor 
and 7% ID/g in the HER2 negative GLC4 tumor) [51].
Mono- and Divalent Fragment Antigen Binding (F(ab)2 and Fab) Fragments
Smith-Jones and coworkers have developed 68Ga labeled trastuzumab derived F(ab’)2 
fragments. Because of the rapid clearance of the fragment and the short half-life of the 
isotope, it was possible to sequentially image the tumor HER2 expression with intervals 
of 24 h. Although the tumor uptake of 68Ga-F(ab’)2-trastuzumab is good (12% ID/g), the 
T/B-ratio is disappointing (0.8 at 3.5 h). Th   is T/B ratio might have improved in time, however 
these data were not presented. Despite the low T/B ratio, it clearly did allow them to image 
the pharmacodynamics of the heat shock protein (HSP) inhibitor 17-allylaminogeldanamycin 
(17-AAG). Administration of 17-AAG causes the degradation of among others the HSP client 
protein HER2. 17-AAG has anti-tumor activity and is currently tested in clinical trials. 68Ga-
F(ab’)2-trastuzumab did non-invasively measure and quantify the loss and recovery of HER2 
induced by 17-AAG administration. HPS90 initiated depletion of HER2 induced an 80% 
decrease in radiopharmaceutical uptake, compared to the control [52]. In a follow-up study 
with sequential (seven times over a period of 3 weeks) HER2 imaging of the tumor, it was 
also shown that a reduction in 68Ga-F(ab’)2-trastuzumab tumor uptake predicted 17-AAG 
induced tumor growth inhibition than did 18F-fl  uorodeoxy-glucose (FDG) uptake [53].
Th   is study is a beautiful example of the opportunity to evaluate the effi   cacy of a targeted 
drug with a radiolabeled mAb derivative. Immunoscintigraphy provided information on the 
pharmacodynamics of an experimental drug. 24
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With 111In Radiolabeled Trastuzumab Fab Fragments, Specifi   c Tumor Uptake was
Demonstrated (7.8% ID/g for a HER2 Overexpressing Breast Cancer Xenograft  
Versus 2.7% ID/g for a control Fab fragment). Th   e T/B ratio of 111In-trastuzumab Fab was 
much higher than that for the control fragment (25 versus 7.0) and T/B ratios found in other 
studies [54].
In a comparable study 10.7% ID/g 99mTc-trastuzumab Fab tumor uptake was shown and 2.6% 
ID/g for the irrelevant control. Th   e T/B-ratio, however, was much lower than with the 111In 
radiolabeled radiopharmaceutical (3.0 versus 25), possibly due to a lower stability of the 
99mTc-trastuzumab [55].
Minibodies
Iodinated anti-HER2 engineered divalent minibody derived from the internalizing 10H8 
rat mAb showed only modest maximum tumor uptake 5.6% ID/g at 12 h in athymic 
mice bearing MCF7/HER2 xenograft  s [56].
In an attempt to improve tumor uptake, the 10H8 minibody was radiolabeled with 111In. 
Th   is alteration did however not increase the tumor uptake (5.7% ID/g), but was associated 
with high uptake in the proximal tubules of the kidneys (34.0% ID/g), due to the presence of 
a cross-reactive antigen and the low molecular weight of the minibody.
With a second minibody, derived from trastuzumab (64Cu-DOTA hu4D5v8) tumor uptake 
was 4.2% ID/g. Again, the 111In radiolabeled minibody (hu4D5v8) exhibited elevated kidney 
u p tak e  ( 28. 4 %  ID / g) ,  ev e n  in  n o n - tum o r - bearin g  mice. An engineered larger hu4D5v8 
fragment [(scFv-CH2-CH3)2; 105 kDa] improved tumor targeting (12.2% ID/g) and reduced 
kidney uptake (13.1% ID/g) [57].
Mono- and Divalent Single Chain Variable Antibody Fragments
Most studies with monovalent and divalent ScFvs have been performed with 741F8 (a 
murine derived antibody) [58]. Monovalent 741F8 ScFvs exhibited rapid and biphasic 
clearance from the blood, while a slightly slower clearance was observed with the divalent 
741F8 (scFv’)2. In SKOV3 xenograft  s, 125I-radiolabeled 741F8 scFv was specifi  cally retained 
and good T/B ratios (15.8 at 24 h) were observed, although the absolute tumor-uptake was 
low (0.79% ID/g at 24 h). Th  e  specifi  city-index (demonstrated with the anti-digoxin 26-10 
scFv monomer) was 13:1 for tumor and 0.8-2.1:1 for non-tumoral tissues. Th  e  specifi  city-index 
was even further increased when the 741F8 (scFv’)2 was compared with the 26-10 (scFv’)2 
dimer (17:1) due to increased 741F8 (scFv’)2 tumor retention [59].
Similar results were obtained in a study with 125I-labeled 741F8 scFv, scFv’, and (scFv)2 
fragments and anti-digoxin 26-10 scFv’ and (scFv’)2 control fragments [60].
In a comparative study, (scFv’)2 homodimers showed improved retention (3.6% ID/g) 
compared to the scFv monomers (1.3% ID/g), due to the valency of the protein rather than 
to slower systemic clearance of the homodimers [61].
In a dose escalation study with 125I-741F8 (scFv’)2 (50-1000 μg), tumor uptake increased 
20-fold, but liver uptake also increased 17-fold, resulting in little overall increase in tumor-
to-organ ratios. Th   e 1000 μg 741F8 (scFv›)2 dose resulted in a tumor uptake, comparable to 
that of 125I-741F8 IgG at 24 h. Th   is indicated that the use of large doses of (scFv’)2 may 
partially off  set their rapid clearance, possibly due to saturation of the excretory organs [62].2  IMMUNOSCINTIGRAPHY AS POTENTIAL TOOL IN THE CLINICAL EVALUATION OF 
HER2/NEU TARGETED THERAPY
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Adams and coworkers improved stability of 125I using the N-succinimidyl p-iodobenzoate 
(PIB) method for radiolabeling 741F8-1 (scFv’)2. PIB is an indirect labeling method, which 
prohibits release of radioiodinated protein upon internalization [63]. Higher tumor retention 
and lower blood, spleen and stomach retention (p<0.005) were observed in biodistribution 
studies when the PIB conjugate was used compared to chloramine-T radiolabeled 741F8-1 
(scFv’)2, resulting in superior tumor-to-organ ratios [64].
In SKOV3 ovarian carcinoma-bearing mice, 1.47% ID/g 125I-C6.5 retention was reached 
aft  er 24 h, at a T/B value of 22.9 [65]. In another study, affi   nity mutants of scFv C6.5 
were generated by site-directed mutagenesis with a 320-fold range in HER2 antigen affi   nity 
(3.2 x 10-7 to 1.0 x 10-9 M). In vitro, the Kd of each scFv correlated closely with the duration of 
its retention on the SKOV3 cell surface. In biodistribution studies with established SKOV3 
xenograft  s, the degree and selectivity of tumor localization increased with an increase in 
affi   nity. Th   e mutant with the lowest affi   nity for HER2 completely failed to accumulate in 
the tumor, indicating the presence of an affi   nity threshold that must be exceeded for in vivo 
tumor uptake. In contrast, tumor retention of the highest affi   nity singe-chain fragments 
was 7-fold greater at 24 h than that of a mutant with a 320-fold lower affi   nity for HER2. 
Because low-weight scFv molecules are rapidly eliminated from the circulation, the 
impact of improved affi   nity on tumor targeting might be underestimated. Th   is was shown 
in surgically rendered anephric mice, the peak tumor retentions of the two higher affi   nity 
scFvs were further increased, to levels as high as those previously reported for IgG targeting 
in similar mouse tumor models with intact kidneys [66].
Diabodies
Th   e C6.5 diabody was derived from the anti-HER2 C6.5 ScFv, which in its turn was obtained 
by phage display technology [65].
Tumor uptake of the radioiodinated C6.5 diabody was already maximal at 4 h post-
injection, but T/B ratios increased approximately tenfold to 9.7 during the next 20 h 
[67]. With a 124I radiolabeled C6.5 diabody, there is a 3.4-fold diff  erence in tumor uptake 
between the xenograft  s derived from the HER2 positive SKOV3 (1.1% ID/g) and the HER2 
negative MDA-MB-468 cell line (0.32% ID/g) at 48 h. In SCID mice bearing subcutaneous 
SKOV3 tumors, 124I-C6.5 diabody reached a tumor uptake between 1.1 and 4.8% ID/g at 48 
h [68, 69].
Affi   bodies
At this moment, all publications on HER2 binding affi   bodies are from Sweden especially 
from the Affi   body AB fi  rm. Some studies have been performed with the 15 kDa bivalent 
Z(HER2/neu: 4)2 low affi   nity affi   body (Kd=3 nM), although the majority has been performed 
with the higher affi   nity Z(HER2/neu:342) affi   body (Kd=22 pM).
125I radiolabeled Z(HER2/neu: 4)2 was primarily excreted by the kidneys. Th  e highest 
tumor uptake was 2.2% ID/g (at 4 h) and T/B-ratios reached a maximum of 11.5 (at 24 h post 
injection). It should be mentioned that the total amount of radiopharmaceutical that is 
still present at that time is very low [70]. Similar results were seen with an affi   body labeled with 
the PET isotope 76Br (4.8% ID/g) [71]. In a biodistribution study with 99mTc-His6-(ZHER2/28
neu:4)2 and 125I-His6-(ZHER2/neu:4)2 in tumor-bearing BALB/c mice, comparable results 
were demonstrated for 99mTc-His6-(ZHER2/neu:4)2 and 125I-His6-(ZHER2/neu:4)2 (2.6 
and 2.3 % ID/g respectively at 4 h). Interestingly, 99mTc-His6-(ZHER2/neu:4)2 displayed 
aspecifi  c tissue uptake as the tumor-to-non-tumor ratios were much more favorable for the 
radioiodinated affi   body [72].
Most HER2 targeting studies, however, have been performed with higher affi   nity mono 
or divalent Z(HER2/neu:342) affi   bodies. Th   e >2,200-fold increase in affi   nity of this affi   body 
was achieved through a re-randomization of relevant positions identifi  ed aft  er the 
alignment of fi  rst-generation variants of nanomolar affi   nity. Tumor uptake of this affi   body 
proved to be higher, possibly due to the improved affi   nity.
125I radiolabeled Z(HER2/neu:342) biodistribution showed clear, high-contrast visualization 
of HER2-expressing xenograft  s in mice at 6 h post-injection and quick clearance from 
blood and normal organs. Tumor uptake was improved 4-fold (to 9% ID/g tissue at 4 h post-
injection), compared to the non-maturated (lower affi   nity) affi   bodies [73]. Labeling with a 
residualizing label (PIB or 111In-Benzyl-DTPA) method further increased tumor uptake 
to approximately 12% ID/g at 4 h [74,75]. In vivo tumor uptake was receptor specifi  c, as 
it could be blocked with an excess of non-labeled Z(HER2/neu:342) [75]. In an attempt to 
improve stability and labeling kinetics, CHX-A’’-DTPA was used as a chelator, resulting in 
similar tumor uptake (10.3% ID/g) but an improved T/B ratio of about 190 [76]. Studies 
performed  with DOTA showed variable tumor uptake: 4.4 for 111In-benzyl-DOTA-
Z(HER2/neu:342) and 23% ID/g for DOTA-Z(HER2/neu:342-pep2). Pretreatment with 
trastuzumab did not interfere with tumor targeting. Administration of 17-AAG before 
111In-DOTA-Z(HER2/neu:342-pep2) diminished tumor uptake [77,78].
Th   e technetium radiolabeled higher affi   nity affi   body (99mTc-CGG-ZHER2/neu:342) displayed 
HER2-specifi  c tumor uptake and a T/B ratio of 9 at 6 h post-injection [79]. A biodistribution 
study with MAG3 chelated 99mTc-Z(HER2/neu:342) showed specifi  c tumor targeting (7% 
ID/g and T/B-ratio: 35 at 6 h), but both the biodistribution and the imaging studies 
indicated that about one third of the radioactivity was hepatobiliary excreted and almost 
completely cleared from the intestine at 24 h [80]. Two diff  erent studies investigated whether 
a reduction of radioactivity in bile and feces could be obtained by substituting glycyl residues 
in the chelating sequence with more hydrophilic residues. A shift   towards renal excretion 
was obtained when glycyl was replaced by serine in the chelating sequence [81]. Hepatobiliary 
99mTc-Z(HER2/neu:342) excretion was reduced 3-fold by a single glycyl to glutamic acid 
substitution and 10-fold by three substitutions [82].
Conclusion
In conclusion, diff   erent antibodies and proteins directed against HER2 show a large 
variation in tumor uptake, T/B and target to non-target ratios.
Radiolabeled intact antibodies generally display high tumor uptake, a maximum being 
reached between 48 and 72 h aft  er injection. Since it takes somewhat longer to clear the 
antibody from the circulation, maximal T/B and target to non-target ratios are usually 
achieved aft  er 48 to 168 h post-injection.
Animal studies with radiolabeled minibodies revealed a disappointing tumor uptake, but 
an acceptable T/B ratio. With the larger (divalent) minibody, tumor uptake was increased, 2  IMMUNOSCINTIGRAPHY AS POTENTIAL TOOL IN THE CLINICAL EVALUATION OF 
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but high radioactivity uptake was noticed in the proximal tubules of the kidneys. Diabody 
studies revealed a variable and slightly lower tumor accumulation than the minibodies, 
although their maximal T/B ratio was comparable. For the small Fab fragments tumor 
uptake was – as expected – limited, but still comparable to that of minibodies and diabodies 
and T/B ratios were higher. Monovalent ScFvs were so rapidly cleared that signifi  cant tumor 
uptake was only achieved at very early time-points. Divalent ScFvs did little better. Until 
now, affi     body experiments have shown promising results. With affi   bodies,  excellent 
tumor-uptake has been demonstrated, especially when the size of the molecule is taken into 
account, and very high T/B ratios were observed.
Although preclinical studies can give insight into the imaging properties of radio-
pharmaceuticals, their potential to predict biodistribution in humans is limited.
Th   ere is generally no cross-over reactivity from the radiopharmaceutical generated against 
the human HER2 and the mouse neu antigen.
What kind of radiopharmaceutical is most suitable for HER2 imaging, will depend upon 
the purpose for which the radiopharmaceutical will be used. If only receptor expression 
is relevant, high affi   nity proteins can be used for receptor expression imaging. When also 
evaluation (and response prediction) of antibody therapy is desired or a high tumor uptake 
is mandatory, radiolabeled intact antibodies that most likely mimic drug behavior more 
accurately, seem preferable.
Clinical Studies 
Intact Antibodies
Currently 99mTc-ICR12,  111In-trastuzumab and 89Zr-trastuzumab have been used for 
scintigraphy studies in patients. An advantage of radiolabeling antibodies that have been 
clinically approved, is that their distribution is more likely to refl  ect the behavior of the drug 
itself. In addition, less validation and toxicity testing and regulatory issues are needed 
before such a radiopharmaceutical can be clinically used.
As early as 1994, the rat Ab 99mTc-ICR12 was administered to eight breast cancer patients. 
Tomographic images were obtained at 24 h. Th   ree patients served as normal controls and 
two patients had strong HER2 membrane staining. In these two patients, excellent tumor 
localization of both breast primary and regional node metastases was observed. Th  e 
remaining patients only had moderate HER2 antigen expression in IHC and in these two 
patients there was no adequate tumor localization observed. Th  is very small study 
suggests that 99mTc-ICR12 could be used for the imaging of HER2 overexpression [42]. No 
further clinical results for ICR12 are available with this Ab, possibly due to an undesired 
response of the human immune system to this rodent protein.
Trastuzumab can induce cardiotoxicity, particularly when combined with anthracyclines. 
Myocardial HER2 expression may be upregulated by a compensatory mechanism following 
cardiac stress, potentially explaining the cardiotoxicity which can occur following 
trastuzumab treatment [83].30
Behr et al. suggested in a preliminary report that scanning with 111In-labeled trastuzumab 
could predict cardiotoxicity and therapeutic effi   cacy of trastuzumab in 20 patients with 
HER2 overexpressing metastatic breast cancer [84].
In a study from our group in HER2-positive metastatic breast cancer patients, 111In-DTPA-
trastuzumab scintigraphy could not predict trastuzumab related cardiotoxicity; myocardial 
uptake was shown in only 1 of the 15 anthracycline-pretreated patients. Because the median 
time interval between the last anthracycline administration in these patients was 11 months, 
it might well be that no uptake in the heart was seen because of the large time span between 
anthracycline administration and the immunoSPECT scan [85].
In a new study, we therefore performed 111In-DTPA-trastuzumab scans shortly aft  er 
completion of anthracycline treatment in breast cancer patients and in patients with non-
anthracycline-related heart failure. Myocardial 111In-DTPA-trastuzumab uptake was 
observed in 5 out of 10 (50%) anthracycline-treated patients, who all were without symptoms. 
In addition in 10 non-oncological heart failure patients, no myocardial uptake was seen. 
111In-DTPA-trastuzumab scintigraphy shortly aft   er anthracycline therapy potentially 
refl  ects a stress response. It potentially identifi  es patients susceptible for trastuzumab-related 
cardiotoxicity and thus may facilitate the optimal timing of trastuzumab therapy [83]. 111In-
DTPA-trastuzumab scintigraphy discovered new tumor lesions in 13 of 15 patients, and may 
therefore be of value for clinical staging with HER2 positive metastatic breast cancer [85].
In an attempt to further optimize HER2 imaging, PET was used instead of conventional 
nuclear medicine techniques, because of its higher spatial resolution and better signal-to-
noise ratio. Zirconium-89 (89Zr), was considered a suitable PET isotope, since it has a suffi   ciently 
long half-life to match the relatively slow pharmacokinetics of an intact antibody and has 
been successfully used in humans [86]. GMP produced 89Zr oxalate (>99.99% pure) is made 
commercially available.
In a clinical feasibility study, 89Zr-trastuzumab immunoPET was used to visualize HER2 
positive lesions and to determine the minimal required trastuzumab dose for optimal 
imaging. HER2 positive metastatic breast cancer patients were eligible for the study. Patients 
were injected with 89Zr-trastuzumab at a total dose of 10, 50 or 200 mg trastuzumab and 
underwent PET-scanning, which was compared with available conventional imaging. In our 
ongoing feasibility study, so far eight patients with HER2 positive metastatic breast cancer 
have been included. 89Zr-trastuzumab uptake was strongly correlated with known tumor 
lesions in the brain, lung, liver and bone. Th  e preliminary clinical data indicate excellent 
tumor uptake and a resolution unapproachable by 111In-DTPA-trastuzumab [51].
Minibodies
No anti-HER2 minibodies have been studied in humans. Th   e anti-CEA chimeric T84.66 
minibody is the only radiolabeled minibody that has ever been tested in humans. In animal 
models, minibody tumor uptake almost approached that of an intact antibody, with high T/B 
ratios, due to high tumor uptake and rapid clearance.
In this clinical study, 123I-cT84.66 minibody (185-370 MBq, 1 mg) was administered to 10 
patients with colorectal cancer. SPECT and CT scans were compared with surgical fi  ndings, 
obtained immediately aft  er the last scan. 123I-cT84.66 minibody imaged 8 of 10 tumors 2  IMMUNOSCINTIGRAPHY AS POTENTIAL TOOL IN THE CLINICAL EVALUATION OF 
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1.0 cm in size, whereas CT imaged only 5. During the study, no responses of the human 
immune system to the injected minibodies were observed. Th   e results suggest that the 
123I-cT84.66 minibody may have a role as a functional tumor-imaging agent to complement 
CT. Because the mean serum residence time of the minibody was extensive (29.8 h), the 
authors intend to perform labeling of the minibody with a longer-lived radionuclide, such 
as 111In [87].
F(ab)2 and Fab Fragments
No clinical studies using anti-HER2 F(ab)2 or Fab fragments have been reported. However, 
various F(ab)2 and Fab fragments have been tested in humans. Th  e  anti-CEA  mono- and 
dimeric radiolabeled mAb Fab fragment have been used for the detection of suspected 
recurrence of the tumor in the clinic. In 28 previously treated colorectal patients, 99mTc 
labeled CEA Fab’ fragment was compared with FDG-PET scintigraphy. SPECT imaging was 
performed 4-6 h aft  er injection and whole-body FDG-PET was performed in parallel. Th  e 
fi  ndings were confi  rmed by conventional diagnostic modalities, surgery, and histology. 
Tumor recurrence was histologically proven in 9 of 28 patients. 99mTc-anti CEA Fab’ 
detected 8 of 9 local recurrences, whereas FDG-PET was able to detect all 9, but was 
false-positive in one patient. Liver, lymph node, lung and bone metastases, however, were 
correctly identifi  ed in all patients by FDG-PET, but not by the 99mTc-labeled anti-CEA Fab’ 
fragment. Th   is indicated that 99mTc-labeled anti-CEA Fab’ detected local recurrences, but 
FDG-PET is clearly superior in the detection of distant (liver, bone, and lung) and lymph 
node metastases [88].
In a prospective, randomized multicenter study 123I radiolabeled IMMU-4 (a murine anti-CEA 
monoclonal antibody) F(ab’)2 (1 or 10 mg) or Fab’ (1 or 10 mg) fragments were evaluated 
in 62 colorectal cancer patients. Radioimmunoscintigraphy disclosed metastases of at least 1 
cm in size. Study outcome was similar for both types of radiopharmaceuticals (F(ab’)2 and 
Fab’ fragments) and there was no dose dependence. Sensitivity, specifi  city, and accuracy were 
86%, 89% and 89%, respectively aft  er 7 months of follow-up. One patient treated with 10 mg of 
IMMU-4 F(ab’)2, who did not have pre-existing HAMA, developed a low level of Ab during 
the course of study [89].
Diabodies, (ScFv)2 and ScFv Fragments and Affi   bodies
No clinical studies have currently been published in humans with radiolabeled diabodies, 
ScFvs or affi   bodies.
Conclusion
Only intact antibodies and HER2 targeting minibodies have been used for clinical 
imaging. Such studies have shown that HER2 immunoscintigraphy could play a role in the 
improvement of staging and the evaluation of mAb targeted therapy, as is discussed in 
more detail in the next paragraph.32
Clinical Applicability of Immunoscintigraphy; Current and Future Use
Staging of the Disease
Adequate staging of cancer is important to determine the patient’s prognosis and guide 
physicians towards the most appropriate treatment. Th   e detection of previously unidentifi  ed 
lesions could have an infl  uence on clinical decision making. Knowing the molecular 
composition of the tumor (e.g. receptor status), allows tailor made instead of generic 
therapy.
Predicting Th  erapy  Response
At this moment, the use of (immuno)scintigraphy is generally limited to staging and restaging 
of cancer. One of the great unmet needs is to predict therapy response non-invasively 
[90], in order to avoid toxicity and high costs. Th  e  eff  ectiveness of current mAbs is still limited, 
with benefi  t for just a small portion of patients, at costs that are expected to rise to tens of 
billions of dollars in the near future [91,92]. Immunoscintigraphy is expensive due to the 
high costs of isotopes such as 124I and the use of antibodies. Nevertheless, if patients with 
the highest chance of benefi  t could be identifi  ed, eff  ectiveness of mAb therapy would be 
improved so immunoscintigraphy could be cost-eff  ective as well as the mAb-based therapy.
Th  en again, even when a tumor expresses appropriate levels of the target, targeted 
therapy may fail if the tumor also has characteristics that will render it resistant to the chosen 
treatment [93]. Biomarkers that allow early response prediction would be very helpful.
Measuring Th  erapy  Response
With the availability of new second- and third-line drugs for the treatment of patients with 
advanced disease, early response prediction allows patient tailored therapy and early decision 
making on whether or not to continue treatment [90].
Currently there are no serum markers for the majority of tumors that can adequately predict 
therapy response [94], therefore anti-cancer therapy is generally monitored by the decrease 
in tumor size, which is a late event in treatment response. It may take months for the 
tumor cells to die and the dead cells to be cleared [90].
An example might be HSP90 inhibiting therapy, where HER2 depletion could be an early 
readout for therapy effi   cacy, as has been demonstrated in preclinical studies [52,53].
Again, this is an area where immunoscintigraphy off  ers potential advantages and may play a 
clinically important role in the future [90, 93].
For the clinical applicability of non-invasive imaging techniques, it is essential that overall 
sensitivity, specifi  city, and accuracy are high. What sensitivity, specifi  city, and accuracy 
values would be suffi   ent for HER2 imaging still needs further validation [95].
Clinical mAb Development
Immunoscintigraphy might help to facilitate fi   rst-in-man clinical trials and provide 
information about the target occupancy, the optimal mAb dose, biodistribution and toxicity 
in a more effi   cient and safer way, with fewer patients [34].2  IMMUNOSCINTIGRAPHY AS POTENTIAL TOOL IN THE CLINICAL EVALUATION OF 
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Discussion
HER2 overexpression has been successfully imaged in both animals and humans. Th  e  choice 
of a radiopharmaceutical for HER2 imaging will depend upon preclinical and clinical results 
and the purpose for which the radiopharmaceutical will be used. If only receptor expression 
is relevant for diagnostic purposes, imaging could be performed with small proteins, 
allowing patients being diagnosed within a single day . If also evaluation ( and response 
prediction) of antibody therapy is desired, radiolabeled intact antibodies that most likely 
mimic drug behavior more accurately, seem preferable. Th   ere are many potential clinical 
applications [34], including improved diagnosis and guidance for targeted therapy. 
Clearly larger studies have to prove whether these imaging techniques can indeed 
aff  ect clinical practice. Immunoscintigraphy could also assist early drug development. Th  e 
distribution of the radiolabeled drug is more likely to refl  ect the behavior of the drug itself, as 
the pharmacokinetics and -dynamic behavior of the antibody are less infl  uenced by the small 
chelating group and radiolabel than smaller proteins.
Currently, several strategies are being followed to further improve tumor uptake and target 
to non-target ratios of radiopharmaceuticals in preclinical studies. Affi   nity and avidity is 
increased to improve tumor uptake, although there is an optimum; proteins with extremely 
high affi   nity display reduced tumor penetration (barrier-eff  ect) [31].
Pegylation or in vivo albumin binding are also used to reduce renal clearance and increase 
tumor uptake. Pegylation improved diabody tumor targeting more than threefold [96]. 
Pegylation of the anti-EGFR1 antibody C225 did not increase tumor uptake, but reduced 
liver uptake by half [97]. Th   e bifunctional albumin and HER2 binding molecule AB.Fab4D5 
was compared with trastuzumab. Maximal tumor uptake was similar for AB.Fab4D5 and 
trastuzumab at 48 h, but tumor-to-tissue ratios were more favorable for AB.Fab4D5 [98]. 
A similar strategy was used for the Z(HER2/neu:342)2 dimeric affi   body molecule, fused 
to an albumin-binding domain. In vivo, albumin binding resulted in a 25-fold reduction of 
renal uptake compared to the non-fused Z(HER2/neu:342)2 dimer molecule [99].
A last strategy, pretargeting, has currently only been exp l o r e d  i n  a n i m a l  s t u d i e s .  I n  
contrast to most radiolabeling methods, in pretargeting a non-radioactive, bispecifi  c Ab is 
injected and given suffi   cient time to localize in the tumor and clear from the blood. Th  en 
a radiometal-loaded chelate with excellent clearance properties is added. Th  is  chelate  will 
have little retention in normal tissues, but is trapped when encountering the bispecifi  c Ab, 
eventually resulting in higher T/B ratios [100].
Conclusion
Numerous studies indicate that PET and SPECT immunoscintigraphy could be very useful 
in the selection of cancer patients, staging and in predicting and evaluating therapy as can be 
seen from the HER2 example. Th   e very fi  rst steps are now made into the clinic. Much work 
in humans needs still to be done to prove their value and make these techniques applicable 
on a larger scale.34
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CHARACTERIZATION OF CLINICAL-
GRADE 89ZR-TRASTUZUMAB FOR 
HER2/NEU IMMUNOPET IMAGING
Abstract
Th   e anti-human epidermal growth factor receptor 2 (HER2/neu, further referred to as ‘HER2’) 
antibody trastuzumab is administered to patients with HER2-overexpressing breast cancer. 
Whole-body noninvasive HER2 scintigraphy could help to assess and quantify the HER2 
expression of all lesions, including non-accessible metastases. Th   e aims of this study were to 
develop clinical-grade radiolabeled trastuzumab for clinical HER2 immunoPET scintigraphy, 
to improve diagnostic imaging, to guide antibodybased therapy, and to support early 
antibody development. Th   e PET radiopharmaceutical 89Zr-trastuzumab was compared with 
the SPECT tracer 111In-trastuzumab, which we have tested in the clinic already. Trastuzumab 
was labeled with 89Zr and (for comparison) with 111In. Th  e minimal dose of trastuzumab 
required for optimal small-animal PET imaging and biodistribution was determined with 
human HER2-positive or -negative tumor xenograft  -bearing mice. Trastuzumab was effi   ciently 
radiolabeled with 89Zr at a high radiochemical purity and specifi  c activity. Th  e  antigen-binding 
capacity was preserved, and the radiopharmaceutical proved to be stable for up to 7 d in solvent 
and human serum. Of the tested protein doses, the minimal dose of trastuzumab (100 μg) proved 
to be optimal for imaging. Th   e comparative biodistribution study showed a higher level of 
89Zr-trastuzumab in HER2-positive tumors than in HER2-negative tumors, especially at day 
6 (33.4 ± 7.6 [mean ± SEM] vs. 7.1 ± 0.7 percentage injected dose per gram of tissue). Th  ere 
were good correlations between the small-animal PET images and the biodistribution data 
and between 89Zr-trastuzumab and 111In-trastuzumab uptake in tumors (R2=0.972). Clinical-
grade 89Zr-trastuzumab showed high and HER2-specifi  c tumor uptake at a good resolution.40
Introduction
Human epidermal growth factor receptor 2 (HER2/neu, further referred to as ‘HER2’) belongs 
to the ErbB tyrosine kinase receptor family, which consists of 4 receptors, HER1-HER4. 
Members of the HER family have growth-stimulating activity and play an important role in 
the regulation of cell growth, survival, and diff  erentiation [1]. HER2 is genetically encoded 
by the HER2 proto-oncogene (HER2/neu or c-erbB-2). HER2 overexpression or amplifi  cation 
occurs in a wide range of human cancers, including breast (incidence, 20-30%), colon, lung, and 
ovarian cancers [2,3]. HER2 overexpression and amplifi  cation are associated with oncogenic 
transformation and, for breast cancer, with a poorer prognosis and more aggressive behavior 
of the tumor in the clinical setting when no HER2-directed therapy is used [4-8]. HER2 is 
therefore a relevant target for therapy in breast cancer in the metastatic setting as well as in the 
adjuvant setting [9]. Th   e monoclonal antibody (mAb) trastuzumab and the dual-target (epidermal 
growth factor receptor 1 and HER2 tyrosine kinase) inhibitor lapatinib are currently used in 
clinical practice to target HER2.
T o  dete rmin e  HER2  o v e r exp r ess i o n  o r  am p lifi  cation in tumor biopsies, a wide variety of 
techniques have been used. Of these, immunohistochemistry and fl   uorescence in situ 
hybridization are currently the standard techniques [10,11].
Although the HER2 status provides important information about the molecular composition 
of the tumor, it is generally only determined at diagnosis of the primary tumor. Th  e HER2 
tumor status can show a time-dependent change aft  er therapy and can be diff  erent 
across tumor lesions in a single patient [12]. Repeat biopsies would be an interesting way to 
analyze the HER2 tumor status during the course of the disease because of the possible 
time-dependent change in status aft  er therapy. However, doctors and patients are frequently 
reluctant to use invasive techniques, particularly for poorly accessible lesions [13]. Whole-body 
noninvasive HER2 scintigraphy could be a strategy for determining the HER2 expression of 
all lesions, including non-accessible distant metastases, in a single scan and overcoming this 
problem. In addition, immunoscintigraphy could help to improve diagnostic imaging and 
to guide antibody-based therapy.
Th  is situation has led to the development of 111Inradiolabeled trastuzumab. Using 
SPECT , we have shown HER2-specifi  c uptake of this radiopharmaceutical in xenograft  -
bearing animals [14] and HER2-positive metastatic breast cancer patients [15]. 111In-
diethylaminetriaminepentaacetic acid (DTPA)-trastuzumab scintigraphy revealed new tumor 
lesions in 13 of 15 patients and was therefore considered to be of potential value for clinical 
staging [15].
In an attempt to further optimize HER2 imaging, PET was used instead of conventional nuclear 
medicine techniques because of its higher spatial resolution, better signal-to-noise ratio, and 
straightforward data quantifi  cation.
In line with our previous studies, our goal was to develop a radiopharmaceutical suitable for 
clinical HER2 immunoPET scintigraphy. Th   e new PET radiopharmaceutical had to be at least 
comparable to 111In-DTPA-trastuzumab in uptake, biodistribution, and imaging quality. Here 
we describe the development and in vitro and in vivo characterization of 89Zr-radiolabeled 
trastuzumab and a comparison of 89Zr-trastuzumab with 111In-trastuzumab.3  DEVELOPMENT AND CHARACTERIZATION OF CLINICAL-GRADE 89ZR-TRASTUZUMAB
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Materials and Methods
Th   e trastuzumab conjugation and labeling procedures described here were performed under 
good manufacturing practice (GMP) conditions at our manufacturing licensed department of 
nuclear medicine and molecular imaging. Materials and solvents for the labeling procedure 
were sterile and endotoxin and metal free (except for the Vivaspin-2 fi  lters [see next 
paragraph]). Protein concentration, endotoxin content, and sterility were measured. Both 
radiopharmaceuticals met European Pharmacopoeia and U.S. Pharmacopoeia requirements 
for sterile radiopharmaceuticals. All chemicals used for the study complied with European 
Pharmacopoeia or U.S. Pharmacopoeia specifi  cations.
89Zr-Trastuzumab Production
In the fi  rst step, reconstituted trastuzumab (21 mg/mL; Roche) was purifi  ed with water for 
injection from excipients by ultrafi  ltration. Vivaspin-2 fi  lters (30 kDa; Sartorius AG; 2 · 
10 min at 2,684g) were used for all ultrafi  ltration purifi  cation steps. Purifi  ed trastuzumab 
was conjugated essentially as described by Verel et al. [16]. In short, trastuzumab was diluted 
with 0.1 M Na2CO3 (pH 9.5; Bufa) and allowed to react with a 2-fold molar excess of a 
tetrafl  uorophenol-N-succinyldesferal-Fe (TFP-N-SucDf-Fe; VU University Medical Center) 
active ester. Aft  er 30 min, the pH was adjusted to 4.0 with sulfuric acid (Merck). Th  e 
number of desferal ligands per antibody was assessed by size exclusion high performance liquid 
chromatography (SE-HPLC) at 430 nm, and ethylenediaminetetraacetic acid (Merck) was 
added to remove Fe(III). Th  e  premodifi  ed antibody was purifi  ed by ultrafi  ltration with 0.9% 
sterile NaCl (B. Braun) and immediately used or stored at -80°C. Frozen N-SucDf-trastuzumab 
proved to be stable for at least 12 mo. In the second step, the conjugate was radiolabeled 
with clinical-grade 89Zr-oxalate (99.99% pure; BV Cyclotron, VU University Medical Center) in 
1 M N-2-hydroxyethylpiperazine N9-2-ethanesulfonic acid (HEPES, pH 6.8; Invitrogen) and 
purifi  ed by ultrafi  ltration with 0.9% NaCl:0.5% gentisic acid (Merck) to obtain a radiochemical 
purity of at least 95%. 89Zr-N-SucDftrastuzumab is hereaft  er referred to as 89Zr-trastuzumab.
111In-Trastuzumab Production
Conjugation and radiolabeling were performed as described by Ruegg et al. [17]. First, purifi  ed 
trastuzumab was conjugated in 0.1 M NaHCO3 (pH 8.4; Merck) with a 25-fold molar excess 
of the bifunctional chelate 2-(4-isothiocyanatobenzyl)-DTPA (p-SCNBn-DTPA; Macrocyclics). 
Unbound conjugate was removed by ultrafi  ltration with 0.15 M acetate buff  er (pH 5.5, freshly 
prepared  from ammonia and acetic acid, both obtained from Merck). Th  e conjugated 
antibody was immediately used or stored at -80 C. Frozen p-SCN-Bn-DTPA-trastuzumab 
proved to be stable for at least 12 mo. Conjugated trastuzumab was radiolabeled with 111InCl3 
(370 MBq/mL, >1.85 GBq/mg, 99.9% radionuclidic purity; Covidien) in 0.15 M acetate buff  er 
(pH 5.5), and the number of DTPA ligands per trastuzumab molecule was established as 
described by Hnatowich et al. [18]. To obtain a radiochemical purity of at least 95%, we purifi  ed 
111In-p-SCN-Bn-DTPA-trastuzumab by ultrafi  ltration with 0.15 M acetate buff  er. 111In-p-SCN-
Bn-DTPAtrastuzumab is hereaft  er referred to as 111In-trastuzumab.42
Quality Control of Premodifi  ed and Radiolabeled Trastuzumab
Radiochemical purity and stability were confi  rmed by SE-HPLC and by 30% trichloroacetic 
acid (TCA; Department of Hospital and Clinical Pharmacy, University Medical Center 
Groningen [UMCG]) precipitation for 89Zr-trastuzumab or thinlayer chromatography (TLC) 
for 111In-trastuzumab.
Th   e Waters SE-HPLC system was equipped with a dual-wavelength absorbance detector, an 
in-line radioactivity detector, and a size exclusion column (Superdex 200 10/300 GL; GE 
Healthcare). Sodium phosphate buff  er (0.025 M Na2HPO4 2H2O and NaH2PO4 H2O, both 
obtained from Sigma-Aldrich) was used as a mobile phase. Th   e retention time for trastuzumab 
was approximately 17 min; 89Zr-N-SucDf, 111In-DTPA, and low-molecular weight impurities 
eluted at 28 min (at a fl  ow of 0.7 mL/min).
TCA precipitation was performed with phosphate-buff  ered saline, 0.5% human serum albumin 
(Sanquin), and 30% TCA. Radioactivity was determined with a calibrated well-type g-counter 
(LKB 1282; Compugamma).
TLC was performed with silica-impregnated glass fi  ber sheets (TLC-SG, 2.5x10 cm; Pall 
Gelman Sciences), and 0.1 M citrate buff  er (pH 6.0) was used for elution. Radioactivity was 
determined  with an instant chromatography scanner (VCS-IOI; Veenstra Instruments) 
equipped with an NaI crystal.
Immunoreactive Fraction
Flow cytometry was performed with trastuzumab and a fl  uorescein  isothiocyanate-labeled 
antihuman antibody (F5016; Sigma-Aldrich) to confi   r m  H E R 2  e x p r e s s i o n  a s  d e s c r i b e d  
earlier [19]. Th  e in vitro binding characteristics (immunoreactive fraction) of radiolabeled 
trastuzumab were determined in a cell-binding assay, essentially as described by Lindmo et al. 
[20], with SKOV3 (a naturally HER2-overexpressing human ovarian cancer cell line) and GLC4 (a 
HER2-negative human small cell lung cancer cell line). SKOV3 cells were cultured in Dulbecco’s 
modifi  ed Eagle’s medium with a high glucose concentration, and GLC4 cells were cultured in 
RPMI 1640 medium, both with 10% fetal calf serum. SKOV3 cells were harvested with trypsin; 
GLC4 cells grow in suspension.
For the antigen-binding experiment, cells were collected, and a fi  xed amount of radioactivity 
( 1 0,000 cpm) was added to an increasing number of cells. Aft  er 1 h of incubation, the cell 
suspensions were centrifuged and repeatedly washed with phosphate buff  ered  saline 
containing 0.5% human serum albumin to determine the radioactivity uptake. Th  e specifi  c 
binding was calculated as the ratio of cell-bound radioactivity to the total amount of applied 
radioactivity and was corrected for nonspecifi  c binding, as determined with a 500-fold excess 
of nonradioactive trastuzumab. All binding assays were performed in triplicate.
Stability Testing of Radiolabeled Compounds
Th   e stability of the labeled compounds was evaluated at 4°C in solution (0.9% NaCl:0.5% gentisic 
acid or ammonium acetate [pH 5.5] for 89Zr-trastuzumab and 111In-trastuzumab, respectively) 
and in human serum at 37°C for 7 d. Th  e radiochemical purity and the immunoreactive 
fraction were determined by SE-HPLC, TLC, or TCA precipitation and the assay described by 
Lindmo et al. [20].3  DEVELOPMENT AND CHARACTERIZATION OF CLINICAL-GRADE 89ZR-TRASTUZUMAB
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In Vivo Biodistribution Studies
An animal study was conducted to assess the minimal dose of trastuzumab required for 
optimal imaging, to determine HER2-specifi  c tumor uptake, and to compare 89Zr-trastuzumab 
and  111In-trastuzumab biodistributions in mice bearing human ovarian carcinoma SKOV3 
(HER2-positive) or human small cell lung carcinoma GLC4 (HER2-negative) xenograft  s. Male 
athymic mice (Hsd:Athymic Nude/nu ) were obtained from Harlan. All animal studies 
were conducted in accordance with the Dutch Law on Animal Experimentation and were 
approved by the local ethics committee. At 4-6 wk of age (weight, 30 g), the mice were 
injected subcutaneously with 106 tumor cells (mixed with equal amounts of Matrigel [Becton 
Dickinson]). Approximately 2 wk aft  er inoculation, animals were used for the in vivo studies 
(tumor diameters, 5-8 mm).
Protein Dose Escalation Study
Before a larger biodistribution study was carried out, a protein dose escalation study was 
performed to determine the minimal dose of trastuzumab required for optimal imaging. 
SKOV3 xenograft  bearing nude mice (5 per group) were injected intravenously in the penile vein 
with 5 MBq of 89Zr-trastuzumab, corresponding to a total amount of 100, 250, or 500 μg of 
trastuzumab per animal. At 1, 3, and 6 d aft  er injection, animals were anesthetized with 2% 
isofl  urane and underwent small-animal PET imaging (Focus 220 microPET scanner; Siemens) 
in the transaxial position for 30-60 min. A transmission scan with a 57Co point source was 
used for scatter and attenuation corrections. Images were reconstructed in the 2-dimensional 
ordered-subset expectation maximization mode with 4 iterations by use of microPET manager 
(Siemens). Th   e voxel size of the images was 0.47 x 0.47 x 0.82 mm, and a gaussian fi  lter of 1.2 mm 
was applied to the images aft  er reconstruction.
In vivo quantifi  cation was performed with AMIDE Medical Image Data Examiner soft  ware 
(version 0.9.1; Stanford University) [21]. Th   e accumulation of radioactivity in tumors and a 
representative subset of the tumor volume were determined by drawing an 80% isodensity 
contour volume of interest around the tumor on the small-animal PET images as previously 
described [22]. Th  e  total injected dose was calculated by decay correction of the activity 
present in the animal at 24 h aft  er injection, at which time the clearance of the injected 
antibodies was considered to be almost negligible, as described earlier [23]. Th  e data are 
presented as the percentage injected dose per gram (% ID/g) of tissue, with the assumption of 
a tissue density of 1 g/cm3.
Aft  er the scan on day 6, the animals were sacrifi  ced and dissected to confi  rm the noninvasive 
small-animal PET data. Th  e radioactivity in dissected tissues was counted in a well-type 
g-counter. All data were corrected for physical decay and compared with known standards. 
Tissue radioactivity was expressed as % ID/g and as a ratio of tumor to normal tissue (T/NT 
ratio).
Comparative Biodistribution Study of 89Zr-Trastuzumab and 111In-Trastuzumab
Once the minimal required trastuzumab dose had been determined in the protein dose 
escalation study, a comparative biodistribution study was performed. Th  e aims of this 
study were to validate HER2-specifi  c tumor uptake and to compare the tumor accumulation 44
and organ biodistribution of 89Zr-trastuzumab with those of 111In-trastuzumab. Mice bearing 
SKOV3 (n=5) or GLC4 (n=4) xenograft  s were coinjected with 1:1 89Zr-trastuzumab and 111In-
trastuzumab (100 μg of trastuzumab, 1 MBq each). Th  e  animals were sacrifi  ced and dissected 
at days 1, 3, and 6, and the radioactivity in tissues was determined and expressed as % ID/g and 
as T/NT ratios.
Immunohistochemistry
Xenograft    H E R 2  e x p r e s s i o n  w a s  c o n fi   rmed by immunohistochemistry. Formalin-fi   xed, 
paraffi   n-embedded  tumors  were  stained with antibodies against HER2 (HercepTest; 
DAKO).  Immunohistochemical results were scored semiquantitatively in accordance with 
the guidelines developed by the American Society of Clinical Oncology and the College of 
American Pathologists for clinical testing. In short, a 4-tier system was used: 0 corresponded 
to no staining; 1+ corresponded to weak and incomplete staining; 2+ corresponded to weak 
to moderate complete staining; and 3+ corresponded to strong, complete circumferential, 
membranous staining [24]. Th   e slides were scored by a pathologist.
Statistical Analysis
Data are presented as mean ± SEM. Statistical analysis was performed with the nonparametric 
Mann-Whitney test (SPSS version 14.0; SPSS Inc.). P values of less than 0.05 were considered 
signifi  cant. Th   e agreement between the quantifi  ed in vivo small-animal PET images and the 
ex vivo biodistribution data was estimated by Bland-Altman analysis [25].
Results
Trastuzumab Conjugation, Radiolabeling, and Quality Control
Trastuzumab was premodifi  ed with either N-SucDf or p-SCN-Bn-DTPA. Th  e number of 
chelating groups per antibody was estimated to be 1.3 for N-SucDf and 1.9 for p-SCN-Bn-
DTPA. Th  e radiolabeling effi   ciency for  89Zrtrastuzumab was 77.6% ± 3.9% (n=3), and 
the radiochemical purity aft  er ultrafi  ltration was 98.1% ± 1.1% (n=3). Th  e radiolabeling 
effi   ciency for 111In-trastuzumab was 89.3% ± 2.1% (n=3), and the radiochemical purity was 
97% ± 1% (n=3). Th   e obtained specifi  c activities were 67.2 ± 2.4 MBq/mg (n=3) for 89Zr-
trastuzumab and 78.2 ± 3.1 MBq/mg (n=3) for 111In-trastuzumab. SE-HPLC analysis 
(column recovery, .95%; data not shown) of both radiopharmaceuticals revealed no aggregates, 
fragments, or radioactive impurities. 89Zr-trastuzumab and 111In-trastuzumab proved to be 
sterile and endotoxin free. 
Immunoreactive Fraction 
Flow cytometry confi  rmed a high level of HER2 expression for SKOV3 (760 ± 59 events) and 
a low level of receptor expression for GLC4 (38 ± 1 events). Th  e  maintenance of the in vitro 
binding characteristics of 89Zrtrastuzumab and 111In-trastuzumab was determined with 
the cell-binding assay described by Lindmo et al. [20]. Th  e  immunoreactive fraction of 89Zr-
trastuzumab was 0.87, and that of 111In-trastuzumab was 0.85. Nonspecifi  c cellular binding 
was less than 0.10 and was comparable to the binding of the radiopharmaceutical to GLC4.3  DEVELOPMENT AND CHARACTERIZATION OF CLINICAL-GRADE 89ZR-TRASTUZUMAB
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Figure 1. Exampels of noninvasive small-animal PET images (dorsal presenta   on). 89Zr-trastuzumab (5 MBq 
per mouse) uptake in human SKOV-3 xenogra   s in 3 mice at 6 h (A), day 1 (B), and day 6 (C, metastasized 
tumor) a   er injec   on is shown. Primary tumors are indicated by arrows.
Stability Testing of Radiolabeled Compounds 
89Zr-trastuzumab appeared to be stable, with mean decreases in radiochemical purity of 
only 0.07% ± 0.03% in solvent at 4°C and 0.39% ± 0.02% in human serum at 37°C per day. 
Th  e immunoreactive fraction was determined directly aft  er labeling and decreased only 
marginally with storage in solvent at 4°C (from 0.87 to 0.85 ± 0.06) and in human serum at 
37°C (from 0.87 to 0.78 ± 0.01) for up to 7 d.
111I n - t r a s t u z u m a b  a l s o  a p p e a r e d  t o  b e  s t a b l e ,  w i t h  m i n i m a l  d e c r e a s e s  i n  p r o t e i n - b o u n d  
radioactivity of 0.09% ± 0.14% in solvent at 4°C and 0.39% ± 0.53% in human serum at 37°C 
per day. Th   e immunoreactive fraction decreased only slightly with storage in solvent at 4°C 
(from 0.85 to 0.75 ± 0.04) and in human serum at 37°C (from 0.85 to 0.78 ± 0.08) aft  er 7 d.
In Vivo Biodistribution Studies
In the protein dose escalation study, small-animal PET imaging revealed excellent tumor 
uptake in all 15 mice. Tumor uptake could already be demonstrated as early as 6 h aft  er 89Zr-
trastuzumab injection, although blood-pool activity was dominant at this time point (fi  gure 
1A). From day 1 to day 6, tumor uptake signifi  cantly increased, whereas blood-pool activity 
decreased (fi  gure 1B). Interestingly, HER2-positive metastases, which could be detected 
easily (fi  gure 1C), spontaneously developed in one mouse, even though some metastases were 
as small as the spatial resolution of the small-animal PET camera (as confi  rmed by dissection 
of the animal and pathology). Ex vivo biodistribution data from the protein dose escalation 
study revealed high tumor uptake (30-33% ID/g) (fi  gure 2) and excellent tumor-to-blood 
(T/B) and T/NT ratios 6 d aft  er injection. Th   e maximal T/B ratio for animals that received 100 
μg of protein was 7.6. Only the liver and the spleen showed slightly higher radioactivity uptake 46
than other organs with a large blood supply; the maximal uptake in the liver and the spleen 
was 9% ID/g. Th   e accumulation of radioactivity in the muscle and the brain was negligible 
(<1% ID/g), resulting in high T/NT ratios.
As shown in fi  gure 2, there appeared to be a statistically signifi  cant diff  erence in radioactivity 
uptake in the blood and several tissues with a large blood supply (including the heart, kidneys, 
pancreas, spleen, and muscle). Tumor uptake was not signifi  cantly diff  erent at the 3 trastuzumab 
doses (P=0.75). Th   e T/B ratios decreased with increasing doses of trastuzumab (7.3, 5.3, and 4.7, 
respectively) but did not diff  er signifi  cantly at the 3 applied doses (P≥0.47). Th  e  tumor-to-liver 
(T/L) ratios varied slightly but not signifi  cantly at the 3 doses (being 3.3, 4.6, and 4.0, 
respectively; P≥0.18).
Overall, of the tested protein doses, the minimal dose of 100 μg of trastuzumab per animal 
(approximately 4 mg/kg) was considered to be optimal for imaging because it resulted 
in excellent tumor uptake and the highest T/B ratios and was therefore used in the 
comparative biodistribution study of 111In-trastuzumab and 89Zr-trastuzumab.
No apoptosis was noted during microscopic evaluation of the tumor tissue at a protein dose of 
100-500 μg.
According to the Bland-Altman analysis, all data were well within the limits of agreement 
and evenly distributed along the mean diff  erence, indicating similarities between the in vivo 
quantifi  ed small-animal PET data and the ex vivo biodistribution data.
Th  e comparative biodistribution study data for 89Zr-trastuzumab and 111In-trastuzumab in 
HER2-positive SKOV3 tumor-bearing mice and HER2-negative GLC4 tumor-bearing 
mice are shown in fi  gure 3. For clarity, only days 1 and 6 and the key organs are shown.
Figure 2. Ex vivo    ssue uptake of 100 (black), 250 (light gray), or 500 (dark gray) μg of protein 6 d a   er 
intravenous injec   on of 5 MBq of 89Zr-trastuzumab. Data are prsentend as %ID/g of    ssue (mean ± SEM for 
5 mice per group). Signiﬁ  cance is indicated (*P<0.05; **P<0.01).3  DEVELOPMENT AND CHARACTERIZATION OF CLINICAL-GRADE 89ZR-TRASTUZUMAB
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Figure 3. Ex vivo     ssue uptake a    er intravenous coinjec   on  of  89Zr-trastuzumab (black) and 111Zr-
trastuzumab (gray) (100 μg of trastuzumab, 2 MBq in total) at day 1 (A and C) and day 6 (B and D). Data 
are presented as %ID/g of tissue (mean ± SEM for 5 HER2/neu-positive mice and for 4 HER2/neu-negative 
mice per group). Signiﬁ  cance is indicated (*P<0.05; **P<0.01).
Th   e biodistribution data revealed signifi  cantly higher uptake of radioactivity in the HER2-
positive tumor than in the HER2-negative tumor. Uptake in the HER2-positive tumor 
could already be demonstrated at day 1 and proved to be similar for 89Zr-trastuzumab and 
111In-trastuzumab (19.3 ± 2.0% ID/g for 89Zr-trastuzumab and 17.7 ± 1.9% ID/g for 111In-
trastuzumab; P=0.47). Th  e  tumor uptake increased even further to day 6 (33.4 ± 7.6% ID/g 
for 89Zr-trastuzumab and 39.3 ± 9.5% ID/g for 111Intrastuzumab; P=0.47). In contrast, the 
uptake of radioactivity in the HER2-negative tumor was lower. At day 1, 89Zr-trastuzumab 
had accumulated to 15.7 ± 1.3% ID/g in the HER2-negative tumor, and 111In-trastuzumab 
had  accumulated to 15.0 ± 1.4% ID/g; there was no signifi  cant diff  erence between  89Zr-
trastuzumab tumor uptake and 111In-trastuzumab tumor uptake (P=0.56). At day 6, the 
accumulation had decreased to 7.1 ± 0.7% ID/g for 89Zrtrastuzumab and 6.8 ± 0.8% ID/g 
for 111In-trastuzumab (P=0.56).
At day 1, however, there was already a signifi  cant diff  erence in tumor uptake in the HER2-
positive tumor and the HER2-negative tumor (P=0.027 for 89Zrtrastuzumab and P=0.049 
for 111In-trastuzumab). At day 6, the radiopharmaceutical uptake in the HER2-negative tumor 
was signifi  cantly lower than that in the HER2-positive tumor (P=0.014 for both 89Zr-
trastuzumab and 111In-trastuzumab).48
Meanwhile, the percentage of radiolabeled trastuzumab circulating in the blood in mice 
with HER2-positive tumors declined from 20.4% ID/g for 89Zr-trastuzumab and 18.6% ID/g 
for 111In-trastuzumab at day 1 to 4.3 and 5.3% ID/g, respectively, at day 6. Because of the 
high tumor uptake and low tissue uptake, excellent T/B and T/NT ratios were achieved 
at day 6. Liver uptake was limited, and T/L ratios for both radiopharmaceuticals (5.2 for 
89Zrtrastuzumab and 7.3 for 111In-trastuzumab) were high and comparable to the data from 
the protein dose escalation study.
Th  e data obtained in the comparative biodistribution study of 89Zr-trastuzumab and 111In-
trastuzumab confi  rmed the data from the noninvasive small-animal PET images and were 
similar to the data from the protein dose escalation study at day 6.
Overall, there was no signifi  cant diff  erence in uptake. In contrast, there was a good correlation 
(R2=0.972) between 89Zr-trastuzumab uptake and 111In-trastuzumab uptake in tumors (fi  gure 
4).
Immunohistochemistry
Immunohistochemistry confi  rmed a high (3+) level of HER2 expression for the HER2-
positive SKOV3 tumor and a low (0-1+) level of receptor expression for the HER2-negative 
GLC4 tumor (data not shown).
Figure 4. Overall correla   on of ex vivo tumor uptake of 89Zr and 111In a   er intravenous coinjec   on 
of 89Zr-trastuzumab and 111In-trastuzumab (100 μg of trastuzumab, 2 MBq in total) at day 1, 3, and 6. 
Correla   on coeﬃ   cient (R2) was 0.972.
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Discussion
Th  e present study showed that 89Zr-trastuzumab could be radiolabeled effi   ciently,  with 
preservation of the antigen-binding capacity, and was stable for up to 7 d. A high level 
of HER2-driven tumor uptake of radiolabeled trastuzumab at excellent T/NT ratios was 
observed.  89Zrtrastuzumab showed a biodistribution similar to that of the control, 111In-
trastuzumab, at a spatial resolution unapproachable by SPECT. Produced according to 
GMP requirements, this radiopharmaceutical is applicable for clinical use.
Th   e tumor uptake of 89Zr-trastuzumab at 100 μg was similar to that at 500 μg, but the T/L 
ratio at 100 μg was lower than that at 500 μg. Th   is result may have been attributable to 
faster blood clearance, as animal studies have shown the rapid clearance of human IgG in 
nude mice with low endogenous IgG titers [26] – a phenomenon restricted to the nude-mouse 
model. Th  e  species-specifi  c IgG pharmacokinetics hamper the prediction of the trastuzumab 
dose required for optimal imaging in humans. Phenomena such as diff  erences in IgG clearance 
and metabolism, shedding of HER2, and tumor load will infl  uence pharmacokinetics 
in humans and imaging characteristics. A dose escalatio n study in patien ts is theref ore 
mandatory.
Compared with other radiopharmaceuticals developed for HER2 immunoPET, 124I-ICR12 
demonstrated reasonable and specifi  c uptake (12% ID/g at 120 h) in athymic mice bearing human 
HER2-overexpressing breast carcinoma xenograft  s [27]. Tumor uptake of ICR12 was further 
increased, to 20% ID/g, with residualizing isotopes [28,29]. Similar to what we observed in 
the present study, tumor uptake of ICR12 was not infl  uenced by the protein dose, but the 
T/B ratio decreased with an increasing amount of protein [30]. With the murine predecessor of 
trastuzumab (4D5), maximal tumor uptake was 35% [31,32], comparable to what we found.
89Zr is a relatively new, yet promising, long-lived PET isotope. 89Zr was considered to be 
a suitable isotope because it has a suffi   ciently long physical half-life (3.3 d) to match the 
relatively slow pharmacokinetics of an intact antibody, is well suited to being combined 
with an internalizing antibody, and can be used clinically [33]. Perk et al. [34] showed that 
89Zr-radiolabeled anti-epidermal growth factor receptor antibody cetuximab could accurately 
predict 177Lu and 88Y (as a substitute for 90Y) biodistributions. 89Zr-cetuximab therefore 
has the potential to be used as a scouting procedure in preparation for radioimmunotherapy, 
for confi  rming tumor targeting, and for estimating radiation dose delivery to both tumor 
and normal tissues [34]. Using 89Zr-radiolabeled bevacizumab (an anti-vascular endothelial 
growth factor mAb), our group reported specifi  c, vascular endothelial growth factor-related 
tumor uptake at 7 d aft  er injection in a preclinical study [23].
In the fi  rst clinical study with a 89Zr-radiolabeled mAb (89Zr-U36, a CD44v6 domain-binding 
chimeric IgG) immunoPET performed at least as well as CT or MRI for the detection of lymph 
node metastases in patients with squamous cell carcinoma of the head and neck [35]. 89Zr 
oxalate produced according to GMP has been commercially available since the end of 2008.
Clinical HER2 immunoscintigraphy has been performed with 99mTc-ICR12,  111In-
trastuzumab, and 89Zrtrastuzumab. In the early 1990s, the rat antibody 99mTcICR12 was 
administered to 8 breast cancer patients. 50
Tomographic images were obtained at 24 h. Th  e  study  indicated that 99mTc-ICR12 could 
be used for the imaging of HER2 overexpression [29], but no further clinical results with this 
rodent antibody have been published. In a preliminary report, Behr et al. suggested that 111In-
trastuzumab could predict the therapeutic effi   cacy of trastuzumab in 20 patients with HER2-
overexpressing metastatic breast cancer [36]. In a study of HER2-positive metastatic breast 
cancer patients, our group reported that 111In-trastuzumab scintigraphy revealed new tumor 
lesions in 13 of 15 patients and was therefore suggested to be of value for the clinical staging of 
HER2-positive metastatic breast cancer [15]. 
Unfortunately, no clinical studies of HER2 targeting of smaller proteins have been published.
HER2 immunoscintigraphy has many potential clinical applications [33], including improved 
diagnosis, guidance for targeted therapy [37,38], and early drug development. Th  erefore, 
larger studies to prove whether this imaging technique can indeed aff  ect clinical practice 
are of major interest [12].
Generally, large intact antibodies penetrate solid tumor tissue more slowly but constantly, 
ultimately resulting in a higher level of tumor accumulation, whereas small proteins (mAb 
fragments, minibodies, single-chain variable antibody fragments, diabodies, or affi   bodies) 
penetrate tumor tissue more swift  ly but show less tumor uptake because of their rapid blood 
clearance [12]. With 68Ga-trastuzumab F(ab)2 fragments, relatively good tumor uptake was 
obtained (12% ID/g), and the loss and recovery of HER2 induced by the HSP90 inhibitor 17-
AAG was quantifi  ed [37]. In a follow-up study, a reduction in 68Ga-F(ab)2trastuzumab tumor 
uptake predicted 17-AAG-induced tumor growth inhibition earlier than a reduction in 
18FFDG tumor uptake [38]. Divalent single-chain variable antibody fragment (scFv) tumor 
accumulation is limited to 2-3% ID/g (T/B ratio, 3-29); diabody and minibody tumor 
accumulation is approximately 6% ID/g (T/B ratio, 3-13) [12]. Affi   body experiments have 
shown promising results. With affi   bodies, excellent tumor uptake has been demonstrated 
(4.4-23% ID/g), especially when the size of the molecule is considered, and high T/B ratios 
(7-190) have been observed [12]. 
We have chosen to use the radiolabeled approved intact antibody trastuzumab instead of smaller 
proteins to determine HER2 expression. Th   e choice of a radiopharmaceutical for HER2 imaging 
should depend on the question to be answered. If only receptor expression is relevant for 
diagnostic purposes, then imaging can be performed with small proteins, allowing patients to 
be diagnosed in a single day. If evaluation (and response prediction) of trastuzumab therapy 
are desired, then radiolabeled intact antibodies, which most likely mimic drug behavior more 
accurately, are preferable.
89Zr-trastuzumab seems to be a valuable addition to the arsenal of radiolabeled intact antibodies 
that can be used in patients. It has a higher spatial resolution and a better signal-to-noise ratio 
than  111In-trastuzumab, and data quantifi  cation is  m o r e  s trai gh tf o rwar d.  Th  e preliminary 
results obtained with 89Zr-trastuzumab immunoPET in HER2-positive breast cancer patients 
indicated good radiopharmaceutical uptake by the tumor and excellent spatial resolution [39].3  DEVELOPMENT AND CHARACTERIZATION OF CLINICAL-GRADE 89ZR-TRASTUZUMAB
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Conclusion
Th   e present study showed that clinical-grade 89Zr-trastuzumab can be manufactured with 
high stability and maintenance of antigen binding. Th  e  fi  rst immunoPET radiopharmaceutical 
displayed excellent tumor accumulation, with high T/NT ratios and a biodistribution similar 
to that of 111In-trastuzumab (which was previously used successfully in a clinical study of 
metastatic breast cancer patients) at a signifi  cantly higher spatial resolution and with better T/
NT ratios. Th   ese data validate this radiopharmaceutical for further clinical testing.
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Abstract
We performed a feasibility study to determine the optimal dosage and time of administration of the 
monoclonal antibody zirconium-89 (89Zr)-trastuzumab to enable positron emission tomography 
(PET) imaging of human epidermal growth factor receptor 2 (HER2)-positive lesions. Fourteen 
patients with HER2-positive metastatic breast cancer received 37 MBq of 89Zr-trastuzumab at one 
of three doses (10 or 50 mg for those who were trastuzumab-naive and 10 mg for those who were 
already on trastuzumab treatment). Th   e patients underwent at least two PET scans between days 2 
and 5. Th   e results of the study showed that the best time for assessment of 89Zr-trastuzumab uptake 
by tumors was 4-5 days aft  er the injection. For optimal PET-scan results, trastuzumab-naive patients 
required a 50 mg dose of 89Zr-trastuzumab, and patients already on trastuzumab treatment required 
a 10 mg dose. Th   e accumulation of 89Zr-trastuzumab in lesions allowed PET imaging of most of the 
known lesions and some that had been undetected earlier. Th   e relative uptake values (RUVs) (mean 
± SEM) were 12.8 ± 5.8, 4.1 ± 1.6, and 3.5 ± 4.2 in liver, bone, and brain lesions, respectively, and 
5.9 ± 2.4, 2.8 ± 0.7, 4.0 ± 0.7, and 0.20 ± 0.1 in normal liver, spleen, kidneys, and brain tissue, respectively. 
PET scanning aft  er administration of 89Zr-trastuzumab at appropriate doses allows visualization 
and quantifi  cation of uptake in HER2-positive lesions in patients with metastatic breast cancer.56
Introduction
Human epidermal growth factor receptor 2 (HER2) is involved in cell survival, cell proliferation, 
cell maturation, metastasis, and angiogenesis, as well as exerting anti-apoptotic eff  ects [1]. 
Targeting of HER2 with the monoclonal antibody trastuzumab (Herceptin) is a well-established 
therapeutic strategy in the metastasized and adjuvant setting, and it has positively aff  ected the 
prognosis of patients with breast cancer characterized by HER2-protein overexpression and/or 
amplifi  cation [2,3].
HER2 status is routinely determined using immunohistochemistry or fl  uorescence in situ 
hybridization at the time of diagnosis of the primary tumor. However, there are data indicating 
that the HER2 status of a tumor can vary during the course of the disease [4]. In addition, there 
can be a discordance in HER2 expression across tumor lesions in the same patient [5-7]. Th  erefore, 
clinical guidelines encourage the use of repeated biopsies during the course of the disease [8,9]. 
Physicians and patients are nevertheless frequently reluctant to use this invasive technique; in 
addition, technical problems can arise when lesions are poorly accessible [10].
Noninvasive HER2 imaging using single-photon emission computed tomography (SPECT) 
and positron emission tomography (PET) could be a strategy to determine HER2 expression and 
localization of HER2-overexpressing tumor lesions, including inaccessible distant metastases. 
Th   is strategy, which could potentially guide HER2-targeted therapies, led to the development 
of 111In-trastuzumab. Using this SPECT tracer, we have shown HER2-specifi  c uptake in patients 
with HER2-positive metastatic breast cancer. 111In-trastuzumab imaging discovered new HER2-
positive lesions in 13 of 15 patients and was therefore considered to be of potential value as a clinical 
diagnostic tool in metastatic disease [11]. It was only aft  er our 111In-trastuzumab clinical study 
was completed that the long-lived PET isotope zirconium-89 (89Zr) became available for clinical 
immunoPET imaging with 89Zr-labeled antibodies [12]. For immunoPET imaging, positron-
emitting radiometals such as 89Zr have an advantage over radiohalogens such as 124I because 
they are residualizing and are therefore retained within the target cell aft  er internalization and 
intracellular degradation of the tracer. 
Th   is results in higher uptake in the tumor when an internalized antibody such as trastuzumab 
is  used  [ 7 ] .  Of  th e  po s i tr o n -e mi ttin g  radiometals, 89Zr has the longest and therefore most 
favorable half-life (78.4 h), allowing antibody imaging up to 7 days aft  er the injection. Preclinical 
evaluation of 89Zr-trastuzumab showed that it displays superior image quality as compared to 
111In-trastuzumab, given the high spatial resolution and sensitivity of PET, although the uptake 
levels of 89Zr-trastuzumab and 111In-trastuzumab in the tumors were equivalent [13]. In addition, 
PET imaging has the advantage of allowing straightforward data quantifi  cation and whole-body 
3D imaging. In view of these advantages, we performed this clinical study using 89Zr-trastuzumab 
PET.
In this clinical study, we evaluated the optimal conditions for the administration of 89Zr-
trastuzumab to enable PET visualization and quantifi  cation of HER2-positive lesions in patients 
with HER2-positive metastatic breast cancer. We did this by comparing three relevant doses at 
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Methods
Patients. In this prospective imaging feasibility study in female patients with metastatic breast 
cancer, the eligibility criteria were (i) proven HER2-positive tumor at diagnosis (as confi  rmed 
by immunohistochemistry or fl  uorescence in situ hybridization), (ii) at least one tumor lesion 
in situ at the time of inclusion, and (iii) age ≥18 years. Available standard staging procedures with 
conventional imaging such as radiography, CT, MRI, and bone scans were used for comparison. 
No standard CT or MRI scans of the brain were performed, except when there were neurological 
symptoms or suspicion of brain metastases, or where 89Zr-trastuzumab uptake in the brain was 
seen on the PET scan. Exclusion criteria were (i) pregnancy, (ii) uncontrolled concurrent illness, 
and (iii) treatment with antibodies other than trastuzumab. Th   e study was approved by the medical 
ethical committee of the University Medical Center Groningen, and written informed consent was 
obtained from all patients.
Tracer and Protein Dose 
Clinical grade 89Zr-trastuzumab was produced as described previously [13]. In short, reconstituted 
trastuzumab (Roche, Woerden, Th  e Netherlands) was conjugated with tetrafl  uorophenol-N-
succinyldesferal-Fe (VU University Medical Center, Amsterdam, Th  e Netherlands), purifi  ed, 
a n d  s t o r e d  a t  - 8 0 ° C .  G o o d  m a n u f a c t u r i n g  p r a c t i c e - p r o d u c e d  89Zr-oxalate (IBA Molecular 
Benelux, Louvain-La-Neuve, Belgium) was used for radiolabeling the conjugate. Quality control was 
performed to ensure (radio)chemical purity (>95%), antigen-binding capacity (>80%), and stability.
Patients received 37MBq (1 mCi) 89Zr-trastuzumab intravenously and were monitored for 30 min 
aft  er the injection to detect any infusion related anaphylactic reactions or adverse events.
To determine the minimal required trastuzumab dose, three cohorts of 89Zr-trastuzumab protein 
dose were used: 10 mg (cohort 1) and 50 mg (cohort 2) in those who were trastuzumab-naive and 
10 mg (cohort 3) for those already on trastuzumab treatment. Each of these doses consisted 
of  89Zr-trastuzumab (~1.5 mg), replenished with nonradioactive trastuzumab. Patients on 
trastuzumab treatment had been receiving up to 6 mg/kg and therefore might already have had a 
signifi  cant amount of trastuzumab in their systems at the time of tracer injection (as is shown in 
Supplementary Table S1 online, the trastuzumab range was 130-675 mg).
We aimed to recruit a maximum of fi  ve to seven patients per cohort. Each cohort was evaluated 
aft  er data from two patients became available. If this evaluation indicated that the trastuzumab dose 
was insuffi   cient for adequate imaging, the cohort was closed.
PET Imaging, Biodistribution, and Quantifi  cation
Each patient underwent at least one PET scan at an early time (1-3 days aft  er injection) and one 
at a later time (4-7 days aft  er injection). Images were obtained using a Siemens Exact HR+ 
PET camera (Siemens AG, Munich, Germany). Acquisition was carried out in 3D mode from 
upper thigh to head, in seven or eight bed positions with 9-12 min of imaging (including 20-22% 
transmission time) per bed position. PET images were reconstructed using the ordered-subsets 
expectation maximization algorithm, with two iterations and eight subsets. Th  e  biodistribution 
of (radiolabeled) antibodies is slow (T½ of days). It was therefore expected that the biodistribution 
during the timeframe of the PET scan would not be a relevant factor. A single frame was acquired 58
to obtain maximal counting statistics and the best image quality. Th  e PET scans were visually 
examined, and 89Zr-trastuzumab distribution was assessed in accordance with the protocol for 
blood pool, liver, spleen, kidneys, bone marrow, and intestines. Th  e number of metastases was 
determined.
Quantifi  cation of 89Zr-trastuzumab distribution was performed using AMIDE soft  -ware (version 
0.9.1; Stanford University, Palo Alto, CA).28 Instead of the frequently used standardized uptake 
value, we used a modifi  ed parameter, RUV, to provide a semiquantitative representation of the 
tissue-to-background ratio. RUV is related to the amount of tracer present in the body at the 
moment of scan acquisition, whereas standardized uptake value is related to the amount of tracer 
injected. RUV is independent of the rate of excretion of the 89Zr-trastuzumab tracer and can 
therefore be used to quantify uptake for a period of days aft  er the injection. For calculating RUV, 
we used the whole-body mean uptake (WBmean) value based on the radioactivity within the fi  eld 
of view (rather than on the radioactivity within the region of interest, which is used in arriving 
at standardized uptake value). Th  e  RUVmean was calculated as the ratio of mean tissue uptake to 
mean whole-body uptake for each scan:
RUVmean =
Tissuemean,scanX
=
Tissuemean,scanX
WBmean,scanX AWB,scanX/VWB,scanX
Th   e mean tissue uptake (Tissuemean) was determined by manually drawing a volume of interest 
in metastatic lesions and in normal tissues (heart, liver, spleen, kidneys, bone, and brain) and 
measuring the mean radioactivity in the volume of interest for all tumor lesions and tissues. 
Th  e  WBmean was calculated by dividing total radioactivity in the fi  eld of view (AWB) by the volume 
represented within the fi  eld of view (VWB). Th  e RUVmax was calculated by dividing the uptake 
in tissues in the most intense voxel of the volume of interest by WB mean. Th  e blood pool 89Zr-
trastuzumab activity was calculated for the fi  rst 5 days aft  er injection by interpolating the volume 
of interest RUVs of each patient’s cardiac blood pool into an exponential fi  tting model.
Statistics 
Data are presented as means ± SD. Statistical analysis was performed using the nonparametric 
Mann-Whitney U-test (Graphpad Prism 5; Graphpad Soft  ware, La Jolla, CA). P values <0.05 
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Results
Patient Characteristics
Between March 2006 and December 2008, 14 patients were enrolled in the study. Patient 
characteristics are presented in table 1. Th   e patients received 38.4 ± 1.6 MBq 89Zr-trastuzumab. 
No infusion-related reactions or adverse events were noticed during the study. Supplementary 
Table S1 online provides study details for individual patients, including the trastuzumab dose 
calculated for patients already on trastuzumab, the number of scans carried out and their timing, 
and the biodistribution of 89Zr-trastuzumab and its uptake in lesions.
Table 1. Pa   ent characteris   cs.
CharacterisƟ  c
Number of pa   ents 14
Age (years)
Median 48
Range 32-74
Body weight (kg)
Median 72
Range 47-97
89Zr-trastuzumab dose (n)
10 mg 89Zr-trastuzumab 2
50 mg 89Zr-trastuzumab 5
10 mg 89Zr-trastuzumab + trastuzumab therapy 7
89Zr, zirconium-89.
Trastuzumab Dose for 89Zr-trastuzumab PET Imaging 
Th   e 10 mg trastuzumab dose in cohort 1 (n=2) resulted in a relatively high uptake in the liver 
and a pronounced intestinal excretion of 89Zr-trastuzumab. As a result, the amount of 89Zr-
trastuzumab in the blood pool was limited in these trastuzumab-naive patients (fi  gure 1a). 
Probably because rapid hepatic clearance prohibited optimal uptake of 89Zr-trastuzumab in the 
tumors, the lesions could be visualized in only one of these two patients. We concluded that 10 
mg trastuzumab was not suffi   cient for adequate imaging in trastuzumab-naive patients, and this 
cohort was therefore closed.
Th  e 50 mg trastuzumab dose in cohort 2 (n=5) resulted in less uptake in the liver and lower 
subsequent intestinal excretion as compared with patients in cohort 1. 89Zr-trastuzumab was 
present in the blood pool during the scan sequence in all fi  ve patients (fi  gure 1b), indicating 
retarded blood pool clearance. Visual analysis revealed good tumor/non-tumor ratios in this 
cohort. Th   erefore, 50 mg trastuzumab was considered to have a favorable biodistribution and to 
be adequate for HER2 PET imaging in trastuzumab-naive patients.60
In the patients in cohort 3, who were already on trastuzumab (n=7), a 10 mg dose of trastuzumab 
resulted in minimal intestinal excretion and slow 89Zr-trastuzumab blood clearance (fi  gure 1c); 10 
mg was therefore considered an adequate dose for patients already on trastuzumab therapy.
Dose-dependent blood clearance of 89Zr-trastuzumab seen in the visual analysis was confi  rmed 
by quantitative analysis of 89Zr-trastuzumab presence in the cardiac blood pool. Figure 1d shows 
the quantitative PET analysis of the relative blood pool activity levels of 89Zr-trastuzumab as fi  tted 
curves for 5 days aft  er injection in all three cohorts. Th   e curve is lowest for cohort 1 and shows 
little change during the 5-day period, indicating rapid blood pool clearance within the fi  rst 24 
h. Patients in cohorts 2 and 3 show a much higher relative blood pool activity, indicating slow 
clearance of 89Zr-trastuzumab from the blood pool.
Interval Between Tracer Injection and PET Scan
Except in the 10 mg dose group (cohort 1), extensive 89Zr-trastuzumab activity was still 
present in the blood pool 1-2 days aft  er the injection, even while uptake was observed in liver, 
spleen, and kidneys. At 4-5 days aft  er the injection, 89Zr-trastuzumab activity in the blood 
pool was lower, and uptake in tumors had increased. Th   is is illustrated by means of the scans 
obtained from a patient already on trastuzumab treatment (fi  gure 2a-c). Th  is representative 
patient showed a slight decrease in blood pool tracer activity and marked 89Zr-trastuzumab 
accumulation in the brain metastasis over time. Scans performed at day 6 or 7 aft  er the injection 
yielded decreased image quality because of insuffi   cient counting statistics. Th   e optimal time for 
the scan represents a balance between good tumor/non-tumor ratios and suffi   cient radioactive 
signal. Th   e best time for assessing uptake of 89Zr-trastuzumab in tumor lesions was found to be 4-5 
days aft  er the injection of 37MBq 89Zr-trastuzumab.
Figure 1. Dose-dependent 89Zr-trastuzumab biodistribu   on. (a-c) Dose-dependent biodistribu   on and 
blood clearance of 89Zr-trastuzumab, the blood pool and intes   nal excre   on are indicated by arrows. (d) 
The “rela   ve blood pool ac   vity” represents the amount of 89Zr-trastuzumab blood pool rela   ve to the 
total amount of 89Zr-trastuzumab present during 5 days a   er the injec   on. 89Zr, zirconium-89.4A  BIODISTRIBUTION OF 89ZR-TRASTUZUMAB AND PET IMAGING OF HER2-POSITIVE LESIONS 
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Figure 2. 89Zr-trastuzumab biodistribu   on in    me. (a-c) Three 89Zr-trastuzumab scans of a pa   ent 
already on trastuzumab treatment (cohort 3) show the increase over    me in the tumor/nontumor 
ra   o as regards uptake of the tracer. Arrow indicates 89Zr-trastuzumab uptake in the only lesion. 
89Zr, zirconium-89.
Visual Analysis and Quantifi  cation of 89Zr-trastuzumab Uptake
At visual examination, the spatial resolution and signal/noise ratios of the 89Zr-trastuzumab PET 
scans were superior to those from our previous 111In-trastuzumab SPECT study [11].
Visual analysis of the PET scans revealed 89Zr-trastuzumab biodistribution to liver, spleen, and 
kidney. Th   is is in accordance with what was expected for these well-perfused organs. Th  e  89Zr-
trastuzumab uptake in other non-tumor tissues (e.g., lung, muscle, bone, and brain) was low.
In cohort 1, one of the two trastuzumab-naive patients showed accumulation of 89Zr-trastuzumab in 
skin and liver metastases. In both cohort 2 and cohort 3, the majority of the lesions previously 
identifi  ed in the patients by computed tomography (CT), magnetic resonance imaging (MRI), 
or bone scans could also be seen on the 89Zr-trastuzumab PET scan. Visually, no diff  erence 
was evident between cohorts 2 and 3 with respect to the uptake of 89Zr-trastuzumab in tumor 
lesions. We anticipated that, because cohorts 2 and 3 would have suffi   cient 89Zr-trastuzumab in 
the circulation (in contrast to cohort 1), there would be suffi   cient 89Zr-trastuzumab available for 
accumulation in the tumors in these two cohorts. In addition, because the relative uptake values 
(RUVs) for these two cohorts were very similar (as shown in Supplementary Table S1 online), the 
cohorts’ data pertaining to uptake of 89Zr-trastuzumab in tumors were pooled (n=12).
In 6 of these 12 patients, 89Zr-trastuzumab PET did not detect all the known lesions. Known 
liver lesions were visualized by 89Zr-trastuzumab in four of seven patients. No uptake of 89Zr-
trastuzumab took place in liver lesions in two of the patients in cohort 2 and one patient in cohort 
3. Figure 3a, an image from a representative patient with liver and bone metastases as revealed by 62
CT and bone scan, shows a clear distinction between normal and pathological 89Zr-trastuzumab 
uptake in the liver on the day-5 scan. 89Zr-trastuzumab PET did not reveal any liver lesions.
Figure 3. Examples of 89Zr-trastuzumab uptake 5 days a   er the injec   on. (a) A pa   ent with liver and bone 
metastases, and (b and c) two pa   ents with mul   ple bone metastases. A number of lesions have been 
speciﬁ  cally indicated by arrows. See Supplementary Movies S1 and S2 online for rota   ng 3D projec   ons 
of a and c. 89Zr, zirconium-89
At the time of the tracer injection, one of the patients with known liver metastases had been 
receiving trastuzumab treatment for 2 months. A CT scan performed directly aft  er the PET scan 
(following 89Zr-trastuzumab administration) showed a partial tumor response. Th  is  response, 
probably associated with tumor cell apoptosis and receptor occupation and/or internalization, 
might explain the negative results of the 89Zr-trastuzumab PET scan.
Multiple bone lesions, noted on bone scans, CT, or MRI, were visualized by 89Zr-trastuzumab PET 
in seven of nine patients. Th   e two patients in whom the bone lesions did not show uptake of 89Zr-
trastuzumab were in cohort 3. Representative examples of 89Zr-trastuzumab uptake in bone 
lesions are shown in fi  gure 3a-c (fi  gure 3a and c are also available online as rotating 3D projections; 
see Supplementary Movies S1 and S2 online). Th  e various bone lesions in the two patients are 
shown in the 89Zr-trastuzumab PET scans and were in good agreement with 99mTc-HDP bone 
scans. Figure 4a shows the 89Zr-trastuzumab uptake in a vertebral metastasis detected earlier 
by MRI. Bone lesions that had not been detected by other scans were discovered by PET scan in 
one patient in cohort 2. In three patients, brain metastases were visualized by 89Zr-trastuzumab 
PET. In one patient (from cohort 2) with two brain lesions as seen on MRI, the PET scan showed 
89Zr-trastuzumab accumulation in one of the metastases (measuring 2.0 × 1.6 cm on MRI); the 
other tumor lesion (measuring 0.5 × 0.5 cm on MRI) did not show up in the PET scan. In two 
other patients (one each in cohorts 2 and 3), 89Zr-trastuzumab PET imaging revealed previously 
undetected brain metastases, both subsequently confi  rmed by MRI (fi  gure 4b). Th  e  smallest 
brain lesion revealed by 89Zr-trastuzumab PET imaging measured 0.7 × 0.7 cm on MRI.4A  BIODISTRIBUTION OF 89ZR-TRASTUZUMAB AND PET IMAGING OF HER2-POSITIVE LESIONS 
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Figure 4. Examples of fusion images from HER2 PET and MRI scans. (a) In a vertebral metastasis seen on 
MRI but unapproachable for biopsy, HER2 status was revealed by 89Zr-trastuzumab uptake on PET imaging. 
(b) Example of HER2-posi   ve brain lesion undetected by conven   onal scans, revealed by 89Zr-trastuzumab 
PET imaging, and subsequently conﬁ  rmed by MRI. Arrows indicate lesions. HER2, human epidermal growth 
factor receptor 2; MRI, magne   c resonance imaging; PET, positron emission tomography; 89Zr, zirconium-89.
Uptake of 89Zr-trastuzumab in metastatic lesions was seen in one of the three patients (all in 
cohort 3) with known lung metastases.
No lymph node metastases were detected during physical examina ti o n ,  CT ,  MRI ,  o r  89Zr-
trastuzumab PET scans.
Th   e uptake of 89Zr-trastuzumab in metastatic lesions and normal tissue was quantifi  ed as RUVmean. 
Th   e uptake in metastatic lesions was also quantifi  ed as RUVmax; this showed an excellent correlation 
(R2=0.974; slope 1.36) between RUVmean and RUVmax, indicating a homogeneous uptake within the 
lesions. Liver lesions displayed the highest level of uptake (12.8 ± 5.8), higher than that of normal 
liver (5.9 ± 2.4, P=0.0070) or that of any other normal tissue (fi  gure 5). Uptake in brain lesions 
was higher than in normal brain tissue (3.5 ± 4.2 vs. 0.20 ± 0.1, P=0.0127), although there was a 
relatively large variation in uptake values between types of lesions. 89Zr-trastuzumab RUVmean in 
bone lesions was 4.1 ± 1.6. Th   e uptake for normal bone was too low to be quantifi  ed. Th  e  RUVmean 
of the only lung lesion was 4.3.64
Figure 5. Rela   ve uptake values (RUVs) are quan   ﬁ  ed for metasta   c lesions and for normal liver, spleen, 
kidney, and brain. RUVs shown here are from the later-   me scans.
Discussion
Th  is  fi  rst-in-human 89Zr-trastuzumab HER2 PET imaging study showed excellent tumor uptake 
and visualization of HER2-positive metastatic liver, lung, bone, and even brain tumor lesions, 
when an adequate trastuzumab protein dose was administered. In trastuzumab-naive patients 
with HER2-positive metastatic breast cancer, 50 mg of trastuzumab was the dose that resulted 
in optimal biodistribution characteristics under the test conditions and proved adequate for 
89Zr-trastuzumab PET imaging. Th   e 50 mg trastuzumab dose in naive patients is a good starting 
point for further optimization in future studies.
In  p a ti e n ts  un d e r g o in g  tr ea tm e n t  wi th  trastuzumab  a t  th e  tim e  o f  tra ce r  in j ecti o n ,  1 0  m g 
trastuzumab was adequate for PET imaging. Higher doses of trastuzumab were not expected 
to improve 89Zr-trastuzumab PET imaging; trastuzumab clearance was already minimal, 
and therefore a further increase in the dose of trastuzumab could induce target saturation. 
Quantifi  cation of the PET images confi  rmed the dose-dependency of trastuzumab clearance and 
revealed a signifi  cantly higher uptake in metastatic tumor lesions as compared to corresponding 
normal tissue. In this study, 89Zr-trastuzumab allowed the researchers to distinguish between 
lesions with HER2 overexpression and those without. Th  e exact amount of HER2 expression 
required for adequate imaging will have to be determined in a future biopsy-aligned study.
Th  e  rapid  89Zr-trastuzumab clearance, as seen with a 10 mg dose administered to trastuzumab-
naive patients in cohort 1, is in accordance with trastuzumab pharma-cokinetic data from phase 
I studies [14,15]. Aft  er multiple doses at therapeutic concentrations, trastuzumab clearance 4A  BIODISTRIBUTION OF 89ZR-TRASTUZUMAB AND PET IMAGING OF HER2-POSITIVE LESIONS 
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has an average terminal half-life of 28.5 days at steady state [16]. However, when given as a single 
dose of 10 or 50 mg, trastuzumab is known to have an average terminal half-life of 1.5 or 4.3 days, 
respectively [14]. Th   is short-terminal half-life is probably too brief to allow adequate accumulation 
of the tracer in the tumors and subsequent imaging when 10 mg of the tracer is used in 89Zr-
trastuzumab-naive patients. Th   is analysis is supported by the presence of 89Zr in the intestinal tract 
in patients in cohort 1.
Dose-dependent pharmacokinetics has also been shown to hold good for the trastuzumab-DM1 
antibody-drug conjugate and for the HER2 antibody pertuzumab [17,18]. Th   e exact mechanisms 
underlying these dose-dependent pharmacokinetics of HER2-targeted antibodies are not 
known, but they probably involve rapid but saturable elimination of low doses from the fi  rst 
compartment of distribution, i.e., the circulation, during the fi  rst elimination phase. Elimination 
of trastuzumab is characterized by two phases; a fi  rst phase with a half-life of approximately 4 
days, followed by a second phase that starts ~1 week aft  er infusion, with a much longer half-life 
[19]. Saturable elimination in the fi  rst phase is probably caused by antibody catabolism followed 
by excretion of the catabolites. A second mechanism that can play a role in increasing 89Zr-
trastuzumab clearance in trastuzumab-naive patients is the presence of high plasma levels of 
extracellular domains shed by HER2 [16]. Aft  er the binding of trastuzumab to these extracellular 
domains, this complex is cleared by the liver and excreted in the intestines.
Th  e  administered  89Zr dose of 37MBq proved to be suffi   cient for adequate imaging up to 5 days 
aft  er the injection. Because of the balance between the relatively slow accumulation of trastuzumab 
in the tumors and the radioactive decay of 89Zr, a suitable time for assessing 89Zr-trastuzumab 
tumor uptake was found to be 4-5 days aft  er the injection. Th   e PET images produced with 89Zr-
trastuzumab showed high spatial resolution and good signal-to-noise ratio, resulting in an image 
quality unapproachable by our previous 111In-trastuzumab SPECT scans [11,20]. As compared to 
the 75MBq used in the only earlier clinical study with 89Zr, the 37MBq used in the present study 
resulted in a lower radiation dose to the patient while preserving image quality [12]. On the basis of 
the previous 111In-trastuzumab study (aft  er substituting nuclide properties) the 89Zr-trastuzumab 
radiation dose was estimated at 18 mSv, comparable to two abdominal CT scans [21].
Although our study was not designed for head-to-head comparison with conventional staging 
modalities or for assessing sensitivity and specifi  city, lesions with 89Zr-trastuzumab uptake were 
generally in agreement with available data from CT, MRI, and bone scans. In approximately half 
the patients evaluated, PET scans showed no uptake of 89Zr-trastuzumab in certain tumor 
lesions, although these lesions had previously been identifi  ed with conventional imaging. 
Th   is may be attributable to variable HER2 expression in diff  erent lesions in the same patient 
[4-7], although this cannot be stated with absolute certainty because no biopsies of those specifi  c 
lesions were carried out. It is unlikely that in cohort 3 (patients on trastuzumab treatment) some 
of the tumor lesions had no uptake of 89Zr-trastuzumab due to saturation, because lesions overall 
showed up very well in this cohort. Th   erefore, future studies to assess the sensitivity and specifi  city 
of HER2 PET imaging should compare the uptake of 89Zr-trastuzumab in tumor lesions with the 
pathological HER2 status of these lesions, as seen from biopsies. Th   e process of obtaining biopsy 
specimens will need to be carefully performed because tumor lesions may be diffi   cult to access; an 
additional consideration is that undergoing more than one biopsy may be too burdensome to the 
patient.66
Until additional information from these future studies becomes available, it will remain 
unclear whether non-detection of known lesions by 89Zr-trastuzumab PET imaging occurs 
because of suboptimal imaging conditions (e.g., dosing and timing, lesion size, spatial resolution) 
or because the level of HER2 overexpression in these lesions has fallen below the limit detectable 
by PET.
Th  e fact that we were able to visualize brain lesions was interesting, given that it is generally 
believed that trastuzumab has poor penetration of the brain [22]. Th   is study shows that 89Zr-
trastuzumab can target brain lesions, with an 18-fold higher uptake in tumors than in normal 
brain tissue. Th   is is probably because of a disruption of the blood-brain barrier at the site of the 
brain metastasis, and it supports the use of trastuzumab therapy in patients with HER2-positive 
breast cancer and brain metastases.
In addition to 89Zr-trastuzumab and 111In-trastuzumab, a few other tracers have been used for 
clinical HER2 imaging. Th  e  99mTc-labeled anti-HER2 rat antibody ICR12 was administered to 
eight breast cancer patients in the early 1990s. Th   is SPECT study suggested that 99mTc-ICR12 could 
be used for the imaging of HER2-positive disease, although no further clinical results involving 
this antibody have been made available [23].
Currently, clinical studies with 111In-and 64Cu-trastuzumab and with 68Ga-trastuzumab F(ab)2 
fragments are at the stage of patient recruitment [24-26]. Th   ese studies will give insight into the 
possibility of using shorter-lived isotopes (such as 64Cu) for imaging with intact antibodies and will 
provide the fi  rst clinical results with the smaller HER2-directed F(ab)2 fragments. Generally, large 
intact monoclonal antibodies penetrate slowly but constantly into solid tumor tissue, ultimately 
resulting in higher accumulation in the tumor than is the case with small proteins; antibody 
fragments penetrate more swift  ly into tumor tissue but show less uptake in the tumor because of 
more rapid clearance from the blood [7].
If, in the future, other tracers prove to be more useful than 89Zr-trastuzumab for HER2 PET 
imaging in patients, the choice of tracer might well depend on the purpose for which HER2 PET 
imaging is to be used. One can envision a role for HER2 PET imaging in improving diagnosis, 
staging (especially in clinical dilemmas such as when lesions are inaccessible for biopsy), guiding 
individual trastuzumab therapy, and early drug development of HER2-targeting agents [7,27].
Th  is feasibility-evaluation of biodistribution and imaging points to the need for further 
exploration of 89Zr-trastuzumab HER2 PET imaging.
Supplementary Material
Supplementary material is linked to the online version of the paper at http://www.nature.com/cpt
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INFLUENCED BY EXTENT HUMAN
EPIDERMAL GROWTH FACTOR RECEPTOR 
2 POSITIVE TUMOR LOAD
To the Editor
We read with great interest the article by Leyland-Jones et al. [1] in which an intensifi  ed trastuzumab 
loading dose was evaluated in patients with human epidermal growth factor receptor 2 (HER2) positive 
metastatic breast cancer. Th   ey conclude that a trastuzumab loading dose of weekly 6 mg/kg during 
the fi  rst 3 weeks followed by once every 3 weeks 6 mg/kg proved to be safe and eff  ective, with higher-
than-steady-state concentrations during the fi  rst cycle. Th  is intensifi  ed schedule was based on 
pharmacokinetic modeling using population-based pharmacokinetic parameters from a pooled phase 
I/II data set. Pharmacokinetic data with this intensifi  ed schedule do indeed show an optimized profi  le 
compared to the standard weekly dosing of trastuzumab. However, pharmacokinetic parameters like 
terminal half-life, area under the concentration-time curve, maximum concentration, and minimum 
concentration do still have remarkably broad ranges: the fi  ft  h to 95th percentile ranged 8.23 to 31.4 days, 
1.790 to 3,450 mg day/L, 173 to 338 mg/L, and 34.8 to 173 mg/L, respectively [1]. Th   is suggests that for 
optimal trastuzumab treatment, dosing on merely kg bodyweight is probably insuffi   cient, and that 
other individual patient factors aff  ecting trastuzumab pharmacokinetics should be taken into account. 
Trastuzumab clearance is highly dose dependent [2] and is increased in case of high tumor load (with 
four metastatic sites) or, to a lesser extent, high HER2 extracellular domain plasma levels [3].
For a complete understanding of trastuzumab pharmacokinetics and optimal dosing, it is necessary 
to gain insight in trastuzumab body distribution and blood pharmacokinetics. We have shown that 
whole-body imaging with radiolabeled trastuzumab can indeed provide quantitative data on 
trastuzumab tumor uptake and organ distribution in addition to blood pool levels [4,5]. Recent 
striking fi  ndings with zirconium-89 (89Zr)-trastuzumab HER2-positron emission tomography 
(PET) imaging in one patient with extensive tumor load signifi  cantly contributed to our knowledge 
on trastuzumab pharmacokinetics and how these can be infl  uenced by tumor load.
A 41-year-old woman was newly diagnosed with HER2-positive breast cancer, with bone and liver 
metastases. Brain metastases were suspected, but could not be detected by means of conventional 
t e c h n i q u e s .  W i t h  H E R 2 - P E T  i m a g i n g ,  w e  h a v e  p r e v i o u s l y  s h o w n  t h a t  89Zr-trastuzumab 70
accumulates in tumor lesions including HER2-positive brain metastases [5]. Th  erefore, this 
patient was referred to our center to exclude presence of HER2-positive brain metastases by means 
of HER2-PET. At this stage, the patient had not yet received therapeutic trastuzumab treatment.
In a feasibility study, we found that 50 mg 89Zr-trastuzumab, consisting of 1.5 mg 89Zr-trastuzumab 
(37 MBq) replenished with nonradioactive trastuzumab, is a dose for optimal HER2 visualization in 
trastuzumab-naive patients. Lower trastuzumab doses resulted in rapid hepato-intestinal excretion [5]. 
Th  e  fi  rst HER2-PET scan of the referred patient was acquired 2 days aft  er injection of 50 mg 89Zr-
trastuzumab. It showed massive 89Zr-trastuzumab uptake in the liver metastases (48% of injected dose; 
fi  gure 1A; Data Supplement) and presence in the colon ascendens/transversum, indicating intestinal 
excretion of 89Zr-trastuzumab or its catabolites. 89Zr-trastuzumab blood pool levels were extremely low, 
bone metastases were hardly visible and no uptake was seen in the brain. 
Figure 1. 89Zr-trastuzumab HER2-PET scan was acquired 2 days a   er injec   on of 50 mg 89Zr-trastuzumab (A). 
Following a trastuzumab loading dose of 220 mg, this pa   ent was re-injected with 10 mg 89Zr-trastuzumab 
and a HER2-PET scan was acquired two days later (B; intense spot in right arm is injec   on site). 89Zr-
trastuzumab uptake was quan   ﬁ  ed as Rela   ve Uptake Value (RUV) for normal    ssue (C) and lesions (D).
Th   is pattern of rapid clearance and low blood pool levels of 89Zr-trastuzumab was unprecedented 
in our feasibility study [5]. Th  e high 89Zr-trastuzumab uptake in the extensive liver metastases might 
have reduced uptake in other tumor lesions, such as bone or brain, and have resulted in a false-negative 
HER2-PET scan for brain lesions. Th   erefore, a second 89Zr-trastuzumab dose was injected 2 days aft  er 
initiation of treatment with paclitaxel and trastuzumab (220 mg; 4 mg/kg loading dose) and the HER2-
PET scan was acquired 2 days later. Th   e protein dose of 89Zr-trastuzumab was reduced to 10 mg, given 
the prior start of therapeutic trastuzumab treatment. Compared with the fi  rst HER2-PET scan, this 
scan showed less 89Zr-trastuzumab liver uptake (33% of injected dose), a higher blood pool level, and more 
uptake in other tumor lesions, such as bone metastases (fi  gure 1B and data supplement). Quantifi  cation of 
89Zr-trastuzumab relative uptake values in tumor and organs (including kidneys and spleen) indicated a 
reduction in uptake in two liver lesions of 47% and 44%, respectively, and increased uptake in vertebrae L3 
and L4 of 16% and 37%, respectively, on the second scan (fi  gures 1C and 1D). Treatment was continued 
with paclitaxel and trastuzumab with an excellent tumor response and all neurological signs disappeared.4B  TRASTUZUMAB PHARMACOKINETICS INFLUENCED BY EXTENT HUMAN EPIDERMAL 
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In this patient, we show that as a result of an extensive HER2-positive tumor mass, 89Zr-trastuzumab was 
predominantly taken up by liver metastases and rapidly cleared from the circulation. Th  e  rapid 89Zr-
trastuzumab clearance in this patient can theoretically be explained as follows. Considering a 2 x 106 
HER2 per tumor cell,6 a liver tumor mass of 1.2 kg (based on patient’s enlarged liver volume of 2,513 cm3 
on PET scan and a calculated [7] normal healthy liver weight of 1.3 kg) and 1 x 109 cells/g tumor, the liver 
metastases alone would already contain approximately 2.4 x 1018 HER2 molecules. Th  e  fi  rst 89Zr-trastuzumab 
dose of 50 mg consists of 2.0 x 1017 trastuzumab molecules and can therefore be easily completely bound 
by the receptors on the tumor cells in the liver metastases, which resulted in a rapid liver uptake and 
89Zr-trastuzumab clearance from the circulation, as was seen with HER2-PET imaging. Th  e  scan  aft  er the 
therapeutic loading dose of 220 mg trastuzumab still showed very low 89Zr-trastuzumab blood pool levels 
compared with previous results [5]. Th   e total amount of trastuzumab administrated to this patient 
within 1 week was 280 mg (both tracer doses plus loading dose), which can only saturate 47% of all HER2 
present in the liver metastases based on our calculations. Th   is indicates that it takes more trastuzumab to 
saturate lesions in case of extensive HER2-positive tumor load.
In conclusion, the current practice of trastuzumab dosing for metastatic breast cancer, may indeed 
have to be reconsidered. Leyland-Jones et al. [1] showed with their intensifi  ed loading schedule 
an  improved pharmacokinetic profi   l e  o f  t r a s t u z u m a b .  I n  a d d i t i o n ,  o u r  d a t a  i n d i c a t e  t h a t  
trastuzumab pharmacokinetics and organ distribution can be heavily aff  ected by an extensive 
tumor load. It could therefore be considered to perform a study with a more patient-tailored 
trastuzumab dosing schedule on the basis of tumor volume in addition to bodyweight. In such a 
study, HER2-PET can be used to assess whether this results in more eff  ective trastuzumab levels in 
all lesions compared with dosing based on a patient’s bodyweight.
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Abstract
Tumor necrosis factor related apoptosis inducing ligand (TRAIL) induces apoptosis through 
activation of death receptors TRAIL-R1 and TRAIL-R2. Recombinant human (rh) TRAIL and 
the TRAIL-R1 directed monoclonal antibody mapatumumab are currently clinically evaluated 
as anticancer agents. Th   e objective of this study was to develop radiopharmaceuticals targeting 
the TRAIL-R1, suitable for clinical use to help understand and predict clinical effi   cacy in 
patients. RhTRAIL was radioiodinated and conjugated mapatumumab was radiolabeled with 
111Indium. Th  e radiopharmaceuticals were characterized, their in vitro stability and death 
receptor targeting capacities were determined, and in vivo biodistribution was studied in nude 
mice bearing human tumor xenograft  s with diff  erent expression of TRAIL-R1. 
Labeling effi   ciencies, radiochemical purity, stability, and binding properties were optimized 
for the radioimmunoconjugates. In vivo biodistribution showed rapid renal clearance of 
125I-rhTRAIL, with highest kidney activity at 15 min and almost no detectable activity aft  er 
4 h. Activity rapidly decreased in almost all organs, except for the xenograft  s. Radiolabeled 
mapatumumab showed blood clearance between 24 and 168 h and a reduced decrease in 
radioactivity in the high receptor expression xenograft  . RhTRAIL and mapatumumab can 
be effi   ciently radiolabeled. Th  e new radiopharmaceuticals can be used clinically to study 
pharmacokinetics, biodistribution and tumor targeting, which could support evaluation of 
the native targeted agents in phase I/II trials.74
Introduction
Tumor necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL) or Apo2L is a 
member of the TNF family that was originally identifi  ed based on its sequence homology to 
Fas and TNF [1]. TRAIL is expressed as a transmembrane type II glycoprotein and can form 
a soluble homotrimeric form upon proteolytical cleavage of the extracellular domain from 
the cell surface. Both full-length surface bound TRAIL and the soluble form are biologically 
active. Soluble recombinant human (rh) TRAIL can induce apoptosis in numerous preclinical 
models, without apparent toxicity to normal tissues [2]. 
Th  e engagement of surface expressed TRAIL receptors by TRAIL or agonistic antibodies 
leads to triggering of the intracellular apoptosis cascade. Currently, four membranous TRAIL 
receptors have been identifi  ed: TRAIL-R1, TRAIL-R2, TRAIL-R3, and TRAIL-R4. TRAIL-R1 
and TRAIL-R2 contain a cytoplasmic death domain (DD), whereas TRAIL-R3 completely 
lacks and TRAIL-R4 possesses a truncated DD [3]. Th   e soluble receptor osteoprotegerin, which 
is not exclusively a TRAIL receptor, is described as a third decoy receptor that can bind TRAIL 
with low affi   nity [4]. Th   e TRAIL receptors are expressed by most tumor types as well as a wide 
range of normal tissues [5-9]. 
While rhTRAIL can bind all TRAIL receptors, agonistic antibodies have receptor specifi  city 
and will therefore either bind to TRAIL-R1 or TRAIL-R2. Ligand or antibody binding will 
lead to trimerisation of TRAIL-R1 or TRAIL-R2 and recruitment of the adaptor protein Fas-
associated death domain (FADD). FADD can recruit and activate the initiator proteases caspase 
8 and 10, that will in turn activate downstream proteins and eff  ector caspases, ultimately 
leading to apoptosis. Mapatumumab (HGS-ETR1) is a fully human IgG1 TRAIL-R1 targeting 
antibody, designed to mimic the activity of natural TRAIL. RhTRAIL and mapatumumab 
have shown in vitro and in vivo effi   cacy in a wide variety of human tumor cell lines and 
xenograft   models [10-12].
A phase I study in patients with solid cancers and non-Hodgkin lymphomas (NHL) showed 
that rhTRAIL administration is safe and well tolerated [13]. Safety and good tolerability was 
shown in a phase I-II mapatumumab study [14]. Mapatumumab has also been evaluated in 
studies, in combination with chemotherapy and bortezomib [15-18].
In patients, radiolabeled rhTRAIL or mapatumumab might be used to study receptor specifi  city 
and density, pharmacokinetics and biodistribution. Th  is may help to determine whether 
rhTRAIL or mapatumumab reach the target and thereby predict clinical effi   cacy of the drug. 
In this paper we describe the development of iodine-125 ( 125I) radioiodinated rhTRAIL and 
indium-111 (111In) conjugated mapatumumab, suitable for clinical TRAIL-R1/R2 or TRAIL-R1 
scintigraphy, their in vitro and in vivo characterization and biodistribution in human tumor 
bearing mouse models.5  DEVELOPMENT OF RADIOIODINATED RHTRAIL AND A RADIOLABELED AGONISTIC 
TRAIL RECEPTOR ANTIBODY FOR CLINICAL IMAGING STUDIES
75
Methods
rhTRAIL and Mapatumumab
RhTRAIL was produced non-commercially in cooperation with IQ-corporation based on a 
protocol described earlier [19]. Briefl  y, a rhTRAIL expression vector (pET15b-TRAIL114-281), 
that harbors the gene encoding for soluble human TRAIL (amino acids 114-281) was 
transformed in competent E.coli BL21-salt-inducible (SI) cells. Soluble rhTRAIL was recovered 
from host BL21-SI cell lysates by sonication and purifi  ed by SP-Sepharose Fast Flow cation 
exchange chromatography, nickel-nitrilotriacetic acid affi   nity chromatography and dialysis. 
Th   e recombinant protein was formulated in a TRIS/glycerol/zinc buff  er pH 7.4 (100 mM zinc 
sulphate and 10% glycerol). 
Mapatumumab was provided by Human Genome Sciences (Rockville, MD, USA).
Th  e conjugation and labeling procedures described for rhTRAIL and mapatumumab were 
performed under Good Manufacturing Practice (GMP) conditions at our manufacturing 
licensed radiopharmacy unit, within the Department of Nuclear Medicine and Molecular 
Imaging.
Radiolabeling of 125I- rhTRAIL
A rhTRAIL solution (45 μg rhTRAIL) of 1 mg·mL-1 in a TRIS/glycerol/zinc buff  er was allowed to 
react with 70 MBq 125I-NaI (GE Healthcare, Eindhoven, the Netherlands) and 50 μg chloramine 
T (Merck, Amsterdam, the Netherlands) at pH 8 for 3 min. Th   e labeling reaction was stopped 
with sodium metabisulphite (Acros Organics, Geel, Belgium) and unbound 125I was removed 
by gel fi  ltration chromatography, to acquire a radiochemical purity of at least 95%. Th  e  PD-
10 gel fi  ltration column (SephadexTM G-25M, Amersham Biosciences AB, Uppsala, Sweden) 
was eluted with the TRIS/glycerol/zinc buff  er, containing 0.5% human serum albumin (HSA, 
Cealb 20%, Sanquin, Amsterdam, the Netherlands). 
Conjugation and Radiolabeling of 111In-mapatumumab
Mapatumumab was conjugated, according to the method described earlier [20]. Glassware, 
materials and solutions used for the conjugation and labeling procedures were sterile, 
endotoxin and metal-free. 
Briefl  y, to 1 mg of antibody, an equimolar amount of cDTPA (Sigma-Aldrich, Zwijndrecht, 
the Netherlands) was added. Aft  er 1 h incubation at room temperature, the reaction mixture 
was purifi   ed by ultracentrifugation (vivaspin-2, Sartorius Mechatronics, Nieuwegein, the 
Netherlands) with ammonium acetate (50 mM, UMC Groningen, the Netherlands) to eliminate 
the excess unconjugated cDTPA. Subsequently, 1 mg purifi  ed cDTPA-mapatumumab was 
allowed to react with 50 MBq 111InCl3 (370 MBq mL-1, >1.85 GBq mg-1, 99.9% radionuclidic 
pure; Covidien, Zaltbommel, the Netherlands) for 1 h at room temperature. Th   e product was 
purifi  ed by ultracentrifugation to obtain a radiochemical purity of at least 95%, diluted in saline 
and sterilised by fi  ltration (0.2 μm Millex GV fi  lter, Millipore, Amsterdam, the Netherlands). 76
Quality Control
Quality control was essentially performed as described earlier [21]. In short, radio-chemical 
purity of the radiolabeled protein was determined by size exclusion high performance liquid 
chromatography (SEC-HPLC). Instant thin-layer chromatography (ITLC) or trichloroacetic 
acid (TCA) precipitation were used in addition to the SEC-HPLC to determine radiochemical 
purity. A Waters 1500 series SEC-HPLC equipped with an in-line radioactivity detector (Ortec, 
Nieuwegein, the Netherlands) and fraction collector (Bio-Rad Laboratories BV, Veenendaal, 
the Netherlands) was used to diff  erentiate between labeled product, aggregates and unlabeled 
111In or 125I. Th   e TSK SW3000 XL 300 x 7.8 mm size exclusion column (Tosoh Bioscience GmbH, 
Stuttgart, Germany) and the Bio Silect SEC 250-5, 300 x 7.8 mm column (Bio-Rad Laboratories 
BV, Veenendaal, the Netherlands) were used for rhTRAIL and mapatumumab SEC-HPLC 
respectively. Th  e mobile phase consisted of phosphate-buff  ered saline (PBS; NaCl 500 mM, 
Na2HPO4 9.0 mM and NaH2PO4 1.3 mM; pH 7.4) with 1% methanol. Column performance 
was tested using a reference Bio-Rad Gel Filtration standard. At a fl   ow of 1.0 mL·min-1 
radioiodinated rhTRAIL eluted at 9.8 min, unbound radioiodine at 12 min, mapatumumab at 
8 min and 111In-DTPA at 11 min. If (radiolabeled) aggregates were present they eluted early at 
5-6 min. Collected fractions were used to determine 125I and establish HPLC column recovery. 
Radioactivity was measured by a calibrated well-type γ-counter (LKB 1282 Compugamma, 
LKB Wallac, Turku, Finland).
In-vitro Stability of the Radiolabeled Compounds
Aft  er optimization of the labeling procedure and assessment of (radio)chemical purity, the 
stability of the radiopharmaceuticals was determined in buff  er (TRIS/glycerol/zinc with 0.5% 
HSA for 125I-rhTRAIL or ammonium acetate for 111In-mapatumumab) and in human serum. 
Solutions were stored at 4oC and 37oC in a humidifi  ed incubator maintained at 5% CO2 and 95% 
air. Frequent HPLC and TCA analyses were performed. 125I-rhTRAIL stability was assessed 
during the fi  rst 4 h and aft  er 24 h. Th  e  111In-mapatumumab stability was determined during 
7 days. 
Cell Lines
Human colon (Colo320 and SW948), breast (SKBR3) and small cell lung cancer (GLC4) 
cell lines were used during the study. Colo320, SW948 and GLC4 expressTRAIL-R1 and 
TRAIL-R2, with the highest TRAIL-R1 and TRAIL-R2 expression in SW948. SKBR3 displayed 
low TRAIL-R1 and TRAIL-R2 expression and was used as a negative control to determine 
aspecifi  c binding. 
All cell lines were cultured at 37oC in a humidifi  ed atmosphere with 5% CO 2. GLC4 and 
Colo320 were cultured in RPMI 1640 medium (Life Technologies, Breda, the Netherlands) 
supplemented with 10% fetal calf serum (FCS, Bodinco BV, Alkmaar, the Netherlands). 
SKBR3 cells were cultured in Dulbecco’s Modifi  ed Eagle’s Medium High (Life Technologies, 
Rotterdam, the Netherlands) with 10% FCS. Cells were harvested by short treatment with 
trypsin. SW948 was cultured in Leibovitz L15-RPMI 1640 (1:1) enriched with 10% FCS, 0.05 
M pyruvate, 0.1 M glutamine and 0.025% ß-mercaptoethanol. SW948 was harvested following 
treatment with protease. 5  DEVELOPMENT OF RADIOIODINATED RHTRAIL AND A RADIOLABELED AGONISTIC 
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TRAIL-receptor membrane expression (TRAIL-R1, TRAIL-R2, TRAIL-R3 and TRAIL-R4) 
was analyzed using fl  ow cytometry (Epics Elite, Coulter-Electronics, Hialeah, FL, USA) as 
described before [22], to confi  rm TRAIL-receptor expression. In short: cells were seeded in 
6-wells plates, left   to adhere, harvested the following day with cell dissociation buff  er for 5 min 
at 37°C and washed twice with cold PBS supplemented with 2% FCS and 0.1% sodium azide. 
Th  e following antibodies were used to determine TRAIL receptor membrane expression: 
TRAIL-R1 (HS101), TRAIL-R3 (HS301), TRAIL-R4 (HS402) from Alexis and secondary PE 
conjugated goat anti-mouse. Mouse IgG (DAKO, Glostrup, Denmark) was used as isotype 
control. For TRAIL-R2, phycoerythrin-conjugated mouse monoclonal TRAIL-R2 antibody 
was used, with mouse IgG2B as isotype control (R&D Systems, Oxon, UK). TRAIL receptor 
membrane expression was analyzed using a fl  ow cytometer (Epics Elite, Coulter-Electronics, 
Hialeah, FL) and is shown as mean fl  uorescent intensity (MFI) of all analyzed cells from at least 
three separate experiments. 
Receptor Cell Binding Assays
Cell binding assays were performed to confi   rm conservation of immunoreactivity. Th  e 
receptor binding assays were essentially similar to the quality control performed during the 
manufacturing of the naive rhTRAIL and mapatumumab.
For  125I-rhTRAIL the immunoreactive fraction was determined by cell-binding assays at 
infi  nite antigen excess, as described by Lindmo et al. [23]. For this assay, SW948, Colo320 
and GLC4 were compared with the negative control (SKBR3). In short, serial dilutions in 
culture medium ranging from 1 to 32 were made of the cell suspension. A fi  xed amount of 
radiolabeled product was added to the cells and incubated at 21°C for 1 h. Cell suspensions 
were subsequently centrifuged (10 min, 167 g) and washed with PBS 5% FCS. Specifi  c binding 
was calculated as the ratio of cell-bound (pellet obtained aft  er the last centrifugation step) 
to total radioactivity applied minus non specifi  c binding, determined by the same procedure 
aft  er adding a 200-fold excess of the unlabeled compound. 
Antibody immunoreactivity was assessed with a surface plasmon resonance assay with the 
BIAcore 3000 analyzer (BIAcore AB, Uppsala, Sweden) by Human Genome Sciences. Th  e 
receptor molecules were directly immobilized to the surface of separate fl  ow cells of a CM5 
chip by amine coupling to a signal of approximately 900 response units (RU), with one lane 
treated by the amine coupling reagents as a control fl  ow cell. A loop-method was created with 
multiple injections cycles of 120 μL of a concentration between 1-480 nM of antibody, followed 
by a dissociation phase and a regeneration of the chip surface with a 1:1 mixture of 10 mM 
glycine, pH 2.0, 1.5 M NaCl, and ethylene glycol for 90 seconds. Th   e experiment was performed 
at a fl  ow rate of 70 μL·min-1 standard HBS-EP buff  er (GE Healthcare Life Sciences, Diegem, 
Belgium) at 25°C.
In Vivo Biodistribution in Tumor-bearing Mice
Th   e in vivo behavior of radiolabeled rhTRAIL and mapatumumab was assessed using nude 
mice bearing SKBR3 or SW948 xenograft  s. Th   e SW948 cell line was used as a TRAIL-R1 and 
TRAIL-R2 high expression cell line. Because there was no good control protein available for 
rhTRAIL and we intended to use the same animal model for rhTRAIL and mapatumumab, the 78
low TRAIL-R1 and TRAIL-R2 expression cell line SKBR3 was used as control to determine 
aspecifi  c binding.
Male nude mice (Hsd:Athymic Nude-nu) were obtained from Harlan Nederland (Horst, the 
Netherlands) at 4-6 weeks of age (30 g). Th   ey were housed in groups of fi  ve in individually 
ventilated solid bottom polycarbonate cages with wood-chips fl  oor bedding (changed weekly), 
with a 12 h light-dark cycle. Mice were provided with deionized autoclaved water and standard 
rodent chow. Aft  er 10 days of acclimatizing, the mice were injected subcutaneously with 1 x 
106 SKBR3 or SW948 cells, mixed equally with 0.1 mL MatrigelTM (Becton Dickinson, Bedford, 
MA, USA). Th   e study was conducted approximately 1-2 weeks aft  er inoculation. 
During anaesthesia, 150 kBq (0.15 mL) 125I-rhTRAIL or 111In-mapatumumab (corresponding 
with 0.5 μg rhTRAIL or 5 μg of mapatumumab) was injected through the penile vein. At 15, 
30, 60 or 240 min aft  er 125I-rhTRAIL or 24, 72 or 168 h aft  er 111In-mapatumumab injection, 
groups of mice (n=4) bearing a SKBR3 or SW948 tumor were sacrifi  ced. Th   e organs and tissues 
were excised, rinsed for residual blood and weighed. Tissue radioactivity was expressed as the 
percentage of the injected dose per gram tissue (%ID·g-1).
Th  e  animal studies were conducted in accordance with the Law on Animal Experimentation 
and local guidelines, and were approved by the local ethical committee. 
Statistical analysis
Data are presented as mean ± standard error of the mean (SEM). Th   e SEM is calculated by 
dividing the standard deviation by the square root of the sample size. Statistical analyses were 
performed using a non-parametric Mann-Whitney U-test (SPSS version 18 for Windows, SPSS 
Inc.) indicated that variances were signifi  cantly diff  erent. A P-value of ≤0.05 was considered 
signifi  cant.
Results
Conjugation, Radiolabeling and Quality control
Radioiodination of rhTRAIL resulted in a mean labeling effi   ciency of 70.3 ± 1.1 % (n=24). 
Radiochemical purity was always more than 98%, as determined by TCA-precipitation. 
Maximal activity was 1.3 MBq·μg-1 and mean specifi  c activity was 0.75 ± 0.05 MBq·μg-1 (n=24). 
Mapatumumab labeling with 111In resulted in labeling effi   ciency of 92.0 ± 1.5% (n=9). Aft  er 
ultrafi  ltration, the radiochemical purity was always more than 96%. Th  e maximal specifi  c 
activity was 0.27 and the mean specifi  c activity was 0.15 ± 0.02 MBq μg-1. No impurities were 
detected. 
In Vitro Stability of the Radiolabeled Compounds
Th  e 125I-rhTRAIL stability was determined in human serum and in a TRIS/glycerol/zinc 
buff  er, containing 0.5% HSA. At 4°C, 125I-rhTRAIL stability was maintained for 24 h. Aft  er 
24 h, aggregation and dehalogenation were shown over time, indicating denaturation of the 
radiolabeled product. Th   e percentage of radiolabeled aggregates (8% aft  er 24 h), increased to 
13% and 16% aft  er 48 h and 72 h respectively, while radiochemical purity decreased to 84 
and 81% respectively. Previous analysis has indicated that these aggregates are most likely 5  DEVELOPMENT OF RADIOIODINATED RHTRAIL AND A RADIOLABELED AGONISTIC 
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rhTRAIL dimers. Th   ese rhTRAIL dimers will not precipitate from the solution and remain 
soluble. Because of their molecular weight they will not be removed by fi  ltration. 
Upon storage in human serum at 37°C, high molecular weight impurities were seen already 
aft  er 4 h (8%), but no free iodine could be detected. Given the short serum elimination half-life 
of less than 30 min in vivo [24,25], this was considered acceptable for (pre)clinical evaluation 
of 125I-rhTRAIL.
Radiolabeled mapatumumab proved to be very stable. Only a small decrease (<6%) in protein-
bound radioactivity was observed for mapatumumab stored during one week at 4oC in buff  er 
and at 37oC in serum, allowing 111In-mapatumumab measurement and imaging during 1 week. 
Receptor Cell Binding Assays
Four diff  erent cell lines with variable TRAIL-R1 and TRAIL-R2 expression were used in this 
study. 
Th  ere was a 13-fold and 2-fold diff  erence in receptor expression between the high SW948 
and low SKBR3 receptor expressing cell lines for TRAIL-R1 and TRAIL-R2 respectively. 
Representative TRAIL-R1, TRAIL-R2, TRAIL-R3 and TRAIL-R4 fl  ow cytometry histograms 
are shown in fi  gure 1.
Th  e 125I-rhTRAIL immunoreactive fraction was calculated from the inverse plot of the 
cell-binding assays. Th  e immunoreactive fraction was always >0.6 for the TRAIL-R1 and 
TRAIL-R2 expressing GLC4, Colo320 and SW948 cell lines (n=2). Th  e immunoreactive 
fraction of the SKBR3 control cell line was <0.1. Th  e  111In-mapatumumab immunoreactive 
fraction was determined by BIAcore analysis. Th   e equilibrium dissociation constant (Kd) of 
the antibody was >0.6. 
In Vivo Biodistribution of 125I-rhTRAIL in Tumor-bearing Mice
Th  e in vivo behavior of 125I-rhTRAIL was assessed using athymic mice bearing SW948 or 
SKBR3 xenograft  s.  125I-rhTRAIL biodistribution data of mice bearing these tumors are 
presented in table 1. Similar activity in tumors and normal tissues was measured in mice with 
SKBR3 or SW948 xenograft  s. Th  e  125I-rhTRAIL biodistribution is characterized by fast renal 
elimination. Already 15 min aft  er intravenous injection considerable amounts of radioactivity 
were detected in the urine. SEC-HPLC revealed that no intact rhTRAIL trimer, but smaller 
fragments were present in the urine. Kidney uptake rapidly decreased from 43.3 ± 2.5 %ID·g-1 
and 41.0 ± 4.8 %ID·g-1 at 15 min aft  er injection to 0.5 ± 0.1 %ID·g-1 and 0.8 ± 0.2 %ID·g-1 aft  er 4 
h for SKBR3 and SW948 respectively. Total blood activity decreased from 6.3 ± 0.3 %ID·g-1 and 
6.6 ± 0.7 %ID·g-1 at 15 min aft  er injection to 0.4 ± 0.1 %ID·g-1 and 0.8 ± 0.2 %ID·g-1 aft  er 4 h for 
SKBR3 and SW948 respectively. Tumor uptake reached a maximum at 60 min: 2.8 ± 0.4 %ID·g-1 
for SKBR3 and 3.6 ± 0.4 %ID·g-1 for SW948. Although borderline signifi  cance was reached at 
240 min post-injection (P=0.06). Uptake in other all well-vascularized organs (lungs, liver 
and spleen) decreased simultaneously with the blood pool activity. Stomach activity slightly 
increased over time and no activity could be detected in the brain, as was expected because of 
the presence of the blood-brain-barrier. Histological analysis showed some core necrosis in the 
SW948 tumors but not in the SKBR3 tumors, which were smaller in size. 80
Table 1a. Biodistribu   on of 125I-rhTRAIL in mice bearing human SKBR3 (a) or SW948 (b) xenogra   s (n= 4). 
Data are expressed as the %ID·g-1    ssue ± SEM.
t=15 min t=30 min t=60 min t=240 min
 125I-rhTRAIL 
(± SEM)
 125I-rhTRAIL 
(± SEM)
 125I-rhTRAIL 
(± SEM)
 125I-rhTRAIL 
(± SEM)
Heart 2.4 0.2 0.8 0.1 1.1 0.2 0.2 0.0
Blood 6.3 0.3 2.1 0.4 2.9 0.2 0.4 0.1
Lung 3.8 0.2 1.7 0.3 2.3 0.2 0.4 0.1
Liver 4.9 0.3 1.5 0.3 1.4 0.1 0.2 0.0
Kidney 43.3 2.5 6.5 1.4 6.2 0.6 0.5 0.1
Bladder 3.7 1.3 7.5 5.0 10.2 4.0 1.1 0.3
Stomach 2.8 0.5 4.1 1.3 6.5 0.9 1.6 0.5
Pancreas 2.0 0.3 1.1 0.3 1.7 0.4 0.2 0.0
Spleen 3.1 0.1 1.6 0.3 2.0 0.3 0.3 0.1
Small intes   ne 2.7 0.3 1.9 0.6 3.2 1.3 0.3 0.1
Colon 2.4 0.6 1.0 0.1 2.1 0.6 0.3 0.2
Muscle 0.5 0.0 0.4 0.1 0.7 0.1 0.1 0.0
Bone 1.3 0.1 0.9 0.2 1.2 0.3 0.3 0.1
Brain 0.3 0.0 0.1 0.0 0.2 0.0 0.0 0.0
Tumour 1.5 0.2 2.1 0.4 2.8 0.4 0.4 0.1
Table 1b 
t=15 min t=30 min t=60 min t=240 min
 125I-rhTRAIL 
(± SEM)
 125I-rhTRAIL 
(± SEM)
 125I-rhTRAIL 
(± SEM)
 125I-rhTRAIL 
(± SEM)
Heart 2.5 0.2 2.3 0.1 1.7 0.1 0.3 0.1
Blood 6.6 0.7 4.6 0.6 3.6 0.1 0.8 0.2
Lung 4.2 0.5 3.7 0.3 3.1 0.2 0.7 0.1
Liver 6.7 0.6 5.7 0.2 1.8 0.2 0.4 0.1
Kidney 41.0 4.8 19.5 3.2 8.8 2.5 0.8 0.2
Bladder 4.7 1.5 8.3 1.0 4.1 0.9 2.3 0.6
Stomach 3.7 1.1 6.6 0.7 11.3 1.4 2.5 1.0
Pancreas 1.8 0.4 2.1 0.1 1.5 0.1 0.3 0.1
Spleen 4.0 0.6 4.2 0.5 2.5 0.3 0.6 0.1
Small intes   ne 3.9 0.4 3.9 0.6 2.4 0.3 0.8 0.1
Colon 1.6 0.2 1.9 0.2 1.5 0.1 0.4 0.1
Muscle 0.7 0.1 0.9 0.1 0.8 0.1 0.2 0.0
Bone 1.9 0.3 2.1 0.3 1.6 0.1 0.4 0.1
Brain 0.3 0.0 0.2 0.0 0.1 0,0 0.0 0.0
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In Vivo Biodistribution of 111In-mapatumumab in Tumor Bearing Mice
Table 2 shows 111In-mapatumumab biodistribution in mice bearing SKBR3 or SW948 
xenograft  s. As seen for rhTRAIL in table 1, there was similar normal non-tumor tissue 
biodistribution of mapatumumab for mice with a SW948 or SKBR3 xenograft  .
Uptake in the well vascularized organs as heart, liver and lung was approximately similar 
for SKBR3 and SW948, except for the spleen which showed an unexplained higher uptake 
in the low compared to the high TRAIL-R1 and TRAIL-R2 receptor expressing cell line (as 
shown in table 2). At 24h post injection the SW948 tumor uptake was lower than that of 
SKBR3, but at end of the experiment at 168h there is higher uptake in SW948 then in SKBR3, 
respectively 5.1 ± 2.1 %ID·g-1and 3.7 ± 1.8 %ID·g-1. Th  e  diff  erence in tumor uptake was however 
not signifi  cantly diff  erent (P=0.63), due to the variance. Maximal tumor accumulation was 
seen at 72h post-injection. Th   is indicated that the 111In-mapatumumab accumulation in time is 
larger for the high TRAIL-R1 and TRAIL-R2 expressing cell line than for the low TRAIL-R1 
and TRAIL-R2 expressing cell line. 
Th   ere was considerable liver and kidney uptake, with highest activity in the kidneys. 
Table 2a. Biodistribu   on of 111In-mapatumumab in mice bearing human SKBR3 (a) or SW948 (b) xenogra   s 
(n = 4). Data are expressed as the %ID·g-1    ssue ± SEM.
t=24h t=72h t=168h
111In-mapatumumab 
(± SEM)
111In-mapatumumab 
(± SEM)
111In-mapatumumab 
(± SEM)
Heart 3.8 0.4 2.3 0.6 1.3 0.3
Blood 8.7 2.5 4.7 2.2 1.2 1.0
Lung 3.5 0.8 2.0 0.7 1.3 0.5
Liver 9.9 2.2 7.1 1.3 3.8 1.6
Kidney 12.9 0.2 15.5 2.3 10.2 1.0
Bladder 4.2 1.9 3.6 0.8 1.5 0.6
Stomach 2.0 0.4 1.6 0.6 0.9 0.3
Pancreas 1.0 0.4 2.3 0.8 1.5 0.6
Spleen 14.2 3.5 10.3 4.5 5.5 3.3
Small intes   ne 7.5 3.6 6.6 3.1 3.2 1.2
Colon 1.8 0.6 1.5 0.6 0.6 0.2
Muscle 0.4 0.1 0.4 0.1 0.6 0.2
Bone 3.4 1.1 6.7 2.3 2.9 1.0
Brain 0.1 0.0 0.1 0.0 0.1 0.0
Tumour 6.2 1.1 7.5 3.5 3.7 1.882
Table 2b
t=24h t=72h t=168h
111In-mapatumumab 
(± SEM)
111In-mapatumumab 
(± SEM)
111In-mapatumumab 
(± SEM)
Heart 3.0 0.8 3.5 0.5 1.1 0.4
Blood 11.9 3.1 9.1 1.9 0.9 0.7
Lung 2.2 0.9 3.0 0.8 1.0 0.4
Liver 5.1 1.4 9.1 0.7 6.2 0.7
Kidney 10.2 3.4 17.1 2.9 8.7 1.8
Bladder 1.3 0.2 3.2 1.1 2.0 0.4
Stomach 0.7 0.3 1.1 0.5 1.2 0.1
Pancreas 1.0 0.3 3.0 0.7 0.8 0.4
Spleen 1.7 0.2 1.2 0.3 3.7 2.9
Small intes   ne 3.5 1.4 3.5 1.6 2.5 1.4
Colon 0.6 0.1 1.1 0.4 0.9 0.3
Muscle 0.4 0.2 0.5 0.3 0.6 0.3
Bone 2.6 1.2 4.9 1.6 5.6 2.7
Brain 0.1 0.1 0.1 0.0 0.1 0.0
Tumour 3.4 0.9 6.2 2.0 5.1 2.1
Discussion
Th  e present study shows the promising development of radioiodinated cytokine rhTRAIL 
and  111I n  r a d i o l a b e l e d  m o n o c l o n a l  a n t i b o d y  m a p a t u m u m a b  f o r  c l i n i c a l  u s e .  Th  e new 
radiopharmaceuticals have appropriate radiochemical purity, stability and receptor binding 
capacity. Th   e biodistribution studies in nude mice bearing human xenograft  s showed specifi  c 
tumor uptake for both radiolabeled rhTRAIL and mapatumumab in time, although the 
diff  erences in tumor uptake between the low and high TRAIL-R1 and TRAIL-R2 expressing 
xenograft  s are generally small for both compounds. Borderline signifi  cance was reached for 
125I-TRAIL. No signifi  cance was reached for the 111In-mapatumumab, although there was a 
diff  erence in tumor uptake at 168 post-injection in favor of SW948. Based on the experiments 
described in this paper, it is concluded that the developed radiopharmaceuticals are stable and 
interesting provide an interesting starting point for further evaluation in humans.
Radioiodination of rhTRAIL was conducted with an electrophilic substitution reaction, 
in contrary to a previous study that made use of the mild lactoperoxidase method for the 
radiolabeling of rhTRAIL (Xiang et al., 2004). We considered enzymatic radioiodination 
undesirable for clinical applications, as the enzymes themselves can be radiolabeled and have 
to be separated from other radioiodinated proteins prior to administration. Only chloramine 
T and iodogen have therefore been tested for the radiolabeling of rhTRAIL. Chloramine T 
showed the highest labeling effi   ciency and least impurity, possibly related to its short reaction 5  DEVELOPMENT OF RADIOIODINATED RHTRAIL AND A RADIOLABELED AGONISTIC 
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time. Radioiodinated rhTRAIL was stable, without signs of aggregation. Zinc was used 
to protect against disulfi  de bond formation, which may occur in oxidative environments 
when free cysteines on rhTRAIL monomers, giving rise to free-standing dimers as well as 
disulfi  de-linked rhTRAIL dimer species within trimeric forms of rhTRAIL. Th  is may lead 
to aggregation, precipitation and/or deactivation of rhTRAIL [patent WO01/00832-PCT/
US00/17579, Ashkenazi]. 
Considering the rapid half life in humans and animals (Ling et al., 2006), the small amount 
of aggregates present aft  er storage of radiolabeled rhTRAIL at 37°C was not considered 
worrisome, as was confi  rmed in the in vivo biodistribution study. Th  e liver uptake rapidly 
decreased in time, indicating non-specifi  c and blood pool related uptake. 
Th   e immunoreactive fraction showed that radiolabeling of rhTRAIL or mapatumumab hardly 
aff  ected the receptor binding potential of the proteins. 
Some stomach accumulation was observed aft  er injection with 125I-rhTRAIL. Th  is could 
be explained by endocytosis and lysosomal catabolism of rhTRAIL and subsequent release 
of the non-residualizing iodine isotope into the circulation [25-27], together with some 
dehalogenation. Th  is is not considered a major issue, because in humans rhTRAIL is very 
rapidly cleared. In addition, in clinical setting potassium perchlorate can be used to block free 
iodine and prevent thyroid toxicity, as is already done for other radiopharmaceuticals. 
In contrast to rhTRAIL, the use of a residualizing isotope is mandatory for the long-circulating 
internalizing antibody mapatumumab. Th  is was the main reason for using 111In, although 
iodination of mapatumumab resulted in loss of immunoreactivity. 
Th  e  125I-rhTRAIL biodistribution in nude human xenograft   bearing mice showed that rhTRAIL 
biodistribution is characterized by fast renal clearance, with highest activity in the kidneys at 
15 min. Th   is is in accordance to what was earlier seen by others [28,29]. In most other organs 
activity decreased from 15 min onwards, following blood pool activity. Th   e steady decrease of 
radioactivity in non-tumor tissue, suggest absence of specifi  c accumulation in these tissues. Th  e 
125I-rhTRAIL tumor uptake in both xenograft  s reached a maximum at 60 min post-injection, 
with the highest values for the TRAIL-R1 and TRAIL-R2 high expressing cell xenograft  . 
Regarding the biodistribution of 111In-mapatumumab, there was in the non-tumor tissues clear 
uptake in liver, kidneys, spleen and bone, with the highest activity in liver and kidneys at 168 
h post-injection. Th  e high liver and spleen uptake was in agreement with known antibody 
metabolism and retention of 111In in the reticuloendothelial system [30], although the diff  erence 
in spleen uptake between the low and high TRAIL-R1 and TRAIL-R2 expressing xenograft  s 
could not be explained. 
111In-mapatumumab kidney uptake was not expected since the molecular size of an antibody 
excludes renal fi  ltration. Although dissociation of 111In-cDTPA might also have caused kidney 
activity, this would have resulted in fast renal 111In clearance and high bone uptake which was 
not the case in our animals. In addition, because the mapatumumab kidney accumulation 
increased in time, this suggested specifi  c antigen-binding. A possible explanation for the 
kidney uptake could be the binding to the mouse killer (MK) death domain containing 
receptor, which has been identifi  ed at high expression levels in the heart, lung and kidney 
of mice [ 3 1,32 ]. Th  e MK death domain possesses 76 and 79% amino acid homology with 
TRAIL-R1 and TRAIL-R2 respectively and can bind human TRAIL. 84
Th  e 111In-mapatumumab xenograft    a c c u m u l a t i o n  a t  t h e  e a r l i e s t  t i m e - p o i n t  w a s  h i g h e r  
in SKBR3 than in the SW948 xenograft  , possible due to a diff  erence in tumor pressure, 
vasculature and size. At immunohistochemical analysis, core necrosis was seen in the SW948 
tumors, which could be an explanation for the diff  erence in tumor penetration velocity for 
large molecules (mapatumumab). At later time-points, there is a steady increase in SW948 
tumor accumulation, and a decrease in the SKBR3 tumor. 
Our results are comparable to what was shown in another animal study [33]. In this study, mice 
bearing a colorectal carcinoma were treated with 60 mg·kg-1 paclitaxel intravenously, which 
gave rise to a 20-fold increase in TRAIL-R1 and TRAIL-R2 xenograft   levels. For comparison: 
in our study, there was a 13-fold diff  erence in TRAIL-R1 receptor expression between the 
SKBR3 and the SW948 cell lines, based on fl  ow cytometry. Imaging and biodistribution with 
111In radiolabeled mapatumumab before and aft  er paclitaxel administration showed results 
comparable to what was seen in our study with high uptake in liver and spleen. A diff  erence 
is that there is less 111In-mapatumumab uptake in the kidneys than what we have seen. Aft  er 
paclitaxel administration there was a 1.4-fold diff  erence in xenograft   uptake of radiolabeled 
mapatumumab. In our study, a similar 1.4-fold diff  erence between the SKBR3 and SW948 
xenograft  s was found in vivo.
Th  e  fl  ow cytometry data indicate that the used cell lines also display TRAIL-R3 and TRAIL-R4 
expression. Although in theory decoy receptors could cause rhTRAIL binding and thus 
increase rhTRAIL accumulation in the tumor xenograft  s, such a mechanism has not been 
described in literature so far. Moreover, in general a clear correlation between decoy receptor 
expression and resistance to rhTRAIL has not been shown [34,35].
For both TRAIL-R1 and TRAIL-R2 targeting radiopharmaceuticals, the absolute tumor 
uptake was low, compared to what for instance can be seen for HER2 imaging with radiolabeled 
trastuzumab [20,21]. It should, however, be taken into account that the tumor receptor 
overexpression levels that have been seen for HER2 (up-to 100-fold due to gene amplifi  cation), 
do not occur for the TRAIL receptors [36]. 
With 111In-trastuzumab it was recently shown that there is only a good correlation between the 
actual HER2 expression and 111In-trastuzumab uptake, if the uptake is corrected for nonspecifi  c 
and circulating radioactivity [37]. Th   is indicates that there is always a certain amount of non-
specifi  c tumor uptake. Correcting for this amount is especially necessary in case of low antigen 
expression levels. Th  erefore, it would be advisable to include a radiolabeled control protein 
(such as IgG for antibodies) in future (pre)clinical studies to allow better discrimination 
between specifi  c and non-specifi  c tumor uptake. Because in this study, there was no good 
control protein available for rhTRAIL and we wanted to use the same animal model for 
rhTRAIL and mapatumumab, we used the low and high TRAIL-R1 and TRAIL-R2 expressing 
cell lines to discriminate between target specifi  c and non-specifi  c radiopharmaceutical tumor 
uptake in the current study. 
Currently a number of clinical phase II studies have been performed with mapatumumab 
or are presently active. At this moment, physicians have no good biomarkers to predict 
mapatumumab response. Radiolabeled rhTRAIL and mapatumumab might help to determine 
if mapatumumab tumor uptake in patients is variable, due to e.g. tumor pressure, vasculature 5  DEVELOPMENT OF RADIOIODINATED RHTRAIL AND A RADIOLABELED AGONISTIC 
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and size and related to therapy effi   cacy. Th   erefore a clinical   study with 111In-mapatumumab is 
currently ongoing in our centre.
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SubmittedSERIAL 111IN-MAPATUMUMAB SPECT 
SCAN IN CANCER PATIENTS TREATED 
WITH MAPATUMUMAB, GEMCITABINE 
AND CISPLATIN
Abstract 
To visualize tumor lesions by serial 111In-mapatumumab scintigraphy and determine 111In-
mapatumumab pharmacokinetics in patients with advanced solid tumors at the start and 
during treatment with the TRAIL-R1 targeting antibody mapatumumab plus gemcitabine and 
cisplatin.
Patients with advanced solid tumors received mapatumumab 20 mg/kg iv and cisplatin 
80 mg/m2 iv on day 1 and gemcitabine 1250 mg/m2 iv on days 1 and 8, every 21 days. Patients 
received 150 MBq 111In-mapatumumab in cycle 1 and cycle 3. Th   irty minutes and at day 1, 3 
and 6 aft  er the fi  rst and second tracer injection planar whole body imaging and single-photon 
emission computed tomography (SPECT) were performed. SPECT images were fused with CT. 
TRAIL-R1 tumor expression was assessed immunohistochemically. Pharmacokinetic analysis 
of 111In-mapatumumab was executed in both cycles.
In 5 of the 12 patients, 11 out of 18 tumor lesions known by CT were visualized with 111In-
mapatumumab SPECT. A large heterogeneity was seen in 111In-mapatumumab uptake between 
these 5 patients. Two melanoma patients showed remarkable intense tracer uptake. In 3 patients 
all lesions were visualized. SPECT results in cycle 3 were comparable to the fi  rst SPECT series. 
Th  ree of the 4 patients having positive 111In-mapatumumab scintigraphy and tumor tissue 
available showed at least low cytoplasmatic TRAIL-R1 expression. Intensity of staining did 
not correlate with positive 111In-mapatumumab scintigraphy or tumor response to treatment. 
Th  e  111In-mapatumumab tumor uptake in this group of patients was variable and the 
value of tumor imaging in upfront patient selection for mapatumumab-based treatment 
needs further evaluation.90
Introduction
Achieving tumor cell death is an ultimate goal in anticancer treatment. Th   e naturally occurring 
Tumor Necrosis Factor (TNF)-Related Apoptosis Inducing Ligand (TRAIL) induces apoptosis 
via activation of the TRAIL receptors (TRAIL-R1 and TRAIL-R2) are present on a broad range 
of tumor cells at variable expression levels. Moreover, TRAIL induces apoptosis in cancer 
cells, but not normal cells. Th  ese  fi  ndings have raised interest in inducing tumor apoptosis via 
TRAIL-R1 and TRAIL-R2 targeting.
Mapatumumab (HGS-ETR1, TRM-1) is a fully human TRAIL-R1 agonistic monoclonal 
antibody (mAb). Single agent mapatumumab showed no major toxicities in two phase I 
studies in patients with advanced solid tumors or non-Hodgkin’s lymphomas [1,2]. Th  e  mean 
terminal elimination half-life of mapatumumab ranged from 14 to 28 days [1,2]. Th  ree  phase 
II single agent studies have been conducted in patients with non-small cell lung cancer, non-
Hodgkin’s lymphoma or colorectal cancer, respectively [3-5]. In the non-small cell lung cancer 
and colorectal cancer studies, the best observed response was stable disease and in the non-
Hodgkin’s lymphoma study two complete and one partial tumor responses were reported. 
Mapatumumab combined with gemcitabine and cisplatin resulted in increased cytotoxicity 
in human tumor cell lines and mouse xenograft   models. In a phase I study patients with solid 
malignancies were treated with this combination [6]. Th   is combination with maptumumab up 
to 30 mg/kg every 3 weeks was well tolerated and safe. No alterations in the pharmacokinetic 
profi  les of the drugs were observed. Partial responses were observed in 12 patients across dose 
levels and stable disease was seen in 25 patients. 
At the moment little is known about the tissue biodistribution of mapatumumab. It is 
unknown whether mapatumumab reaches the tumor in suffi   cient levels to be eff  ective against 
tumor cells. Interestingly, in mice bearing human colorectal tumor xenograft  s, TRAIL-R1 
was upregulated by chemotherapy and antitumor activity was markedly enhanced [7]. It is 
unknown whether upregulation of TRAIL-R1 in the tumor occurs in patients as a result of 
concomitant chemotherapy. 
W e  h yp o th e s ize d  th a t  r a di o l a b e l e d  m a p a tum um a b  can  h e l p  t o  vi s u alize  hi gh  T RAI L - R 1  
expressing tumor lesions and support future selection of patients that may benefi  t from this 
treatment. We therefore developed indium-111 (111In) radiolabeled mapatumumab suitable 
f o r  c l i n i c a l  u s e .  I n  h i g h  T RA I L - R 1  e x p r e s s i n g  h u m a n  x e n o g r a ft  s in mice specifi  c  111In-
mapatumumab uptake was shown [8]. 
Th  e aim of this study was to evaluate tumor lesion visualization (targeting) by serial 111In-
mapatumumab scintigraphy in patients with advanced solid tumors at the start and 
during treatment with mapatumumab plus gemcitabine and cisplatin. Furthermore, the 
biodistribution of 111In-mapatumumab was studied, including calculation of pharmacokinetic 
parameters.6  SERIAL 111IN-MAPATUMUMAB SPECT SCAN IN CANCER PATIENTS TREATED 
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Patients and Methods
Eligibility Criteria
Eiligibility criteria for this study were similar to inclusion criteria in the preceding phase I 
study [6]. Eligibility criteria included: patients with histologically or cytologically confi  rmed 
advanced solid malignancies for whom no standard therapeutic options were available 
or for whom gemcitabine and cisplatin was considered an appropriate treatment; Eastern 
Cooperative Oncology Group (ECOG) performance status 0 or 1; age ≥18 years; a life 
expectancy ≥3 months; adequate bone marrow, hepatic, and renal function; no other anti-
cancer treatment within previous 3 weeks. Excluded were patients with known positive human 
immunodefi  ciency virus status; known chronic or acute viral hepatitis; clinical signs of brain 
metastases; hearing loss requiring the use of a hearing aid; neuropathy ≥ grade 2; myocardial 
infarction, cerebrovascular accident or ≥ NYHA class III congestive heart failure within 6 
months.
Th   e study was approved by the local medical ethical committee and is registered under trial 
number NTR2103. All patients provided written informed consent. 
Treatment
Patients were treated as in the previous phase I study [6]. Gemcitabine (Eli Lilly) 1250 mg/m2 
iv on days 1 and 8 and cisplatin (Pharmachemie) 80 mg/m2 intravenously (iv) on day 1 were 
administered. In addition, patients received mapatumumab (provided by Human Genome 
Sciences Inc) 20 mg/kg iv in 2 hours on day 2 of cycle 1 and 3 and on day 1 of cycles 2 and 4-6. 
Cycles were repeated every 3 weeks for a maximum of 6 cycles. 
Chemotherapy doses were reduced according to the phase I study protocol [6]: when treatment 
was delayed for >1 week, in the case of severe toxicity (≥ grade 3 according to the National 
Cancer Institute Common Toxicity Criteria for Adverse Events version 3.0) considered to 
be at least possibly related to chemotherapy or for the patient’s safety in the opinion of the 
investigator. Cycle delays up to 2 weeks were permitted for hematologic recovery. A baseline 
CT scan was performed within 28 days before the start of cycle 1. CT-response was assessed 
aft  er 3 and 6 cycles by Response Evaluation Criteria in Solid Tumors (RECIST version 1.0) [9]. 
In the absence of disease progression aft  er 6 cycles, continuing mapatumumab monotherapy 
was allowed. 
111In-mapatumumab Production and Scintigraphy
Clinical grade 111In-mapatumumab was produced as described earlier [10]. In short, 
reconstituted mapatumumab was conjugated with the chelator 2-(4-isothiocyanatobenzyl)- 
diethylenetriaminepentaacetic acid (p-SCN-Bn-DTPA, Macrocyclics), purifi   ed by ultra-
fi  ltration and stored at -80°C. GMP-produced 111InCl3 (Covidien) was used to radiolabel the 
conjugate. Quality control was performed to ensure antigen binding capacity (>80%), stability 
and (radio)chemical purity (>95%). Size-exclusion chromatography (SE-HPLC), thin-layer 
chromatography (TLC) and BIAcore analysis were performed as described earlier [8,10]. 
Patients received 150 MBq 111In-mapatumumab (10 mg), iv 1.5 hours aft  er the start of the 
unlabeled mapatumumab infusion in cycle 1. If aft  er 4 patients tumor lesions were not 92
adequately visualized with this treatment scheme, possibly due to TRAIL-R1 saturation by 
therapeutic mapatumumab dose, 150 MBq 111In-mapatumumab would be administered 
7 days before the unlabeled mapatumumab infusion in cycle 1. On day 2, cycle 3, the 150 MBq 
111In-mapatumumab was administered 1.5 hours following the start of the therapeutic dose 
mapatumumab for both imaging schemes. All patients were monitored for the fi  rst 4 hours 
aft  er mapatumumab infusion, for infusion related reactions. 
Planar whole body imaging and single-photon emission computed tomography (SPECT) was 
performed at 30 minutes and on days 1, 3 and 6 aft  er the fi  rst and second tracer injection. Planar 
whole body imaging was performed using a two-headed gamma-camera (Ecam or MultiSpect 
2, both Siemens), equipped with parallel-hole medium-energy all purpose collimators, at a 
scan speed of 10 cm/minute (at 30 minutes and 1 day postinjection) or 5 cm/minute (at 3 and 
6 days postinjection) and stored digitally in a 256x1024 matrix. SPECT images were acquired 
of pre-defi  ned tumor regions, using 180 degrees of sampling with 32 projections per head, 45 
seconds acquisition time per projection and a 128x128 matrix size. 
Image an  d Data Analysis
Non-scatter corrected SPECT images were reconstructed iteratively with an ordered subset 
expectation maximization algorithm (8 iterations, 16 subsets). A 9.00 mm Gaussian fi  lter was 
applied. Whole body and SPECT reconstruction images were analyzed by two investigators 
(AB and CO) for 111In-mapatumumab uptake in possible tumor lesions. SPECT images were 
fused with conventional computed tomography (CT) images (obtained before start and aft  er 
3 cycles of treatment for response assessment) to validate regions of increased tracer uptake as 
tumor lesions, using a LEONARDO e.soft   workstation (Siemens).
Dosimetry
Th   e radiation-absorbed whole body and organ dose was estimated using the conjugated views 
counting technique with partial background subtraction and correction for attenuation and 
physical decay, as described previously [11,12]. Briefl  y, regions of interest (ROI) were drawn on 
the anterior and posterior whole body images of organs of interest that showed tracer uptake. 
Residence times were calculated using the SPRIND soft  ware package [13]. Subsequently, 
OLINDA soft  ware was used to calculate the organ radiation-absorbed doses and the eff  ective 
dose, according to ICRP60 [14].
111In-mapatumumab uptake in tumor lesions was assessed using the day 3 scan which showed 
the best image quality. 3D volumes of interest (VOIs) were drawn around tumor lesions 
and normal muscle in the fused SPECT/CT images. 111In-mapatumumab accumulation was 
quantifi  ed as the mean and maximum counts per voxel, using a threshold of 40% of the 
maximum value. AMIDE Medical Image Data Examiner soft  ware (version 0.9.2, Stanford 
University [15]) was used as described previously [16]. Tumor to normal muscle tissue ratios 
were calculated, to allow inter patient comparison.
111In-mapatumumab Pharmacokinetics
Venous blood samples in heparin collection tubes were obtained prior to, aft  er 10 and 
30 minutes, 1 and 4 hours and 1, 3, 6 and 13 days following the fi  rst and second 111In-6  SERIAL 111IN-MAPATUMUMAB SPECT SCAN IN CANCER PATIENTS TREATED 
WITH MAPATUMUMAB, GEMCITABINE AND CISPLATIN
93
mapatumumab injection. Urine (24 hours) was collected during the fi  rst 4 days aft  er tracer 
injection. Total radioactivity in the whole blood, plasma, and urine samples was determined 
using a calibrated gamma counter (well type LKB-1282-Compu-gamma system, LKB Wallac).
Pharmacokinetic parameters were derived using the Bayesian ITS module (KINPOP) of MW/
PHARM (version 3.50, MediWare) for 111In-mapatumumab blood clearance. Th  e data from 
plasma, blood and urine were analyzed in a 1-, 2- and 3-compartment model to determine 
the best fi  t. 111In-mapatumumab blood clearance was calculated using non-linear regression 
analysis. Based on the blood curves, the area under the curve (AUC) half life (T½) during 
distribution (α) and elimination (β) phase, total clearance (CL), volume of distribution (V1) 
and steady-state volume (Vss) were determined. 
Statistics
Associations between parameters were assessed with Pearson correlation coeffi   cients. 
Diff  erences between pharmacokinetic data were calculated using the non-parametric Mann 
Whitney U-test in SPSS 16.0 (SPSS Inc.). Two-sided P-values ≤0.05 were considered statistically 
signifi  cant. 
Immunohistochemistry
For immunohistochemistry, pretreatment tumor tissue was used. Slides of 3 μm were cut from 
paraffi   n blocks and stained immunohistochemically for TRAIL-R1 as described previously 
[17]. Th   ey were scored for TRAIL-R1 staining intensity into four categories (no staining, low, 
moderate, and strong) by two investigators (CO, not blinded for clinical outcome, and JB, 
blinded for clinical outcome). Sections of normal human liver served as positive controls. 
Results 
Patients
Twelve patients were enrolled. Patient characteristics are summarized in table 1. One patient 
was taken off   study aft  er one treatment cycle because of severe nausea and vomiting. Two 
patients discontinued the study aft  er 1 and 2 cycles because of early disease progression. 
Th   ese 3 patients therefore did not undergo the second imaging series. One melanoma patient 
was treated with 22 cycles before progressive disease was observed. Th   e best response in this 
patient was stable disease.
Th  e treatment was in general well tolerated. Th  e observed toxicity was comparable to the 
previous phase I study and consisted mainly of nausea, vomiting, and fatigue [6]. Th  ree  patients 
discontinued cisplatin prematurely, two because of nausea and vomiting, despite optimization 
of antiemetic treatment aft  er 2 and 5 cycles respectively and in one patient asymptomatic 
decrease in glomerular fi  ltration rate occurred aft  er the day 1 treatment of cycle 1. 
Of the 9 evaluable patients, 8 showed stable disease. One patient with pancreatic cancer had a 
confi  rmed partial response aft  er 3 cycles. 94
Table 1. Pa   ent Characteris   cs.
PaƟ  ent CharacterisƟ  cs (n=12)
Age (years)
Median (range) 56 (47-70)
Sex
Male 8
Female 4
Prior treatment
Systemic 4
Radiotherapy 2
Tumor types
Pancrea   c adenocarcinoma 5
(Adeno)carcinoma of unknown primary 3
Non-small cell lung cancer 2
Melanoma 2
Number of treatment cycles
Median (range) 5 (1-22)
111In-mapatumumab Scintigraphy
No infusion related anaphylactic reactions or other adverse events were seen upon 111In-
mapatumumab administration. 
Twelve patients underwent the fi  rst imaging series. Visual analysis of the SPECT scans showed 
retained  111In-mapatumumab blood pool activity during the scan sequence in all patients 
(fi  gure 1). Th   is was confi  rmed by the calculated long 111In-mapatumumab elimination half-life 
of approximately 13 days (table 2). In addition to the blood pool, highest 111In-mapatumumab 
uptake was seen in liver, spleen, and kidneys. Th  e  111In-mapatumumab mean eff  ective whole 
body dose determined in this study was 0.20 mSv/MBq (table 3). Th  e calculated radiation 
absorbed dose for normal organs did not diff  er signifi  cantly aft  er the fi  rst and second 111In-
mapatumumab injection (table 3). 
Th  e fi  rst 4 evaluable patients showed limited tumor visualization. Th  erefore, in the next 
patients, 111In-mapatumumab was administered 7 days before the mapatumumab infusion in 
cycle 1.
Th   e optimal time for the SPECT represents a balance between good tumor/nontumor ratios 
and suffi   cient radioactive signal. Th   e best tumor to background ratio was obtained 3 days post-
tracer injection. Th   e scans performed at day 6 were of inferior image quality as a consequence 
of insuffi   cient counting statistics.
In 2 of the 12 patients, strong 111In-mapatumumab uptake in tumor lesions was detected 
when the whole body scintigraphy and SPECT reconstructions were visually analyzed. Aft  er 
fusion of CT and SPECT images, tumor lesions were visible in 3 additional patients. In these 
5 patients, 11 out of 18 tumor lesions known by CT were imaged. Tracer uptake in these 11 
lesions was variable. 6  SERIAL 111IN-MAPATUMUMAB SPECT SCAN IN CANCER PATIENTS TREATED 
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  30 minutes  day 1  day 3  day 6
Figure 1. Coronal and transversal SPECT images of the chest and upper abdomen 30 minutes and 1, 3 
and 6 days post-injec   on of  111In-mapatumumab. Physiological 111In-mapatumumab uptake is seen in 
predominantly the heart, the descending aorta and the liver. No tumor lesions are visible in these images.
Table 2. Pharmacokine   c parameters a   er 10 mg 111In-Mapatumumab-injec   on (mean ± SD).
AUC
(h*mg/L)
T½, α
(d)
T½, ß
(d)
CL
(mL/d/kg)
V1
(mL/kg)
Vdss
(mL/kg)
Urinary excreƟ  on
(% ID/d)
N=17 956.0 ± 314.4 1.0 ± 0.6 12.7 ± 4.2 4.3 ± 1.1 44.0 ± 6.8 70.2 ± 19.7 1.4 ± 0.01
Abbrevia   ons: SD, standard devia   on; AUC, area under plasma concentra   on-   me curve; T½,α and T½,β,  111In-
mapatumumab half-life during distribu   on phase and elimina   on phase respec   vely; CL, total clearance; V1, 
volume of distribu   on for the central compartment; Vdss, volume of distribu   on at steady state; %ID/d, percentage 
of the injected dose/day. 
Table 3. Radia   on absorbed dose (organs) and eﬀ  ec   ve dose (whole body).
Scan 1 (n=9) Scan 2 (n=7)
Mean ± SD (mGy/MBq) Mean ± SD (mGy/MBq)
Heart 0.34 ± 0,04 0.34 ± 0.03
Kidneys 0.26 ± 0,03 0.23 ± 0.04
Liver 0.36 ± 0.07 0.36 ± 0.07
Lungs 0.25 ± 0.03 0.25 ± 0.02
Bone marrow 0.14 ± 0.01 0.14 ± 0.00
Spleen 0.32 ± 0.07 0.32 ± 0.09
Thyroid 0.14 ± 0.01 0.14 ± 0.00
Eﬀ  ec   ve dose (whole body; mSv/MBq)  0.20 ± 0.01 0.21 ± 0.01
Abbrevia   on: SD, standard devia   on.96
Th  e relation between mean and maximum 111In-mapatumumab uptake was linear (r2=1.00, 
P<.00001). Further analysis was therefore performed using the maximum uptake value, which 
is not infl  uenced by individual drawing of VOIs. Quantifi  cation showed a 111In-mapatumumab 
tumor to muscle ratio of median 3.5 (range, 2.2-8.0) (fi  gure 2). 
Figure 2. Tumor to normal muscle    ssue ra   os for the pa   ents with 111In-mapatumumab uptake in their 
tumor lesions (muscle uptake denoted as 1). Abbrevia   on: pt, pa   ent.
Out of the 5 patients with 111In-mapatumumab tumor uptake, 2 patients showed markedly 
intense visualization of metastases (fi  gure 3). Both patients were diagnosed with metastatic 
melanoma. One melanoma patient showed optimal 111In-mapatumumab uptake in tumor 
lesions on the day-3 scan. In the other melanoma patient, the tumor lesion was already 
visible immediately aft  er injection and continued to show on subsequent scans with the same 
intensity. In these 2 melanoma patients, 4 out of the 6 metastases positive in the fi  rst scan were 
also visualized in the second imaging series. One lesion not detected during the fi  rst imaging 
series, showed 111In-mapatumumab tumor uptake during the second series. 
In the remaining 3 patients, visual analysis of images showed 111In-mapatumumab tumor 
uptake in the identical lesions in both the fi  rst and second imaging series. 
CT evaluation aft  er the second scan in the 5 patients with 111In-mapatumumab tumor uptake 
showed no diff  erence in size of the individual tumor lesions if compared to baseline. No new 
tumor lesions were found with both CT scan and 111In-mapatumumab scintigraphy at the time 
of the second scan (cycle 3).
Th  ere was no signifi  cant  diff  erence  in  111In-mapatumumab pharmacokinetic parameters 
between the fi  rst and second group of patients (P=0.53) and between the fi  rst and second 
imaging series (P=0.70). Data were therefore pooled (table 2). In total 5 out of 22 datasets 
were excluded because of insuffi   cient numbers of samples to allow reliable estimation of the 
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 A  B
Figure 3. Coronal, transversal and sagi   al CT images and 111In-mapatumumab SPECT/CT fusion images of 
two melanoma pa   ents, 3 days post-injec   on. (A) Tumor lesions in the upper abdomen and the le    lower 
pelvic region show 111In-mapatumumab uptake. (B) Intense 111In-mapatumumab uptake in a tumor lesion 
in the abdominal wall.
Immunohistochemistry
Suffi     cient tumor tissue was available for immunohistochemical analysis in 9 patients. 
Pretreatment tumor tissue was used in 8 patients (obtained 2-9 months before enrollment). 
In 1 patient a tumor sample was obtained 20 months aft  er completion of the study treatment. 
Eight patients showed at least low cytoplasmatic TRAIL-R1 expression in tumor cells. In 4 out 
of 5 patients with 111In-mapatumumab uptake in tumor lesions, tumor tissue was available. 
Th   ree of these patients showed at least low cytoplasmatic TRAIL-R1 expression in their tumor 
cells. In the remaining patient no TRAIL-R1 in tumor cells was detected. No membranous 
staining was seen. Intensity of staining did not correlate with positive 111In-mapatumumab 
scintigraphy or tumor response to treatment.
Discussion
Th   is study showed that 111In-mapatumumab scintigraphy is feasible and can identify tumor 
lesions in advanced solid tumor patients. Tracer uptake in tumor lesions occurred in 5 out 
of 12 patients. In patients showing tumor uptake, not all tumor lesions detected by CT scan 
were visualized. Th  e most intense uptake was seen in 2 patients diagnosed with metastatic 
melanoma. Th   is is the fi  rst proof that a TRAIL-R targeting monoclonal antibody can show 
preferential uptake in known sites of tumor in a subgroup of patients. 
Mapatumumab was well-tolerated and can be administered repeatedly, in some cases for 
several year without apparent adverse eff  ects [6]. In the phase I studies, the maximum tolerated 
dose was not reached and the observed toxicity was mild when combined with chemotherapy. 98
As single agent activity has been seen in lymphoma [5], it is possible that the drug might play 
a role in combination therapy. Proper patient selection of those that might benefi  t from this 
antibody is critical. Nuclear imaging may contribute to selecting the appropriate patients for 
the drug by visualizing specifi  c uptake that accumulates in the tumor, as a potential predictor 
of effi   cacy of the therapy is suffi   cient drug reaching the target.
111In-mapatumumab showed long blood pool circulation, indicated by the extended elimination 
half-life. Th  is  refl  ects a distribution which is generally seen for intact radiolabeled monoclonal 
antibodies [18]. Th  e  long  111In-mapatumumab circulation allows suffi   cient time for the 111In-
mapatumumab to accumulate in tissues during the time-frame of the imaging.
Large heterogeneity was seen in 111In-mapatumumab uptake between the various patients 
with known metastases by CT. Given the heterogeneity of tracer uptake during the study, 
111In-mapatumumab scintigraphy could potentially identify patients that can benefi  t from 
mapatumumab-containing therapy. 
Patients showing tumor tracer uptake in the fi  rst imaging series, also showed uptake in the 
second imaging series. Th   is probably indicates that target saturation has not been reached, 
despite the fact the patients at that time had already received 3 therapeutic dosing cycles of 20 
mg/kg each. Th   is is likely explained by the high TRAIL-R1 receptor turnover that is seen aft  er 
TRAIL-R1 endocytosis induced by TRAIL-R1 targeting [19]. In our study we performed 111In-
mapatumumab scintigraphy before the start as well as during treatment. Th   e absence of tumor 
saturation implies that both timing strategies can be used. 
Th  e  111In-mapatumumab tumor uptake was highest in the 2 melanoma patients. A 
microarray study showed a higher TRAIL-R1 expression in 546 melanomas than in their 
benign nevi [20]. Similar results were obtained in a study including 80 melanoma patients 
by immunohistochemical staining for TRAIL-R1 [21]. In the current small study TRAIL-R1 
expression was however not predictive for visualization of tumor lesions. Th   e use of archival 
tumor tissue in this study may not represent the TRAIL-R1 expression status of the tumor at 
the time of imaging, as receptor status of tumors can change over time. A future larger study 
in patients with diff  erent tumor types will be needed to establish if high 111In-mapatumumab 
tumor uptake is typical for patients with metastatic melanoma. Th  e fact that one of the 
melanoma patients was treated for 22 cycles before the disease progressed may indicate that 
high 111In-mapatumumab uptake may be predictive for at least disease stabilization following 
mapatumumab containing treatment. 
In human colorectal cancer bearing mice treated with 60 mg/kg paclitaxel iv TRAIL-R1 
expression levels increased 20-fold and 111In-mapatumumab uptake was increased 1.4 fold 
[7]. Th  e current clinical trial with 111In-mapatumumab scans before and aft  er 3 cycles of 
chemotherapy did not indicate that this uptake increased following mapatumumab combined 
with gemcitabine and cisplatin.
111In-mapatumumab diff  ers from a number of other radiopharmaceuticals visualizing cell 
membrane receptors, as its target, TRAIL-R1, shows no real overexpression in tumor cells 
versus normal cells. Th   is is in contrast to, for example, the folate receptor (up to 6 fold higher 
expression in ovarian cancer), or the human epidermal growth factor receptor 2 (HER2) (up to 
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Because TRAIL-R1 shows no apparent overexpression, it can be anticipated that there is less 
driving force when compared with radiopharmaceuticals aimed at targets that show clear 
antigen overexpression, in terms of radiopharmaceutical accumulation. Because, in our 
study there is no clear correlation between immunohistochemically determined TRAIL-R1 
expression and 111In-mapatumumab tumor uptake, other factors determining drug tumor 
uptake might be involved including vascular density and intratumoral pressure. In addition, 
the tumor accumulation will be infl   u e n c e d  b y  t h e  r a t e  o f  T R A I L - R 1  e n d o c y t o s i s  u p o n  
mapatumumab antigen binding and renewal and recycling of the TRAIL-R1 membrane 
receptors [19]. Th  e current patient study shows much higher 111In-mapatumumab tumor 
uptake in the two patients with metastatic melanoma than was seen in our animal study and 
higher than we anticipated.
SPECT was used to monitor mapatumumab tumor uptake. In future studies, mapatumumab 
could also be radiolabeled with the positron emission tomography (PET) isotope 89Zr. Th  e 
long-lived positron emitter 89Zr has ideal physical characteristics for antibody imaging, such as 
a half-life comparbable to 111In of 3.3 days. Interesting results were seen in a recent clinical trial 
of 89Zr-trastuzumab in patients with breast cancer and 89Zr-U36 in patients with head and neck 
cancer [24-26]. PET imaging would have advantages over SPECT in terms of spatial resolution, 
signal to noise ratios and quantifi  cation. 
Th  e  111In-mapatumumab tumor uptake in a subgroup of patients was variable and the value of 
tumor imaging in upfront patient selection for mapatumumab-based treatment needs further 
evaluation.
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Abstract
Th   e translation of in academic laboratories developed recombinant anti-cancer biopharma-
ceuticals to the clinic, can be hampered due to diffi   culties of manufacturing these proteins 
in suffi   cient quantity, of appropriate quality and retained biological activity. Th  e in-house 
generated anti-cancer protein scFv425:sTRAIL was produced by using a novel solid-support cell 
growth matrix system, to study whether the production could be optimized. Th  e  recombinant 
fusion protein sFv425:sTRAIL is composed of the scFv425 antibody fragment directed against 
the epidermal growth factor receptor 1, that is genetically fused to the tumor-selective pro-
apoptotic tumor necrosis factor-related apoptosis inducing ligand (TRAIL). In previous in 
vitro experiments, anti-tumor activity has been demonstrated for sFv425:sTRAIL. Transfected 
CHO-K1 cells, transfected with plasmid pEE14-scFv425:sTRAIL were cultured in a disposable 
high-end solid-support cell growth matrix system (FibraStage). Th   e scFv425:sTRAIL fusion 
protein was purifi  ed from the culture medium, aft  er which quantity and biological activity were 
determined. Th   e mean concentration of scFv425:sTRAIL as excreted in the culture medium 
was 13.8 ± 3.7 mg/L, cumulatively yielding more than 55 mg unpurifi  ed scFv425:sTRAIL 
in one production run. On average this represents an 6-fold increase in production yield as 
compared to T-fl  ask production. Th   e overall purifi  cation effi   ciency was 15.4%. Moreover, the 
ScFv425:sTRAIL fusion protein retained its biological activity. Th   is solid-support cell growth 
matrix systems can be of value for the rapid and effi   cient production of suffi   cient quantities 
anti-cancer biopharmaceuticals, such as the fusion protein scFv425:sTRAIL. 104
Introduction
Many new anti-cancer agents belong to the so called ‘biopharmaceuticals’; medicinal protein 
drugs produced using biotechnology. Th   e majority of these are monoclonal antibodies (mAbs) 
[1,2]. In order to maximize biopharmaceutical production, high-end production systems 
including the Lonza Biologics Glutamine Synthetase (GS) and dihydrofolate reductase (DHFR) 
system have been developed [3]. 
Currently, numerous anti-cancer biopharmaceuticals are being designed and produced in 
academic research laboratories, some of which are of interest to be further evaluated in the 
clinic. It is however , diffi   cult for non-commercial research institutes to produce suffi   cient 
amounts of purifi  ed protein to allow for preclinical animal studies and early clinical evaluation. 
Novel solid-support cell growth matrix system have been developed that may be applied to 
improve production of experimental biopharmaceutical agents. In these production systems 
high cell densities up to 100 x 106 cells per cm3 can be obtained, enhancing biopharmaceutical 
production effi   cacy [4,5]. 
An important subgroup of current biopharmaceuticals belongs to the category of the so-
called ‘targeted drugs’: compounds aimed at tumor-specifi  c targets such as the epidermal 
growth factor receptor (EGFR), which is a member of the human epidermal growth factor 
receptor (HER) family. Members of this family have growth stimulating activity and play an 
important role in the regulation of cell growth, survival (e.g. through inhibition of apoptosis) 
and diff  erentiation. Importantly, HER family members are selectively overexpressed in a wide 
range of human cancers. 
Anti-EGFR monoclonal antibodies selectively bind to and block the EGFR ligand binding 
site, resulting in reduced mitotic signaling, which renders EGFR-positive tumor cells more 
sensitive to chemo- and radiotherapy. Currently, the EGFR blocking mAbs cetuximab and 
panitumumab are routinely used in the clinic [6].
Th  erapeutic apoptosis can be initiated through two separate pathways: the intrinsic (mito-
chondrial) or the extrinsic (death receptor) pathway. Th   e extrinsic pathway is activated upon 
extracellular binding of a death receptor ligand to the cognate receptors: TRAIL-R1 and 
TRAIL-R2 [7]. 
Preclinical studies have demonstrated that (TNF)-related apoptosis inducing ligand (TRAIL) 
has shown potent tumor-selective pro-apoptotic activity towards a variety of human cancer 
types, without any apparent toxicity towards normal human cells and tissue [8,9]. Th  erefore, 
recombinant human (rh) TRAIL has been subject to many preclinical studies in various forms 
of cancer. Th   ese studies collectively confi  rmed its potential as a new anti-cancer drug [7,10,11]. 
Both rhTRAIL and various TRAIL-receptor antibodies are currently in diff  erent stages of 
clinical research [7,12-16].
Next to conventionally produced mAbs and proteins, genetically engineered derivatives with 
rationally designed properties are now emerging as second generation drugs with enhanced 
clinical potential. A typical example is the fusion protein scFv425:sTRAIL, in which an 
EGFR-blocking antibody fragment scFv425 is genetically fused to human soluble (s)TRAIL. 
ScFv425:sTRAIL was designed to combine anti-EGFR mAb 425 blocking activity [17] with 
the tumor-selective pro-apoptotic activity of sTRAIL. In vitro experiments demonstrated that 7  SCFV425:STRAIL FUSION PROTEIN PRODUCTION IMPROVED BY SOLID-SUPPORT 
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scFv425:sTRAIL specifi  cally accumulates at the cell surface of EGFR-positive tumor cells, 
resulting in EGFR-restricted apoptosis induction in EGFR-positive tumor cells, while sparing 
normal cells [18,19]. 
Here, we describe the production of the in-house generated anti-cancer protein scFv425:sTRAIL 
by using a novel solid-support cell growth matrix system, to study whether the scFv425:sTRAIL 
production could be optimized.
Materials and Methods
Obtaining High scFv425:sTRAIL Producing Cells
Th  e fusion protein scFv425:sTRAIL was constructed and produced as previously described 
[18-20]. In short, in the multiple cloning site (MCS) of vector pEE14, the high affi   nity antibody 
fragment scFv425 (Vh-(G4S)3-Vl format) was directionally inserted using the unique Sfi  I 
and NotI-restriction enzyme sites. Th   e plasmid is equipped with a strong CMV promoter to 
drive recombinant protein expression and the GS selectable marker gene to induce amplifi  ed 
expression of the transgene. In the second MCS, the PCR-truncated DNA-fragment coding 
for the extracellular domain of sTRAIL was inserted using restriction-sites XhoI and HindIII, 
yielding pEE14-scFv425:sTRAIL plasmid. Th   e plasmid encodes an N-terminal hemaglutinin 
(HA) tag upstream of two MCS for identifi  cation and purifi  cation purposes. Th  e pEE14-
scFv425:sTRAIL plasmid was transfected into Chinese Hamster Ovary-K1 (CHO-K1 Lonza 
biologics, Portsmouth, NH, USA) cells, using the FuGENE 6 reagent kit (Roche Diagnostics, 
Almere, the Netherlands) [18]. Th   e correct and in-frame fusion of the scFv425 and sTRAIL 
encoding DNAs was confi  rmed by DNA sequence analysis. Stable transfectants were obtained 
using the GS selection method [21]. Transfected CHO-K1 cells were cultured in Glasgow’s 
Modifi  ed Eagle’s Medium (GMEM-GS, First Link, West Midlands, UK) supplemented with 
5% dialyzed fetal bovine serum (dFBS, Sigma-Aldrich Chemie, Zwijndrecht, the Netherlands) 
and 100 μM L-methionine-sulfoximine (MSX, Sigma-Aldrich Chemie). Single cell-sorted 
clones were analyzed for stable and high scFv425:sTRAIL secretion in the culture medium. 
Production of scFv425:sTRAIL
Transfected CHO-K1 cells were cultured in T75 T-fl  asks as described above to obtain 100 x 106 
cells. A disposable FibraStage cell culture system (New Brunswick Scientifi  c, Edison, NJ, USA) 
was used as the solid-support cell growth matrix-based system. Inoculation and culture of 
the solid-support cell growth matrix system was performed according to the manufacturers’ 
recommendations [22] in using serum free GMEM-GS culture medium supplemented with 5% 
dFBS and 100 μM MSX. Th   e culture medium was buff  ered with 1.9 mM NaHCO3 (B Braun, 
Oss, the Netherlands) and 13 mM HEPES (Sigma-Aldrich Chemie), to obtain a stable pH of 
approximately 7.4. 
Th  e solid-support cell growth matrix was operated in fed-batch mode, according to the 
manufacturers’ instructions. Th   e solid-support cell growth matrix system was placed in a CO2 
incubator (5%) at 37°C. A single disposable FibraStage bottle (500 mL) was inoculated with 
the 100 x 106 transfected CHO-K1 and cells were left   to settle for 4 hours. Th  e  scFv425:sTRAIL 106
fusion protein was produced during a period of 28 days at fi  xed conditions (rising rate: 2 mm/
sec, holding time: 20 sec, down rate: 2 mm/sec and bottom holding time. 
During the scFv425:sTRAIL production period, culture medium pH and glucose concentration 
were monitored daily and spend culture medium was replaced with fresh pre-warmed 
culture medium when needed. Periodically, a FibraCel disk was removed from the culture, 
hematoxylin & eosin stained and microscopically inspected for cell growth and adherent cell 
vitality. Harvested culture medium was fi  ltered (0.22 μm) and immediately stored at -80°C. Th  e 
scFv425:sTRAIL concentration was determined using the TRAIL ELISA as indicated below.
Purifi  cation of scFv425:sTRAIL
Purifi  cation of scFv425:sTRAIL was performed in batches of 250 mL by immunoaffi   nity 
chromatography exploiting the fusion protein N-terminal HA-tag. A column was packed 
with 2.0 mL of monoclonal anti-HA agarose-conjugate clone HA-7 (Sigma-Aldrich Chemie), 
according to the manufacturers’ instructions. Th  e settled 2.0 mL of anti-HA agarose 
has a binding capacity of approximately 40-67 nmol (corresponding with 9.2-15.1 mg 
scFv425:sTRAIL) [23].
Purifi  cation of scFv425:sTRAIL was performed in small batches. A maximum of 250 mL 
defrozen culture medium was supplemented with 5% NaCl 2 M, 0.05% EDTA 0.2 M and 
0.05% Tween 20 and recycled over the column for 16 hours at 4°C. In addition, the amount of 
scFv425:sTRAIL that remained in the culture medium aft  er the purifi  cation procedure (‘run-
through’) was determined by TRAIL ELISA. Next, the column was washed twice with 50 mL 
phosphate-buff  ered saline (PBS, NaCl: 136.9 mM, KCl: 2.7 mM, Na2HPO4: 8.1 mM, KH2PO4: 
1.5 mM), supplemented with 5% NaCl 2 M, 0.05% EDTA 0.2 M and 0.05% Tween 20 and once 
with 50 mL PBS without additives. Th   e scFv425:sTRAIL protein concentration in the ‘waste’ 
was also determined.
Elution was performed using 50 mL MgCl2 3.5 M (pH 6.5). Th   e 2.5 mL fractions were collected 
and the presence of the scFv425:sTRAIL fusion protein in the individual fractions was assessed 
by an immuno dot blot, using the an anti-HA peroxidase conjugate MAb (clone HA-7) (Sigma-
Aldrich Chemie) as described earlier [24]. In the fractions with the highest scFv425:sTRAIL 
concentration, the fusion protein concentration was determined by TRAIL ELISA. Th  e 
fractions with the highest concentrations were pooled and desalted using a PD-10 desalting 
column (GE Healthcare, Piscataway, NJ, USA) and TRIS buff  er pH 7 .6 containing 10 mM 
TRIS, 100 μM zinc-sulphate and 10% glycerol as eluate. Th  is  buff  er will further be referred to 
as ‘TRIS/glycerol/Zn buff  er’. Th  is  buff  er appeared to be suitable for the long-term storage of 
biological active rhTRAIL. 
Th  e scFv425:sTRAIL fusion protein was concentrated by ultrafi   ltration using a 30 kDa 
Centriprep fi  lter (Millipore, Bedford, MA, USA). Again, the amount of scFv425:sTRAIL in the 
desalted and concentrated eluate was determined by a sensitive TRAIL ELISA kit. 
Th  e  purifi  ed fusion protein was immediately stored at -80°C in TRIS/glycerol/Zn buff  er. No 
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Quality Control of scFv425:sTRAIL
Quality control was intended to establish scFv425:sTRAIL identity, quantity, purity and 
biological activity. Identity and purity were assessed by SDS-PAGE with silver-staining and 
Western-blot analysis, using anti-HA-FITC conjugated antibody as a fl  uorescent marker. 
In addition, protein size distribution under nonreducing conditions was performed by size 
exclusion  high-performance liquid chromatography (SE-HPLC). A VWR/Hitachi Elite 
LaChrome SE-HPLC system (VWR international, Amsterdam, the Netherlands), was equipped 
with a diode array absorbance detector and a size exclusion column (Superdex 200 10/300 GL, 
GE Healthcare, Hoevelaken, the Netherlands) as described earlier [25]. Sodium phosphate 
buff  er (0.025 M Na2HPO4·2H2O and 0.025 M NaH2PO4·H2O, Sigma-Aldrich Chemie) was 
used as a mobile phase. Protein size distribution was estimated using a reference Bio-Rad Gel 
Filtration standard (Bio-Rad Laboratories, Veenendaal, the Netherlands). Th  roughout the 
study, scFv425:sTRAIL concentrations were determined with a solid-phase sandwich TRAIL 
ELISA kit, according to the manufacturers’ recommendations (Diaclone SAS, Besançon, 
France). ScFv425:sTRAIL concentrations determined by this ELISA essay were corrected for 
the diff  erence in molecular weight between scFv425:sTRAIL and rhTRAIL, assuming similar 
binding for scFv425:sTRAIL and rhTRAIL. 
Th  e biological activity of scFv425:sTRAIL was assessed using a DiOC6 apoptosis fl  ow 
cytometry assay, as described earlier [18]. In short, RC21 renal cell carcinomas (generously 
provided by Dr C Löwik, University Medical Center Leiden, Leiden, the Netherlands) were 
seeded at a concentration of 4 x 104 cells per well. Cells were incubated overnight with 
increasing concentration of fusion protein, in the absence or presence of a 10-fold excess of 
mAb 425 (kindly provided by Merck) [17]. Th   e mAb 425 competes with scFv425:sTRAIL for 
the same epitope on EGFR. Subsequently, cells were washed with PBS, harvested with trypsin 
and incubated with 0.1 μM DiOC6 dissolved in culture medium for 20 minutes at 37°C, 
followed by centrifugation (5 minutes, 900 g) and resuspended in culture medium. 
Biological activity of scFv425:sTRAIL was determined aft  er 14-days storage at 4°C and during 
3 freeze-thaw cycles. In addition, biological activity was established aft  er a 1:25 dilution with 
TRIS/glycerol/Zn and PBS buff  er aft  er 4, 7 and 14 days at 4°C.108
Results
Obtaining High scFv425:sTRAIL Producing Cells
Th  e pEE14-scFv425:sTRAIL plasmid was successfully transfected into CHO-K1 cells, as 
determined by sequence analysis. Correct and in-frame fusion of the DNA encoding for 
scFvC425 and sTRAIL was confi  rmed by sequence analysis (data not shown). 
Th   e GS selection method was used to obtain transfected CHO-K1 cell clones with stable and 
amplifi  ed scFv425:sTRAIL secretion. Clone 100F1 was indentifi  ed as the highest producing cell 
line with a secretion of 2.2 mg/L scFv425:sTRAIL fusion protein into the culture medium in 
T-fl asks. Th   is clone was therefore selected for our high-scale lab production in the disposable 
FibraStage cell culture system.
Production of scFv425:sTRAIL
Th  e FibraStage cell culture system was inoculated and scFv425:sTRAIL was produced 
during 28 days at fi  xed conditions. Th  e initial culture medium glucose concentration of 
4.5 g/L steadily decreased to approximately 2.5 g/L aft  er 3-4 days of production, while the pH 
remained unchanged. Based upon the glucose consumption of the cells, the culture medium 
was replaced with new culture medium every 3 to 4 days. 
A FibraCel disk was removed from the culture at day 5, 13 and 23. Microscopic inspection of 
the HE colored cells indicated good cell viability and a steady growth aft  er inoculation. Th  e 
FibraCel disk appeared fully grown at day 28 (fi  gure 1). 
Th  e glucose concentration, pH and scFv425:sTRAIL concentration in the culture medium 
are depicted in fi  gure 2. Th  e mean scFv425:sTRAIL concentration obtained during the 28 
culture days of 13.8 ± 3.7 mg/L, resulted in more than 55 mg unpurifi  ed scFv425:sTRAIL. Th  e 
scFv425:sTRAIL production did not appear to be cell density dependent, as there was already 
constant fusion protein production right aft  er inoculation of the solid-support cell growth 
matrix system. 
 A  B  C
Figure 1. (A) HE-coloured FibraCel disks at 5, (B) 13 and (C) 23 days a   er inocula   on of 100 M CHO-K1 cells. 
The microscopic evalua   on indicates good cell vitality and excellent growth during the successive days. By 
day 23 the FibraCel disks appear fully grown.7  SCFV425:STRAIL FUSION PROTEIN PRODUCTION IMPROVED BY SOLID-SUPPORT 
CELL GROWTH MATRIX
109
Figure 2. Data  obtained  during  the  28  da ys  gro wth  period  of  the  CHO-K1  inoculat ed  FibraS tag e  cell  
culture system. The glucose concentra   on shows a stable decrease in 3-4 days a   er change of the culture 
medium (indicated by the arrows). The pH remained unaltered during the growth period. The medium 
scFv425:sTRAIL concentra   on is shown in the graph, as measured by TRAIL ELISA.
Purifi  cation of scFv425:sTRAIL
Purifi   cation of the scFv425:sTRAIL fusion protein was performed by immunoaffi   nity 
chromatography, exploiting its N-terminal HA-tag. Th  e effi     ciency of the purifi  cation 
process is depicted in fi  gure 3. Th   is graph shows the percentage scFv425:sTRAIL at diff  erent 
purifi  cation steps, relative to the initial concentration in the culture medium. Almost 30% 
of the scFv425:sTRAIL remains in the culture medium aft  er 16 hours of recycling (fi  gure 3). 
Longer recycling or increasing amounts of anti-HA agarose did not improve scFv425:sTRAIL 
binding to the column. 
During the wash-step less than 1% of the total scFv425:sTRAIL was present in the waste. Th  e 
majority of the protein (>90%) eluted in fractions 3 and 4. Th   e pooled scFv425:sTRAIL eluation 
fractions 3 and 4 equaled approximately 23% of the total amount of fusion protein that was 
present in the culture medium. Nearly 17% of the scFv425:sTRAIL appeared to be irreversible 
bound to the column’s resin (fi  gure 3).
Purifi  ed scFv425:sTRAIL was obtained aft  er desalting and concentrating. Th   e overall multi-
step purifi  cation effi   ciency was 15.4%, equal to approximately 8.5 mg purifi  ed protein for the 
entire batch of scFv425:sTRAIL. 
Quality control of scFv425:sTRAIL
Th   e level of purifi  cation was determined by SDS-PAGE, Western-blot and SEC-HPLC. SEC-
HPLC showed that the majority of the protein had an apparent molecular size of approximately 
150 kDa. A minority of the protein had a molecular weight of approximately 50 kDa. 
Purifi  ed scFv425:sTRAIL showed a high intensity silver-stained band around 50 kDa on SDS-
PAGE (fi gure 4). Other less intense bands were visible of approximately 30, 100 and 150 kDa. 110
Silver-stained Western-blot analysis confi  rmed the SDS-PAGE data (not shown). Th  e  protein 
band detected at 50 kDa (fi gure 4) is in close proximity of the monomeric form of scFv425:sTRAIL 
(51 kDa). Th   e 30, 100 and 150 kDa bands correspond to respectively monomeric sTRAIL (30 
kDa), dimeric scFv425:sTRAIL (102 kDa) and trimeric scFv425:sTRAIL (154 kDa). At 10 kDa, 
unpurifi  ed protein and/or fragments due to the SDS procedure can be seen. 
Figure 3. ( A) Rela   ve scFv425:sTRAIL concentra   on during the various puriﬁ  ca   on steps. The overall 
eﬃ   ciency was approximately 15.4%. (B) In addi   on, the frame shows that the majority of the scFv425:sTRAIL 
is concentrated in two eluate frac   ons.
Figure 4. A representa   ve example of the SDS electrophoresis gel, coloured by silver staining. The blot 
clearly shows the increase in scFv425:sTRAIL concentra   on. The 1:10 and 1:20 diluted samples indicate that 
the majority of the present protein consists of (monovalent) scFv425:sTRAIL.7  SCFV425:STRAIL FUSION PROTEIN PRODUCTION IMPROVED BY SOLID-SUPPORT 
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When tested before purifi  cation, the scFv425:sTRAIL fusion protein was biological active as 
evidenced by its potent pro-apoptotic activity towards RC21 cancer cells (83% apoptosis). Co-
incubation with a 10-fold amount of mAb 425 effi   ciently blocked scFv425:sTRAIL activity. 
Th   e scFv425:sTRAIL biological activity was not infl  uenced by three subsequent freeze-thaw 
cycles, as shown in fi  gure 5. Storage at 4°C in culture medium for a period of 14 days only 
slightly reduced scFv425:sTRAIL pro-apoptotic activity. When stored in TRIS/glycerol/Zn 
or PBS buff  er at 4°C, a more signifi  cant reduction in scFv425:sTRAIL potency was observed. 
Immediate storage of the purifi  ed scFv425:sTRAIL at -80°C therefore appears to be advisable, 
although the exact scFv425:sTRAIL stability will have to be determined. 
Figure 5. Rela   ve apoptosis induc   on in RC21 cells, measured by a DiOC6 FACS apoptosis assay a   er three 
freeze-thaw cycles and at various    me-points a   er 1:25 dilu   on with TRIS and PBS.
Discussion
Th   e current study shows the added value of a solid-support cell growth matrix system for the 
scFv425:sTRAIL fusion protein production. A high cell density was maintained during 28 days 
in transfected CHO-K1 cells, resulting in 6-fold higher scFv425:sTRAIL concentrations than 
in T-fl  asks and a total production of 55 mg unpurifi  ed scFv425:sTRAIL. Th   is was superior to 
what was expected, as a manufacturer’ reference mAb production in CHO cells was 74 mg 
protein per bottle in 28 days [22] and the production of complex protein production, is usually 
signifi  cantly lower than that of antibodies.
Th   e low-shear environment of the solid-support cell growth matrix system reduces damage 
and apoptosis during growth of the production cells, which in turn will decrease cell debris 
and simplifi  es protein purifi  cation. 
Because the solid-support cell growth matrix system is batch-fed and cultured production 
CHO-K1 cells remain in the system, there is little workload compared to spinner-, roller-, 
shake or T-fl  asks [26]. In order to produce the same 55 mg of unpurifi  ed scFv425:sTRAIL in 
T75 fl  asks, over 1,000 fl  asks and more than 25 L culture medium would have been needed. 112
In contrast, the batch-fed solid-support cell growth matrix system, which was used here 
was performed in a single bottle and with only 4 L of culture medium. A basic calculation, 
which takes into account FibraStage redemption, material costs (culture bottles, GMEM-GS 
culture medium and dFBS) and labor wages, shows that the solid-support cell growth matrix 
system is approximately 3 times more cost-eff  ective than T-fl  asks for the production of 50 mg 
unpurifi  ed scFv425:sTRAIL. Th  e FibraStage production can, however, easily be quadrupled 
at little increase in labor by using 4 bottles simultaneously. Th   is would make the FibraStage 
system almost 8 times more cost-eff  ective than T75 T-fl  asks. 
In addition to the 500 mL FibraStage cell culture system used in our study, small industrial 
scale (up to 150 L) solid-support cell growth matrix systems are available on the market 
[3,27-29]. Th   ese larger systems can facilitate the translation from the laboratory to high-scale 
productions.
In the context of the experiments described above, additional development and quality 
assessment of scFv425:sTRAIL is necessary to start patient studies. Th   e European Medicines 
Agency (EMEA) guidelines concerning the manufacturing of human medicinal products and 
non-clinical safety studies [30-41] demands a thorough description of the production process, 
properties of the manufactured biopharmaceutical and genetic characterization. In addition, 
a master and working cell banking system should be established and the risk of transmittable 
diseases should be minimized throughout the entire process. Finally, thorough testing of the 
end product should be performed before the scFv425:sTRAIL can be applied in the clinic. All 
EMEA requirements for biopharmaceuticals are summarized in appendix 1. Prior to clinical 
trials, extensive animal studies have to be performed to determine the maximum tolerated 
dose and safety, as is summarized in appendix 2.
In this fi  rst explorative study we produced the scFv425:sTRAIL fusion protein in the presence 
of dFBS and MSX. In future experiments serum-free and MSX-free production should be 
explored to minimize the risk of both MSX toxicity and bovine serum-associated transmittable 
diseases [42].
Th  e relatively low observed purifi  cation effi   ciency requires further optimization to make 
optimal use of the produced scFv425:sTRAIL fusion protein. 
Conclusion
Th  is study shows the added value of a solid-support cell growth matrix system for the 
production of the biopharmaceuticals. Th   e system provides an easy lab-scale, low-labor and 
high biopharmaceutical production, which can facilitate early (pre)clinical evaluation and the 
translation from the laboratory to the clinic. Additional development and quality assessment 
is necessary before patient studies can be conducted.
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APPENDIX 1
EMEA requirements for biopharmaceutical human medicinal products
Development of the geneƟ  cs 
Gene of interest, vector and host 
cell [30]
  − A detailed descrip   on of origin, iden   ﬁ  ca   on and isola   on of the 
cloned gene and expression vector.
Expression construct [30]   − Nucleo   de sequence of the gene of interest and of the ﬂ  anking 
control regions of the expression vector.
Status of the rDNA within the 
host cell [30] 
  − Method of vector introduc   on into the host cell and the status 
of the rDNA within the host. Molecular gene   c studies should 
establish the correct sequence has been made and incorporated 
in the host cell. Both the structure and the number of copies of 
the inserted sequence should be maintained within the cell during 
culture to the end of produc   on. 
Expression [30]    − How is the expression of the relevant gene promoted and controlled 
during produc   on?
Stability of the expression system 
[30] 
  − All biological systems are inherently subject to gene   c altera   on, 
therefore the stability of host/vector gene    c and phenotypic 
characteris    c s  s h o u l d  b e  i n v e s     gated up to and beyond the 
popula   on doubling level or genera   on number used for rou   ne 
produc   on.
  − Products expressed in foreign hosts may deviate structurally, 
biologically or immunologically from their natural counterparts, 
due to altera   ons at pos   ransla   onal level or during produc   on 
or puriﬁ  ca   on. The product must be jus   ﬁ  e d  a n d  s h o w  t o  b e  
consistently controlled.
  − Suﬃ   cient in-process controls and quality control tests during each 
produc   on are required to show compliance of the material with 
the speciﬁ  cica   on.
DerivaƟ  on and characterizaƟ  on of cell substrates [cell banks)
Origin, source, and history 
of cells [31]
The characteriza   on of the cell substrates is dependent on source of 
the cell:
1. Human cell lines: describe the    ssue or organ of origin, ethnic and 
geographical origin, age, sex and general physiological condi   on.
2. Animal cell lines: describe the species, strains, breeding condi   ons, 
   ssue or organ of origin, geographical origin, age and sex, the 
results of tests for pathogenic agents, and general physiological 
condi   on of the original donor.
3. Microbes: describe the strain, and known genotypic and phenotypic 
characteris   cs of the organism from which the cell substrate was 
derived, pathogenicity, toxin produc    on, and other biohazard 
informa   on, if any.116
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GeneraƟ  on of the cell substrate 
[31]
  − Methodologies that have been used in developing the cell substrate 
[e.g. cell fusion, transfec   on, selec   on, colony isola   on, cloning, 
gene ampliﬁ  ca   on, and adapta   on to speciﬁ  c culture condi   ons or 
media) should be described.
ConƟ  nued . DerivaƟ  on and characterizaƟ  on of cell substrates [cell banks) 
Development of a cell 
banking system [31]
Produc   on of the biopharmaceu   cal should be performed with a well 
deﬁ  ned master and working cell bank system
  − The size and methods and media used for prepara   on of the cell 
bank and storage should be described.
CharacterizaƟ  on of the 
cell bank [30,31]
  − Iden    ty, purity, and suitability of the cell substrate for 
manufacturing use should be conﬁ   rmed prior to and during 
manufacture of the biopharmaceu   cal.
  − The cell bank should be examined for adven      ous agents [viral, 
bacterial, fungal and mycoplasma).
  − The cell bank should periodically be tested for cell viability, gene   c 
and phenotypic stability and any other relevant parameters. 
  − The  cell  bank  stability  should  be  exam ined  at  le ast  twice :  at  a  
minimal number of subcul   va   ons, and at or beyond the limit of in 
vitro cell age for produc   on use.
  − Unintended variability in the culture during produc   on may lead 
to changes to the product itself [e.g. in the nature and degree of 
glycosyla   on) and/or in quan   ta   ve and qualita   ve diﬀ  erences 
in the impuri   es present. Procedures to ensure consistency of 
produc   on condi   ons as well as the ﬁ  nal product are impera   ve.
Viral safety
Viral safety [32]    − Valid throughout the en   re produc   on process of the medicinal 
product
  − Three complementary approaches are used to control the poten   al 
viral contamina   on of biopharmaceu   cal products:
1. Select and test cell lines and other raw materials for the absence of 
viruses infec   ous and/or pathogenic for humans.
2. Evaluate the capacity of the processes that is used to remove/
inac   vate infec   ous viruses.
3. Test the product at appropriate steps of produc   on for absence of 
contamina   ng infec   ous viruses.
  − Recommended assays for the detec   on of various types of viruses 
are described [32].7  SCFV425:STRAIL FUSION PROTEIN PRODUCTION IMPROVED BY SOLID-SUPPORT 
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Appendix 1. ConƟ  nued
Transmissible Spongiform Encephalopathy [TSE) and the use of bovine serum
Minimizing the risk of 
transmiƫ   ng animal spongiform 
encephalopathy agents & 
guidelines for the use of bovine 
serum [33-36] 
  − TSE guidelines are limited to ruminant derived materials and 
materials derived from animals suspected to infec   on with TSE 
through the oral route. These animals include ca   le, sheep and 
goats. These guidelines are valid throughout the en   re produc   on 
process of the medicinal product.
  − Minimizing the risk of transmission of TSE is based upon three 
complementary parameters:
1. Source animals and their geographical loca   on. 
2.  Nature of animal material and procedures to avoid cross-
contamina   on with high risk materials [e.g. central nervous system 
   ssues are highly infec   ous).
3. Produc   on process, including quality assurance to assure product 
consistency and traceability.
  − The annex [33] gives an overview of the risk of infec   vity of various 
animal    ssues.
  − For exis    ng master and working cell banks, a risk assessment 
should be performed, although manufacturers are encouraged to 
replace exis   ng cell banks when not all relevant TSE informa   on 
is available.
  − No bacteria, fungi, mycoplasma or viruses may be detected in the 
ﬁ  nal batch of bovine serum and there must be compliance with the 
TSE guidelines.
Development, producƟ  on, characterizaƟ  on and speciﬁ  caƟ  on of produced the produced 
biopharmaceuƟ  cal
General tests [30,37,38]    − Visual appearance, solubility, pH, osmolality, extractable volume, 
sterility, bacterial endotoxins, stabilizer and water, should be 
assessed where appropriate.
  − Physicochemical proper    e s  s u c h  a s  m o l e c u l a r  w e i g h t  o r  s i z e ,  
isoform pa   ern, ex   nc   on coeﬃ   cient,  electrophore   c proﬁ  les, 
chromatographic data and spectroscopic proﬁ   les should be 
determined. 
  − Visible and sub-visible par   culate  ma    e r  i n  d r u g  p r o d u c t  
should comply with the requirements set forth in the European 
Pharmacopoeia.118
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IdenƟ  ty and physicochemical 
characterizaƟ  on [30,37,38] 
  − The iden   ty of the biopharmaceu   cal should be determined by 
a highly speciﬁ  c test, based on unique aspects of the product’s 
molecular structure and/or other speciﬁ  c proper   es [e.g. pep   de 
map, an   -idiotype immunoassay, or other appropriate method).
  − If applicable, the [sub)class, light chain composi   on and primary 
structure should be determined. 
  − In addi    on, the amino acid sequence should be deduced and 
conﬁ  rmed experimentally by appropriate methods [e.g. pep   de 
mapping, amino-acid sequencing, mass spectrometry analysis). 
Variability of N- and C- terminal amino-acid sequences should be 
analyzed.
  − Free sulphydryl groups and disulﬁ  de bridges should be determined. 
Disulﬁ  de bridge integrity and mismatch should be analyzed.
  − Carbohydrate content should be determined. In addi   on,  the 
oligosaccharide pa   ern and glycosyla   on should be analyzed.
  − The rela   ve molecular mass and pI value should be determined.
  − For monoclonal an    bodies: higher-order structure should be 
characterized.7  SCFV425:STRAIL FUSION PROTEIN PRODUCTION IMPROVED BY SOLID-SUPPORT 
CELL GROWTH MATRIX
119
Appendix 1. ConƟ  nued
QuanƟ  ty, [im)purity and 
contaminants [30,37,38] 
  − Quan   ty of the drug substance, usually based on protein content, 
should be determined using an appropriate physicochemical and/
or immunochemical assay.
  − Due to the eﬀ  ect of glycosyla   on, deamida   on, or other hetero-
genei    es, the absolute purity of a biotechnological product 
is extremely diﬃ     cult to determine. Thus, the purity of a bio-
pharmaceu   cal/biological product should be typically assessed by 
more than one method and the purity value derived is method-
dependent. For the purpose of stability tes    ng and tests for 
purity should focus on methods for determina   on of degrada   on 
products. 
  − Biopharmaceu   cal medicinal products commonly display several 
sources of heterogeneity, which lead to a complex purity/impurity 
proﬁ  le. The purity/impurity proﬁ  le [including e.g. C-terminal lysine 
processing, N-terminal pyroglutamate, deamida   on,  oxida   on, 
isomerisa   on, fragmenta   on, disulﬁ  de bond mismatch, N-linked 
oligosaccharide, glyca   on) should be assessed by a combina   on of 
orthogonal methods.
  − Mul    mers and aggregates should also be appropriately 
characterised using a combina   on of methods. Poten   al process-
related impuri   es [e.g. HCP , host cell DNA, cell culture residues, 
downstream processing residues) should be iden   ﬁ  ed,  and 
evaluated qualita   vely and/or quan   ta   vely, as appropriate.
  − The use of relevant physico-chemical, biochemical and immuno-
chemical analy   cal methodologies should permit a comprehensive 
characteriza   on of the ac   ve substance and/or medicinal product 
[e.g. molecular size, charge, hydrophobicity) and the accurate 
detec   on of degrada   on changes that may result from deamida   on, 
oxida   on,  sulphoxida   on,  aggrega    on or fragmenta   on  during 
storage. Methods that may contribute to this include electro-
phoresis [SDS-PAGE, immunoelectrophoresis, Western blot, 
isoelectrofocusing), high-resolu   on chromatography, and pep   de 
mapping.
  − Chromatographic and/or electrophore    c methods capable of 
detec    ng product trunca   on,  dissocia    on and polymeriza   on 
should be included, and quan   ta   ve limits should be proposed for 
these, as appropriate.
  − Appropriate acceptance criteria should be considered for the 
glycosyla   on.
  − Contaminants, which include all adven      ously  introduced 
materials not intended to be part of the manufacturing process 
[e.g. microbial species, endotoxins) should be strictly avoided and/
or suitably controlled. The puriﬁ  ca   on processes must be shown to 
be capable of removing impuri   es. 
Biological acƟ  vity [30,37,38]    − The biological ac   vity should be assessed in vitro and/or in vivo. 
  − The mechanism of ac    on and the importance of the product 
eﬀ  ector func   ons with regards to the safety and eﬃ   cacy of the 
product should be discussed.
  − For biologicals where eﬀ  ector func   on may play a role in the 
mechanism of ac   on, and/or have an impact on the product safety 
and eﬃ   cacy, a detailed analysis of ADCC, cytotoxic proper   es, 
ability for complement binding and ac   va   on should be provided. 
In addi   on, other eﬀ  ector func   ons, including Fc gamma receptor 
binding ac   vity, and neonatal Fc receptor binding ac   vity should 
be men   oned, as appropriate.120
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Potency [30, 37-39]    − Potency assay should be part of the speciﬁ  ca    ons for drug 
substance and/or drug product, and should ideally reﬂ  ect  the 
biological ac   vity in the clinical situa   on.
  − For biopharmaceu   cal medicinal products for which the clinical 
ac   vity is only dependent on binding/neutralizing proper   es, a 
potency assay that measures binding to the target may be deemed 
acceptable. Where eﬀ  ector  func    ons are relevant for clinical 
ac   vity, an assay that takes eﬀ  ector func   ons into account should 
be performed.
Immunological properƟ  es 
[30,37,38] 
  − Immunological proper    es should be fully characterized when 
applicable. 
  − The complementary determining regions should be iden   ﬁ  ed and 
the epitope and molecule bearing the relevant epitope should be 
deﬁ  ned. This should include a biochemical iden   ﬁ  ca   on of these 
structures [e.g. protein, oligosaccharide, glycoprotein, glycolipid), 
and relevant characteriza   on studies.
  − Binding assays to puriﬁ  ed  an    gens and deﬁ   ned regions of 
an   gens should be performed to determine aﬃ   nity, avidity and 
immunoreac   vity [including cross-reac   vity with other structural 
homologous proteins). 
  − Uninten   onal  reac    vity/cytotoxicity for human    ssues  dis   nct 
from the intended target should be documented. Cross-reac   vity 
with a range of human    ssues should be determined. Suggested 
human    ssues are listed in annex I [37].
Stability tesƟ  ng of the biopharmaceuƟ  cal
Tests during the manufacturing 
process 
[40] 
  − The stability of the biopharmaceu   cal has to be determined during 
diﬀ  erent steps of the manufacturing process:
  − Where ac   ve substance bulk material is stored a   er manufacture, 
but prior to formula   on and ﬁ  nal manufacturing, stability data 
should be provided on at least three batches for which manufacture 
and storage are representa    ve of the manufacturing scale of 
produc   on.
  − Intermediates: certain intermediates may be cri    cal to the 
produc   on of the ﬁ  nal product.
  − Medicinal product [Final Container Product): stability informa   on 
should be provided on at least three batches of ﬁ  nal container 
product representa   ve of that which will be used at manufacturing 
scale.7  SCFV425:STRAIL FUSION PROTEIN PRODUCTION IMPROVED BY SOLID-SUPPORT 
CELL GROWTH MATRIX
121
Appendix 1. ConƟ  nued
Stability-indicaƟ  ng proﬁ  le, 
storage condiƟ  ons and 
tesƟ  ng frequency.
  − A stability-indica   ng, validated essay, which can detect changes in 
iden   ty, purity and potency of the ﬁ  nal product must be developed.
  − When the intended use of a product is linked to a deﬁ  nable and 
measurable biological ac   vity, tes   ng for potency should be part 
of the stability studies. Potency studies should be performed at 
appropriate intervals.
  − The use of relevant physicochemical, biochemical and 
immunochemical analy    cal methodologies should permit a 
comprehensive characteriza   on of the ac   ve substance and/or 
medicinal product [e.g. molecular size, charge, hydrophobicity) 
and the accurate detec    on of degrada    on changes that may 
result from deamida   on, oxida   on, sulphoxida   on, aggrega   on 
or fragmenta   on during storage. Methods that may contribute to 
this include electrophoresis [SDS-PAGE, immunoelectrophoresis, 
Western blot, isoelectrofocusing), high-resolu   on  chrom-to-
graphy, and pep   de mapping.
  − Visual appearance, pH, sterility, container closure and addi   ve 
degrada   on should be monitored.
  − Temperature, humidity, light, container closure, stability a   er 
recons   tu    on [if applicable) and inﬂ   uence of accelerated and 
stress condi   ons should be tested to determine [op   mal) storage 
condi   ons. 
  − The tes   ng frequency is based upon the expected shelf-live.122
APPENDIX 2
Non-Clinical Safety Studies for the Conduct of Human Clinical Trials and Marketing 
Authorization for Pharmaceuticals
Preclinical animal studies to establish the MTD and MDF [41] 
  − Establishing the maximum tolerated dose [MTD) or the maximal feasible dose [MFD) in animals
  − Limit doses for acute, subchronic, and chronic toxicity studies of 1000 mg/kg/day for rodents and non-
rodents are almost always considered appropriate. 
  − Where a dose of 1000 mg/kg/day does not result in a 10-fold to the clinical exposure and the clinical 
dose exceeds 1 g per day, the doses in the toxicity studies should be limited by a 10-fold exposure margin 
or a dose of 2000 mg/kg/day or the MFD, whichever is lower. 
  − In those rare situa   ons in which the dose of 2000 mg/kg/day results in an exposure that is less than the 
clinical exposure, a higher dose up to the MFD can be considered.
Exploratory clinical trials [41]
4. Total clinical dose ≤100 μg [providing total dose ≤1/100th No Observed Adverse Eﬀ  ect Level [NOAEL) and 
≤1/100th pharmacological ac   ve dose)
Pharmacology General toxicity Genotoxicity/other
  − In vitro target/receptor 
proﬁ  ling.
  − Characteriza   on of 
primary pharmacology in 
a pharmacodynamically 
relevant model.
  − Extended single dose toxicity 
study in one species by intended 
route of administra   on with 
toxicokine   c data. A maximum 
of 1000-fold the clinical dose can 
be used.
  − Genotoxicity studies are not 
recommended.
  − For highly radioac   ve agents, 
pharmacokine   cs and dosimetry 
es   mates should be submi   ed.
  − Total clinical cumula   ve dose ≤500 μg, maximum of 5 administra   ons [providing each dose ≤100 μg and 
each dose ≤1/100th NOAEL and ≤1/100th pharmacological ac   ve dose)
  − In vitro target/receptor 
proﬁ  ling.
  − Characteriza   on of 
primary pharmacology in 
a pharmacodynamically 
relevant model.
  − 7-day repeated-dose toxicity 
study in one species by intended 
route of administra   on with 
toxicokine   c data. Hematology, 
clinical chemistry, necropsy, and 
histopathology data should be 
included. A maximum of 1000-
fold the clinical dose can be used.
  − Genotoxicity studies are not 
recommended.
  − For highly radioac   ve agents, 
pharmacokine   cs and dosimetry 
es   mates should be submi   ed.
  − Single dose clinical studies into the an   cipated therapeu   c range [up to ½ NOAEL exposure in the most 
sensi   ve species, providing toxicity in animals is reversible)
  − In vitro target/receptor 
proﬁ  ling.
  − Characteriza   on of 
primary pharmacology in 
a pharmacodynamically 
relevant model.
  − Core ba   ery of safety 
pharmacology.
  − Extended single dose toxicity 
study in rodent and non-
rodent by intended route of 
administra   on with toxicokine   c 
data.
  − Hematology, clinical chemistry, 
necropsy, and histopathology 
data should be included. The top 
dose should be the MTD, MFD of 
limit dose.
  − Ames assay [or an alterna   ve 
assay if Ames is inappropriate, 
for example, for an an   bacterial 
product).7  SCFV425:STRAIL FUSION PROTEIN PRODUCTION IMPROVED BY SOLID-SUPPORT 
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  − Clinical dosing up to 14 days into the therapeu   c range but not intended to evaluate clinical MTD 
[star   ng dose: 1/50th of the NOAEL. Subsequent doses should not exceed 1/10th of the lower exposure, 
the NOAEL or 1/2 the AUC at the highest dose tested, dependent on toxicity)
  − In vitro target/receptor 
proﬁ  ling.
  − Characteriza   on of 
primary pharmacology in a 
pharmacodynamically relevant 
model.
  − Core ba   ery of safety 
pharmacology.
  − 2-week repeated-dose 
toxicity studies in rodent and 
non-rodent with standard 
parameters assessed and where 
dose selec   on in animals is 
based on exposure mul   ples 
of an   cipated clinical AUC at 
maximum dose.
  − Ames assay [or an appropriate 
alterna   ve assay if Ames is 
inappropriate, for example, for 
an an   bacterial product) and an 
assay [in vitro or in vivo) capable 
of detec   ng chromosomal 
damage in a mammalian system.
  − Clinical dosing up to 14 days and not to exceed dura   on of dosing in non-rodent, into therapeu   c 
range but not intended to evaluate clinical MTD [star   ng dose: 1/50th of the NOAEL. Subsequent doses 
should not exceed 1/10th of the lower exposure, the NOAEL or 1/2 the AUC at the highest dose tested, 
dependent on toxicity)
  − In vitro target/receptor 
proﬁ  ling.
  − Characteriza   on of 
primary pharmacology in a 
pharmacodynamically relevant 
model.
  − Core ba   ery of safety 
pharmacology.
  − 2-week repeated-dose 
toxicity study in rodents [with 
jus   ﬁ  ca   on of the rodent as an 
appropriate species). The top 
dose should be the MTD, MFD 
or limit dose.
  − Conﬁ  rmatory study in non-
rodent [n=3) at the an   cipated 
NOAEL exposure in rodent, with 
dura   on of a minimum of 3 days 
and at least the intended clinical 
study dura   on or an dose-
escala   ng study in non-rodent.
  − Ames assay [or an appropriate 
alterna   ve assay if Ames is 
inappropriate, for example, for 
an an   bacterial product) and an 
assay [in vitro or in vivo) capable 
of detec   ng chromosomal 
damage in a mammalian system.
DuraƟ  on of repeated-dose toxicity studies to support clinical trials [41]
Maximum duraƟ  on trial Minimum duraƟ  on rodent Minimum duraƟ  on non-rodent
  − Up to 2 weeks   − 2 weeks   − 2 weeks
  − Between 2 weeks and 
6 months
  − Same as clinical trial   − Same as clinical trial
  − >6 months   − 6 months   − 9 months
DuraƟ  on of repeated-dose toxicity studies to support markeƟ  ng [41]
DuraƟ  on of indicated treatment Minimum duraƟ  on rodent Minimum duraƟ  on non-rodent
  − Up to 2 weeks   − 1 month   − 1 month
  − >2 weeks to 1 month   − 3 months   − 3 months
  − >1 month to 3 months   − 6 months   − 9 months
  − >3 months   − 6 months   − 9 months8SUMMARY, DISCUSSION AND 
FUTURE PERSPECTIVES
In recent years, many new anticancer drugs have been developed and numerous others are 
in the pipeline. Most of these drugs belong to the category of the so-called ‘targeted drugs’: 
compounds aimed at tumor-specifi  c targets. In order to be eff  ective, it is mandatory that the 
target is present at time of treatment. Th   ere are, already a number of established predictive 
biomarkers available for anticancer drugs. Th  e best examples are Estrogen Receptor (ER), 
Progesterone Receptor (PR) and Human Epidermal Growth Factor Receptor 2 (HER2/neu, 
further referred to as ‘HER2’) expression in breast cancer, c-KIT mutations in gastrointestinal 
stromal tumors (GIST) and HER1/epidermal growth factor receptor 1 (EGFR1) mutations in 
non-small-cell lung carcinoma (NSCLC). In addition to the availability of the tumor target, it 
is necessary that suffi   cient drug penetrates into the tumor. 
At this moment, tumor tissue is oft  en required for predictive biomarker assays. Whole body 
non-invasive scintigraphy providing information of all tumor lesions could be a strategy to 
determine eligibility of patients for targeted therapy, determine biodistribution of the drug 
and help predict and evaluate therapy response. Suitable radiopharmaceuticals, however, will 
have to meet the criteria of good selectivity and specifi  city and be capable of detecting small 
tumor lesions, including non-accessible distant metastases in a single scan. 
Two important targets for current and new anticancer drugs are explored in this thesis: the 
HER2 member of the ErbB tyrosine kinase receptor family and the extrinsic apoptotic pathway.
Th   e ErbB tyrosine kinase receptor family consists of four receptors: HER1-4. Th  ese  receptors 
are composed of an extracellular binding domain, a transmembrane segment and an 
intracellular protein tyrosine kinase domain. Members of the HER family have a growth 
stimulating activity, and play an important role in the regulation of cell growth, survival (e.g. 
through inhibition of apoptosis), diff  erentiation and have been detected in a wide range of 
human cancers. Gene amplifi  cation and receptor overexpression of HER2 is associated with 
oncogenic transformation in tumors. In case of breast cancer, there is a worse prognosis and 
more aggressive tumor behavior in the clinical setting when no additional HER2 directed 126
therapy is used. Current available therapy consists of the humanized anti-HER2 monoclonal 
antibody trastuzumab or the HER1/EGFR1 and HER2 dual tyrosine kinase inhibitor lapatinib. 
Th   e HER2 tumor status can show changes during therapy and may diff  er across tumor lesions 
within a single patient. As a consequence, patients with a tumor that turned HER2 positive 
would be entitled to receive trastuzumab treatment, while those with a tumor that lost HER2 
(over)expression should no longer receive trastuzumab. Additional biopsies during the course 
of the disease to analyze the tumor characteristics, are advised in several guidelines, although 
lesions can be diffi   cult to access and there may also be heterogeneity between lesions. We 
hypothesize that whole body non-invasive HER2 scintigraphy could be a strategy to determine 
H E R 2  e x p r e s s i o n  o f  a l l  l e s i o n s ,  i n c l u d i n g  n o n - a c c e s s i b l e  d i s t a n t  m e t a s t a s e s  w i t h  h i g h  
selectivity and specifi  city in a single scan and thus overcome these problems.
Besides growth factor receptor blockage, which makes tumor cells more vulnerable for 
chemotherapy induced apoptosis, proteins that activate the extrinsic cellular pathway can 
directly initiate apoptosis. Apoptosis or regulated cell death is an evolutionary well conserved 
mechanism that can be induced through two separate pathways: the intrinsic (mitochondrial) 
or the extrinsic (death receptor) pathway. Th   e extrinsic pathway is activated upon extracellular 
binding of death receptor ligands to their cognate receptors (TRAIL-R1 and TRAIL-R2), 
setting an apoptosis cascade in motion, ultimately resulting in tumor cell death. Among the 
death receptor ligands are tumor necrosis factor alpha (TNF-α), Fas ligand and naturally 
occurring recombinant human (rh) tumor necrosis factor (TNF)-related apoptosis inducing 
ligand (TRAIL). Of these TRAIL is seems most suitable for clinical use. RhTRAIL and death 
receptor targeting antibodies are currently explored in the (pre)clinic. An example of such 
a monoclonal antibody is mapatumumab (HGS-ETR1), a fully agonistic human TRAIL-R1 
targeting antibody.
Th   e overall goal of this thesis is to develop and explore the preclinical and clinical use of new 
radiopharmaceuticals targeting HER2 and TRAIL death-receptors for patient selection and 
to predict 
Chapter 2 presents an overview of the radiopharmaceuticals that have been developed and 
evaluated for HER2 imaging in animals and patients. Th   e aim of this review is to describe 
the available radiopharmaceuticals, and their potential role in improving diagnostic imaging, 
guiding monoclonal antibody-based therapy and support the development of HER2 monoclonal 
antibody-based drugs. Th   e radiopharmaceuticals that have been developed against HER2 can 
be divided into two groups, namely the radiolabeled intact antibodies and smaller proteins 
(including fragment antigen binding) fragments, minibodies, single chain fragment variables 
(ScFvs), diabodies and affi   bodies). 
Large, intact monoclonal antibodies penetrate slowly but constantly into solid tumor 
tissue, ultimately resulting in relatively late maximal tumor accumulation. Smaller (bio)
pharmaceuticals penetrate more swift  ly into tumor tissue, but are rapidly cleared by the 
kidneys, resulting in a lower tumor uptake. When the proteins are radiolabeled to produce 
tracers, intact antibodies generally show high tumor uptake but low tumor-to-blood ratios, 
particularly at early time points. Radiolabeled small proteins – on the contrary – show widely 
diff  ering values for tumor uptake and tumor-to-blood ratios, but generally a lower tumor 8  SUMMARY, DISCUSSION AND FUTURE PERSPECTIVES 127
uptake and higher tumor-to-blood ratios than intact monoclonal antibodies. Th   e current data 
explored in this review indicate that clinical HER2 immunoscintigraphy is already feasible 
with intact radiolabeled antibodies and possibly with smaller proteins. Additional research is 
however needed to prove its value and make this technique applicable on a larger scale.
In chapter 3 clinical grade zirconium-89 ( 89Zr) radiolabeled trastuzumab was developed as 
a new PET radiopharmaceutical for HER2 imaging. 89Zr-trastuzumab was compared with 
indium-111 (111In) trastuzumab SPECT, which was already tested in the clinic. In the study, 
the minimal required trastuzumab dose for optimal microPET imaging and biodistribution 
was determined in human HER2 positive or negative tumor xenograft   bearing mice. It was 
shown that 89Zr-trastuzumab was effi   ciently radiolabeled with high radiochemical purity and 
specifi  c activity. Th  e antigen binding capacity was preserved and the radiopharmaceutical 
proved to be stable for up to 7 days in solvent and human serum. Th   e minimal required dose 
for optimal imaging was 100 μg per animal and the comparative biodistribution study showed 
a higher uptake of 89Zr-trastuzumab in the HER2 positive tumor, when compared to the HER2 
negative control tumor, especially at day 6 (33.4 ± 7.6% versus 7.1 ± 0.7 percent injected dose 
per gram tissue (% ID/g); P=0.014). Th   ere was a good correlation between the microPET and 
the ex vivo tumor uptake and between 89Zr- and 111In-trastuzumab tumor uptake (R2=0.972). It 
was therefore concluded that clinical grade 89Zr-trastuzumab showed high and HER2 specifi  c 
tumor uptake, at a good resolution and was considered suitable for clinical application. 
In  chapter 4A, the developed clinical grade 89Zr-trastuzumab was thereaft  er studied in 
metastatic breast cancer patients. In this fi  rst in man clinical study, 89Zr-trastuzumab imaging 
was performed to determine 89Zr-trastuzumab antibody dose and timing. HER2-positive 
metastatic breast cancer patients received 37 MBq 89Zr-trastuzumab at 3 trastuzumab protein 
doses (10 or 50 mg when trastuzumab naive and 10 mg while on trastuzumab treatment) and 
underwent ≥2 PET-scans around day two and fi  ve. Fourteen patients were included. Th  e  best 
moment to assess 89Zr-trastuzumab tumor uptake was 4-5 days post-injection. Trastuzumab 
naive patients required 50 mg 89Zr-trastuzumab and patients on trastuzumab treatment 10 mg. 
Accumulation of 89Zr-trastuzumab allowed PET imaging of most known lesions and some 
unknown lesions. Th   e relative uptake value (mean percentage radioactivity of injected dose 
± SEM) was, 12.8 ± 5.8, 4.1 ± 1.6 and 3.5 ± 4.2 in liver, bone and brain lesions and 5.9 ± 2.4, 
2.8 ± 0.7, 4.0 ± 0.7 and 0.20 ± 0.1 in normal liver, spleen, kidneys and brain tissue. In conclusion, 
89Zr-trastuzumab PET at appropriate antibody dose allows visualization and quantifi  cation of 
uptake in HER2 positive lesions in metastatic breast cancer patients. 
Chapter 4B describes a case were 89Zr-trastuzumab HER2-PET imaging was applied in a breast 
cancer patient with extensive HER2 positive bone- and liver metastases. Th  is trastuzumab 
naive patient received 89Zr-trastuzumab with an optimal trastuzumab protein dose for 
imaging of 50 mg, as was earlier described in chapter 4. Th  e fi  rst HER2 PET-scan showed 
extensive 89Zr-trastuzumab uptake in the liver metastases (48% of injected dose) in addition 
the 89Zr-trastuzumab blood pool levels were extremely low and other tumor lesions were hardly 
or not visible. Two days aft  er a 4 mg/kg trastuzumab loading dose, a second 89Zr-trastuzumab 
injection was given. Compared to the fi  rst HER2-PET scan, this second scan showed less 89Zr-128
trastuzumab liver uptake (33% of injected dose), a higher blood pool level and more uptake 
89Zr-trastuzumab in other tumor lesions, such as bone metastases. Th  e almost complete 
trastuzumab clearance from the blood aft  er the fi  rst injection and the performed calculations, 
seem to indicate that insuffi   cient protein was initially available to saturate the large amount 
of tumor lesion. Th   e imaging results in this patient showed that an extensive HER2 positive 
tumor mass can signifi  cantly infl  uence (89Zr-) trastuzumab distribution and clearance. It could 
therefore be considered to perform a study with a more patient tailored trastuzumab dosing 
schedule based on tumor volume instead of dosing only based on bodyweight which is now 
common practice.
Similar to the development of 89Zr-trastuzumab, we have also manufactured and evaluated 
radiolabeled rhTRAIL and the TRAIL-R1 monoclonal antibody mapatumumab for clinical 
TRAIL-R1 and TRAIL-R2 imaging. RhTRAIL and mapatumumab have shown in vitro and 
in vivo effi   cacy in a wide variety of human tumor cell lines and xenograft   models and both 
have been evaluated in phase I-II clinical trials. Radiolabeled rhTRAIL and mapatumumab 
were used to study biodistribution and tumor accumulation in animals with a low and high 
TRAIL-R1 and TRAIL-R2 expressing human xenograft   (chapter 5). For TRAIL-R1 and 
TRAIL-R2, there was a 2-4 fold diff  erence in receptor expression between the low and high 
expressing cell lines. RhTRAIL was radioiodinated and mapatumumab was conjugated and 
radiolabeled with 111In. Th  e radiopharmaceuticals were characterized, in vitro stability and 
death receptor targeting capacities were determined, and in vivo biodistribution was studied 
in nude mice bearing human tumor xenograft  s with low or high TRAIL-R1 expression. 
Labeling effi   ciencies, radiochemical purity, stability, and binding properties were optimized 
for the radioimmunoconjugates. 
In vivo biodistribution showed rapid renal clearance of 125I-rhTRAIL, with highest kidney 
activity at 1 5 min and almost no detectable activity aft  er 4 h. Activity rapidly decreased 
in almost all organs, except for the xenograft   s. Radiolabelled mapatumumab showed 
blood clearance between 24 and 168 h and a reduced decrease in radioactivity in the high 
receptor expression xenograft  . RhTRAIL and mapatumumab can be effi   ciently radiolabelled. 
Concluding, the new radiopharmaceuticals can be used clinically to study pharmacokinetics, 
biodistribution and tumour targeting, which could support evaluation of the native targeted 
agents in phase I/II trials. 
In chapter 6, 111In-mapatumumab was evaluated in patients to visualize tumor lesions by serial 
111In-mapatumumab scintigraphy and determine 111In-mapatumumab pharmacokinetics in 
patients with advanced solid tumors before and during treatment with the TRAIL-R1 targeting 
antibody mapatumumab plus gemcitabine and cisplatin. 
Patients with advanced solid tumors received mapatumumab 20 mg/kg iv and cisplatin 
80 mg/m2 iv on day 1 and gemcitabine 1250 mg/m2 iv on days 1 and 8, every 21 days. Patients 
received 150 MBq 111In-mapatumumab in cycle 1 and cycle 3. Th   irty minutes and at day 1, 3 
and 6 aft  er the fi  rst and second tracer injection planar whole body imaging and single-photon 
emission computed tomography (SPECT) was performed. SPECT images were fused with CT. 
TRAIL-R1 tumor expression was assessed immunohistochemically. Pharmacokinetic analysis 
of 111In-mapatumumab was performed in both cycles.8  SUMMARY, DISCUSSION AND FUTURE PERSPECTIVES 129
Twelve patients were enrolled. Visual analysis of the SPECT scans showed retained 111In-
mapatumumab blood pool activity during the scan sequence in all patients. In addition to the 
blood pool, substantial 111In-mapatumumab uptake was seen in well-perfused organs as the 
liver and spleen. Th  e  111In-mapatumumab mean eff  ective radiation dose determined in this 
study was 0.41 mSv/MBq. Th   e best tumor to background ratio was obtained 3 days post-tracer 
injection. In 5 of the 12 patients, 11 out of 18 tumor lesions known by CT were visualized with 
111In-mapatumumab SPECT, but a large heterogeneity was seen in 111In-mapatumumab uptake 
between these 5 patients. Two melanoma patients showed remarkable intense tracer uptake. 
In 3 patients all lesions were visualized. SPECT results in cycle 3 were comparable to the fi  rst 
SPECT series. Quantifi  cation showed a 111In-mapatumumab tumor uptake of median 3.5 
(range, 2.2-8.0) relative to muscle tissue. CT evaluation aft  er the second scan in the 5 patients 
with 111In-mapatumumab tumor uptake showed no diff  erence in size of the individual tumor 
lesions if compared to baseline.
Th  ree of the 4 patients having positive 111In-mapatumumab scintigraphy and tumor tissue 
available showed at least low cytoplasmatic TRAIL-R1 expression. Intensity of staining did 
not correlate with positive 111In-mapatumumab scintigraphy or tumor response to treatment. 
Th  e  111In-mapatumumab tumor uptake in a subgroup of patients was variable and the 
value of tumor imaging in upfront patient selection for mapatumumab-based treatment 
needs further evaluation.
S o  f a r ,  a l l  p r o t e i n s  u s e d  i n  t h e  t h e s i s  h a d  a l r e a d y  b e e n  a v a i l a b l e .  E i t h e r  a s  c o m m e r c i a l  
authorized medicinal products for human use or previously produced proteins. 
In chapter 7, a new genetic fused protein (scFv425:sTRAIL) is developed, as an example for 
the upscaled production of potential anti-cancer biopharmaceuticals, using a solid-support 
cell growth matrix system. Currently, many new anti-cancer drugs are also developed in the 
academic setting and of interest to be tested in the clinic. In order to bring these drugs from the 
bench to the bedside, it is important to produce suffi   cient amounts for advanced pre-clinical 
animal studies and early phase clinical trials. A solid-support cell growth matrix system might 
help to facilitate in producing larger amounts of the required biopharmaceutical. We aimed to 
test this for scFv425:sTRAIL, a genetically fused protein consisting of anti-epidermal growth 
factor receptor 1 single chain variable antibody fragments and TRAIL. 
For the scFv425:sTRAIL production, transfected CHO-K1 cells were cultured in a disposable 
FibraStage cell culture system which served as a solid-support cell growth matrix system. Th  e 
produced scFv425:sTRAIL was purifi  ed and the quality was evaluated. Th   e mean concentration 
was 13.8 ± 3.7 mg/L, resulting in more than 55 mg of unpurifi  ed scFv425:sTRAIL. Th  e  overall 
multi-step purifi  cation  effi     c i e n c y  w a s  1 5 . 4 % .  C o m p a r i s o n  w i t h  t h e  E u r o p e a n  g u i d e l i n e s  
showed a need for thorough additional research to characterize and validate scFv425:sTRAIL. 
It can be concluded that a solid-support cell growth matrix system, like the FibraStage can be 
used to produce a larger amount of a biopharmaceutical protein (such as scFv425:sTRAIL). 
According to the European legislation on biopharmaceuticals, additional detailed research is 
needed to further characterize and validate the produced fusion protein scFv425:sTRAIL.
Overall, three new radiopharmaceuticals (89Zr-trastuzumab,  125I-rhTRAIL and 111In-
mapatumumab) against 2 diff  erent important targets (HER2 and TRAIL-R1/TRAIL-R2) have 130
been developed and evaluated in animals. 89Zr-trastuzumab and 111In-mapatumumab tumor 
imaging was feasible in cancer patients. 
In conclusion, this thesis describes the development and exploration of three new 
radiopharmaceuticals suitable for clinical use, with the intention to improve patient selection 
and to evaluate therapy. Th   ese radiopharmaceuticals could potentially be used as biomarkers. 
Future Perspectives
Although the detection of previously unidentifi  ed lesions and knowledge on the molecular 
composition of the tumor (e.g. receptor status) allows tailor made instead of generic therapy, 
one of the great unmet needs is to predict therapy response non-invasively [1], in order to avoid 
ineff  ectivity, toxicity and high costs upfront. Th  e  eff  ectiveness of current targeted therapy is 
limited [2,3]. 
If further research would indicate that the immunoscintigraphy described in this thesis 
has predictive value for therapy response, it will not be conclusive. Radiopharmaceuticals 
generally only accumulate on a single tumor target, where multiple targets can be responsible 
for tumor growth. Moreover, downstream signaling, which is generally not measured by 
radiopharmaceutical accumulation plays an important role in therapy effi   cacy. Th  erefore,  even 
when a tumor expresses appropriate levels of the target, targeted therapy may fail if the tumor 
also has characteristics that will render it resistant to the chosen treatment [4]. Biomarkers 
that allow early response prediction would be very helpful. Currently there are, however, no 
serum markers that can adequately predict therapy response [5], therefore anti-cancer therapy 
is monitored by the objectively measured anatomic decrease in tumor size. 
An example might be heat shock protein-90 inhibiting therapy, where HER2 depletion could 
be an early readout for therapy effi   cacy, as has been demonstrated in preclinical studies [6,7]. 
In animals treated with the heat shock protein-90 inhibitor NVP-AUY922, PET tumour 
quantifi  cation showed a mean reduction of 41% (p=0.0001) in 89Zr-trastuzumab xenograft   
uptake 144 h post tracer injection. PET results were confi  rmed by ex-vivo 89Zr-trastuzumab 
biodistribution and HER2 immunohistochemical staining [8]. 
Finally, immunoscintigraphy might help to facilitate fi  rst-in-man clinical trials and provide 
information about the target occupancy, optimal drug dose, biodistribution and toxicity in a 
more effi   cient and safer way, with fewer patients [9]. 
For the clinical applicability of non-invasive imaging techniques, it is essential that overall 
sensitivity, specifi  city, and accuracy are high. In what extend still needs further validation 
[10]. So far, only the fi  rst steps into radiopharmaceutical validation have been made. In order 
to accelerate this process, identical radiopharmaceuticals should be available worldwide to 
compare results properly.
It is realistic to expect that in the near future several techniques will be combined such as 
thorough tumor analysis whole body immunoscintigraphy, measurements of circulating 
tumor cells, depending on tumor type and situation to determine the right targeted drug and 
drug dose for the right patient [11]. 8  SUMMARY, DISCUSSION AND FUTURE PERSPECTIVES 131
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De afgelopen jaren zijn diverse nieuwe geneesmiddelen tegen kanker ontwikkeld en ter 
beschikking gekomen voor patiënten. Vele andere zullen op afzienbare termijn volgen. Een 
groot deel van deze geneesmiddelen behoort tot de zogenaamde in het Engels aangeduide 
‘targeted drugs’ of wel ‘doelgerichte geneesmiddelen’. Dit zijn geneesmiddelen gericht tegen 
doelen, in afwijkende mate in tumorcellen voorkomen. Voor de werkzaamheid van dit type 
geneesmiddelen is het van belang dat - ten tijde van de behandeling met deze geneesmiddelen 
  het aangrijpingspunt ook daadwerkelijk in de tumorcel aanwezig is. Om te helpen dit te 
voorspellen, is een aantal veelgebruikte ‘biomarkers’ beschikbaar. Het meest bekend zijn: 
de oestrogeenreceptor (ER), de progestageenreceptor (PR) en de humane epidermale 
groeifactorreceptor 2 (HER2/neu, hierna aangeduid als ‘HER2’) expressie in borstkanker, 
c-KIT mutaties in gastro-intestinale stromatumor (GIST) en epidermale groeifactorreceptor 1 
(EGFR1) mutaties in het niet-kleincellig longcarcinoom (NSCLC). Ondanks de beschikbaarheid 
van deze biomarkers kan het selecteren van het juiste geneesmiddel, voor de juiste patiënt, nog 
aanmerkelijk beter. 
Bovendien is het voor de werkzaamheid van het geneesmiddel niet alleen noodzakelijk dat het 
beoogde aangrijpingspunt in de tumor aanwezig is, maar is het ook belangrijk dat voldoende 
geneesmiddel de tumor bereikt. 
Voor veel biomarkers is tumormateriaal nodig is. Niet-invasieve nucleair diagnostische 
technieken zoals ‘Single Photon Emission Computed Tomography’ (SPECT) en ‘Positron 
Emission Tomography’ (PET) zouden kunnen bijdragen aan het selecteren van de juiste 
patiënt voor een bepaald geneesmiddel. Bovendien zou met behulp van deze technieken de 
verdeling van het geneesmiddel over het lichaam in kaart gebracht kunnen worden en zou 
vroegtijdig mogelijk voorspeld kunnen worden of iemand op de een anti-kankerbehandeling 
reageert. De hierbij gebruikte radioactieve stoff  en, tracers of radiofarmaca genoemd, dienen 134
voldoende selectief en specifi  ek te zijn en moeten in staat zijn om kleine tumorlaesies, inclusief 
niet-biopteerbare uitzaaiingen, in één scan af te beelden. 
In dit proefschrift   worden twee belangrijke doelen van de huidige en toekomstige anti-
kankergeneesmiddelen verkend: HER2 en de extrinsieke apoptotische route. 
De ‘human epidermal growth factor receptor’ (HER) leden HER1-4 behoren tot een familie 
van tyrosinekinasereceptoren. HER1-4 zitten in de celwand. Aan het buiten de celmembraan 
gelegen gedeelte van de receptor kunnen signaalstoff  en binden. Het gedeelte van de receptor 
dat zich in de cel bevindt, heeft   een tyrosinekinasedomein en zorgt voor het doorgeven van 
het signaal binnenin de cel. De HER familie speelt een rol in diverse kankersoorten. Onder 
invloed van HER2 wordt de celgroei bevorderd en zijn bestaande cellen minder gevoelig voor 
sterft  e. Door genamplifi  catie, met overexpressie van de receptor als gevolg, gaan tumorcellen 
sneller groeien. Bij borstkankerpatiënten die een tumor hebben met HER2 overexpressie geldt 
dat, indien ze niet behandeld worden met anti-HER2 therapie, hun ziekte agressiever is en ze 
een slechtere overleving hebben. Om dit te voorkomen worden patiënten behandeld met anti-
HER2 therapie, die bestaat uit het gehumaniseerde monoklonale antilichaam trastuzumab en 
de duale (HER1/EGFR en HER2) tyrosinekinaseremmer lapatinib. 
Er kunnen binnen eenzelfde patiënt verschillen bestaan in de HER2 expressie tussen de 
verschillende tumorlaesies. Ook kan de HER2 expressie in de loop van de ziekte veranderen, 
als gevolg van anti-kankerbehandelingen. Dit is van belang omdat indien de tumor in de 
patiënt eerst geen HER2 tot expressie bracht, maar de uitzaaiingen dit later wel doen, de patiënt 
alsnog met anti-HER2 gerichte therapie behandeld kan worden. Omdat tumoreigenschappen 
in de tijd kunnen veranderen, wordt in de richtlijnen aanbevolen patiënten te herbiopteren, 
indien een andere therapie overwogen wordt. In de praktijk kan dit lastig zijn, omdat sommige 
tumorlaesies moeilijk bereikbaar zijn en er heterogeniteit tussen de verschillende metastasen 
kan bestaan, waardoor eigenlijk meerdere laesies gebiopteerd zouden moeten worden om 
defi   nitief zekerheid te krijgen. Nucleair diagnostische technieken zoals PET en SPECT, 
waarbij alle laesies in één scan met hoge selectiviteit en specifi  citeit zichtbaar gemaakt worden, 
zouden een oplossing voor dit probleem kunnen bieden. Geschikte radiofarmaca zijn hiervoor 
noodzakelijk.
In het geval van anti-HER2 therapie wordt de tumorgroei geremd door blokkade van de 
g r o e i f a c t o r r e c e p t o r .  H i e r d o o r  w o r d t  d e  t u m o r c e l  g e v o e l i g e r  v o o r  c h e m o t h e r a p i e .  E e n  
alternatieve manier om tumorcellen te doden is het rechtstreeks stimuleren van apoptose. 
Apoptose, ofwel gereguleerde celdood, is een evolutionair goed geconserveerd mechanisme 
waarbij cellen ‘zelfmoord’ plegen. Dit mechanisme kan worden geïnduceerd door middel 
van twee routes: de intrinsieke (mitochondriële) en de extrinsieke (death receptor) route. 
De extrinsieke route wordt in gang gezet door extracellulaire binding van liganden aan de 
TRAIL-R1 en/of TRAIL-R2 death receptor. De daaropvolgende cascade resulteert uiteindelijk 
i n  c e l d o o d .  T o t  d e  ‘ d e a t h  r e c e p t o r ’  l i g a n d e n  b e h o r e n  o n d e r  a n d e r e  t u m o r n e c r o s e f a c t o r -
alpha (TNF-α), Fas ligand and natuurlijk voorkomend tumornecrosisfactor (TNF)-
gerelateerd apoptose inducerend ligand (TRAIL). Van deze drie liganden lijkt TRAIL, dat via 
recombinante technieken gemaakt kan worden, het meest geschikt voor klinische toepassing. 
Daarnaast zijn agonistische TRAIL-receptorantilichamen beschikbaar. Een voorbeeld van een 
dergelijk antilichaam is het volledig humane monoklonale antilichaam mapatumumab (HGS-9  NEDERLANDSTALIGE SAMENVATTING 135
ETR1) dat aangrijpt op de TRAIL-R1 death receptor. Recombinant geproduceerd humaan 
(rh) TRAIL en diverse monoklonale antilichamen worden momenteel zowel preklinisch als 
klinisch onderzocht.
Het doel van dit proefschrift   is het (pre)klinische evalueren van nieuwe radiofarmaca die 
aangrijpen op de HER2 en de TRAIL death receptoren, met als doel het selecteren van het juiste 
geneesmiddel voor de juiste patiënt en de vroege evaluatie van het eff  ect van de toegepaste 
therapie. 
Hoofdstuk 2 geeft   een overzicht van de tot nu toe ontwikkelde – en in mens en dier geteste 
– HER2 tracers en hun mogelijke toepassing bij het verbeteren van diagnostiek, het kiezen 
van de juiste antikankertherapie en de ontwikkeling van nieuwe geneesmiddelen. De huidige 
ontwikkelde HER2 radiofarmaca kunnen onderverdeeld worden in twee groepen: de radioactief 
gelabelde intacte antilichamen en de kleinere eiwitten, waaronder: antigeen bindende (Fab) 
fragmenten, minibodies, single chain fragment variables (ScFvs), diabodies and affi   bodies. 
Grote eiwitten, zoals intacte antilichamen, dringen slechts langzaam in de tumor door, maar 
wel gedurende lange tijd. Hierdoor is de uiteindelijke opname van het antilichaam in de tumor 
pas enige dagen na toediening op zijn maximum. Kleine eiwitten, zoals fragmenten van een 
antilichamen, dringen veel gemakkelijker in de tumor door, maar worden ook snel weer door 
de nieren uit het bloed verwijderd. Daardoor komt uiteindelijk toch minder van het kleine 
eiwit in de tumor terecht.
Wanneer het eiwit radioactief wordt gemaakt om als radiofarmacon te dienen, zal bij de intacte 
monoklonale antilichamen doorgaans een latere, maar hogere tumoropname te zien zijn. Deze 
opname wordt uitgedrukt als het percentage van de geïnjecteerde dosis per gram weefsel 
(% ID/g). De tumor/bloed-ratio’s van antilichamen zijn laag, vooral direct na injectie van het 
radiofarmacon, wanneer het grootste deel van het radiofarmacon nog circuleert in het bloed. 
Radioactief gelabelde kleinere eiwitten daarentegen, hebben een lage absolute tumoropname 
dan intacte antilichamen, zeker op de latere tijdstippen. De tumor/bloed-ratio’s van kleinere 
eiwitten zijn over het algemeen echter wel hoger, hoewel deze ratio wel sterk kan variëren. 
De in dit overzichtsartikel aangehaalde studies laten zien dat klinische HER2 beeldvorming 
momenteel alleen plaatsvindt met intacte gelabelde monoklonale antilichamen maar dat dit 
wellicht in nabije toekomst ook mogelijk is met kleinere radioactieve eiwitten. Aanvullend 
onderzoek is echter noodzakelijk om de toegevoegde waarde van deze vorm van beeldvorming 
aan te tonen en deze breder voor de patiënt toepasbaar te maken.
In hoofdstuk 3 wordt de ontwikkeling beschreven van de nieuwe PET tracer 89Zr-trastuzumab, 
voor HER2 beeldvorming. 89Zr - trastuzumab  w e r d  in  ee n  di e rstu di e  v e rg el eke n  m et  111In-
trastuzumab, een SPECT tracer die al in de kliniek was toegepast. Doel van de studie was in 
eerste instantie het achterhalen van de minimaal noodzakelijke trastuzumab eiwitdosis voor 
optimale microPET beeldvorming. Daarna werd de 89Zr-trastuzumab verdeling in muizen met 
een HER2 positief of HER2 negatief humaan tumortransplantaat geëvalueerd.
Uit de experimenten bleek dat 89Zr-trastuzumab effi     ciënt kon worden gelabeld met een 
hoge radiochemische zuiverheid en specifi  eke activiteit. De antigeenbindingcapaciteit bleef 
behouden en het 89Zr-trastuzumab bleek stabiel gedurende zeven dagen in het oplosmiddel en 136
in humaan serum. De minimaal benodigde dosis voor een optimale beeldvorming was 100 μg 
per muis en de vergelijkende biodistributiestudie liet een hogere 89Zr-trastuzumab opname in 
de HER2 positieve tumor zien dan in de HER2 negatieve controle tumor. Dit verschil was het 
grootst op dag 6 na injectie van het radiofarmacon. De opname in de HER2 positieve tumor 
was 33,4 ± 7,6% ID/g, terwijl de opname in de HER2 negatieve tumor slechts 7,1 ± 0,7% was 
(P=0,014). Er was bovendien een goede correlatie tussen de met de microPET gekwantifi  ceerde 
tumoropname en de 89Zr-trastuzumab tumoraccumulatie die ex-vivo werd bepaald (R2=0,972). 
De conclusie was dat het door ons ontwikkelde 89Zr-trastuzumab een hoge en HER2 specifi  ek 
tumoropname liet zien bij een goede resolutie en geschikt is voor klinische toepassing.
In  hoofdstuk 4A werd het in hoofdstuk 3 ontwikkelde 89Zr-trastuzumab voor het eerst 
in mensen toegepast. In vrouwen met gemetastaseerde borstkanker werd onderzocht of 
89Zr-trastuzumab geschikt was voor beeldvorming van HER2 met PET. Daarnaast werd 
gekeken naar de optimale eiwitdosering van het trastuzumab en naar het ideale moment van 
beeldvorming. Patiënten kregen 37 MBq 89Zr-trastuzumab geïnjecteerd. Aan de patiënten die 
op het moment van de 89Zr-trastuzumab injectie niet met trastuzumab werden behandeld, 
werd in totaal 10 of 50 mg eiwit toegediend. Patiënten die al met trastuzumab (tot 6 mg/
kg) werden behandeld ten tijde van de scan, kregen 10 mg. Zo ontstonden drie trastuzumab 
eiwitdosisgroepen (patiënten met 10 mg, 50 mg en >50 mg trastuzumab). Na injectie van het 
89Zr-trastuzumab kregen de patiënten in ieder geval rondom dag 2 en dag 5 na injectie van het 
radiofarmacon een PET-scan. In totaal werden 14 patiënten in de studie geïncludeerd. De 89Zr-
trastuzumab opname in de tumor kon het beste worden vastgesteld op dag 4 of 5. Optimale 
beeldvorming werd verkregen, wanneer patiënten die ten tijde van de 89Zr-trastuzumab injectie 
niet met trastuzumab werden behandeld, 50 mg trastuzumab kregen toegediend. Bij patiënten 
die wel met trastuzumab werden behandeld, bleek 10 mg voldoende. 
De 89Zr-trastuzumab PET-scans lieten tumoropname zien in het merendeel van de al bekende 
tumoren en enkele tot dan toe onontdekte tumorlaesies. De relatieve opname (gemiddeld 
percentage radioactiveit van de geïnjecteerde dosis ± standard error of the mean) was 
12,8 ± 5,8, 4,1 ± 1,6 en 3,5 ± 4,2 in lever-, bot- en hersenmetastasen. De relatieve opname in 
normaal lever-, milt-, nier- en hersenweefsel was respectievelijk 5,9 ± 2,4, 2,8 ± 0,7, 4,0 ± 0,7 
en 0,20 ± 0,1.
Samenvattend is 89Zr-trastuzumab PET beeldvorming bruikbaar voor visualisering en 
kwantifi  cering van HER2 positieve laesies in patiënten met uitgezaaide borstkanker, mits de 
juiste trastuzumab eiwitdosis wordt gegeven.
Hoofdstuk 4B beschrijft   de casus waarbij het HER2 PET radiofarmacon 89Zr-trastuzumab 
is toegepast in een borstkankerpatiënt met zeer uitgebreide HER2 positieve bot- en 
levermetastasen. Deze patiënt, die nog niet eerder met trastuzumab was behandeld, kreeg 
een totale eiwitdosis van 50 mg, in overeenstemming met met wat in hoofdstuk 4 was 
beschreven. De eerste 89Zr-trastuzumab HER2 PET-scan liet een zeer uitgebreide opname in 
de levermetastasen zien (in totaal 48% van de geïnjecteerde dosis). Hierbij was de hoeveelheid 
89Zr - trastuzumab  in  h et  b l oed  zeer  laag  en  war en  an der e  tum o r laesi es  ni et  o f  na u w eli jks  
waarneembaar. Twee dagen na een therapeutische trastuzumab dosis (4 mg/kg) werd opnieuw 
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scan een lagere 89Zr-trastuzumab leveropname zien (33% van de geïnjecteerde dosis), was de 
hoeveelheid  89Zr-trastuzumab in het bloed hoger en waren ook andere tumorlaesies, zoals 
botlaesies, waarneembaar. De vrijwel volledige klaring van trastuzumab uit het bloed na de 
eerste injectie en de uitgevoerde berekeningen, lijken erop te duiden dat onvoldoende eiwit 
aanwezig was om de grote hoeveelheid tumorlaesie te verzadigen. Beeldvorming in deze patiënt 
laat zien dat een zeer grote hoeveelheid HER2 positieve tumor de (89Zr-)trastuzumab verdeling 
en klaring drastisch kan beïnvloeden. Het kan daarom overwogen worden om een studie op 
te zetten waarbij de therapeutische trastuzumab dosering niet alleen op het lichaamsgewicht, 
maar ook op de tumormassa wordt gebaseerd. 
Naast  89Zr-trastuzumab, zijn ook rhTRAIL en mapatumumab radioactief gelabeld voor 
klinische beeldvorming van de TRAIL death receptoren. In een breed scala aan verschillende 
tumoren en in tumortransplantaten in dieren bleken rhTRAIL en mapatumumab eff  ectief. 
Beide eiwitten worden momenteel daarom ook in fase I-II klinische studies onderzocht. 
Met behulp van radioactief gelabeld rhTRAIL en mapatumumab werd de biodistributie en 
tumoraccumulatie bestudeerd in dieren met een humaan tumortransplantaat met hoge of 
lage TRAIL-R1 en TRAIL-R2 death receptor expressie op de tumorcellen (hoofdstuk 5). Het 
verschil in receptorexpressie tussen het humane tumortransplantaat met een hoge en een lage 
death receptor expressie was een factor 2-4. RhTRAIL werd radioactief gelabeld met behulp 
van jodium-125 (125I), mapatumumab met indium-111 (111In).
De radiofarmaca werden gekarakteriseerd en de in vivo stabiliteit en het behoud van TRAIL 
death receptorbinding werden bepaald. De in vivo biodistributie werd bestudeerd in naakte 
muizen met een humaan tumortransplantaat. De in vivo biodistributie werd gekarakteriseerd 
door een snelle renale klaring van 125I-rhTRAIL. De accumulatie in de nier was al maximaal 
na 15 minuten en vier uur na injectie van het 125I-rhTRAIL was sprake van vrijwel volledige 
uitscheiding. De 125I-rhTRAIL activiteit nam in bijna alle organen snel af, behalve in het 
tumortransplantaat. Radioactief gelabeld mapatumumab liet een duidelijke afname in het 
bloed zien tussen de 24 en 168 uur. Ten opzichte van het bloed nam de radioactiviteit in het 
tumortransplantaat met de hoge TRAIL-R1 expressie minder af. Concluderend kunnen 
rhTRAIL en mapatumumab effi   ciënt gelabeld en toegepast worden om de farmacokinetiek, de 
verdeling in het lichaam en de opname in de tumor in patiënten te bestuderen. Hierdoor zou 
een bijdrage geleverd kunnen worden aan de evaluatie van niet-radioactief gelabeld rhTRAIL 
en mapatumumab in fase I/II studies. In hoofdstuk 6 werd 111In-mapatumumab in patiënten 
met gemetastaseerd kanker geëvalueerd. Het doel van de studie was het visualiseren van 
tumoren en het vaststellen van de 111In-mapatumumab farmacokinetiek voorafgaande aan en 
tijdens de gecombineerde behandeling met het anti-TRAIL-R1 antilichaam mapatumumab 
en gemcitabine en cisplatin. Patiënten werden driewekelijks intraveneus behandeld met 
mapatumumab (20 mg/kg) and cisplatin (80 mg/m2) op dag 1 en gemcitabine (1250 mg/m2) 
op dag 1 en 8. Op cyclus 1 en 3 kregen de patiënten 150 MBq 111In-mapatumumab toegediend. 
Dertig minuten nadien en op dag 1,3 en 6 werden planaire single-photon emission computed 
tomography (SPECT) scans gemaakt. De SPECT beelden werden gefuseerd met CT en de 138
TRAIL-R1 receptor expressie werd immunohistochemisch vastgesteld. Aan de hand van de 
111In-mapatumumab data werden de farmacokinetische parameters berekend.
Twaalf patiënten werden in de studie geïncludeerd. Visuele analyse van de SPECT scans liet 
aanhoudende 111In-mapatumumab activiteit in het bloed zien, gedurende de scandagen in alle 
patiënten. Daarnaast was duidelijk 111In-mapatumumab opname te zien in goed doorbloedde 
organen zoals de lever en de milt. De gemiddelde eff   ectieve stralingsdosis van 111In-
mapatumumab was 0.41 mSv/MBq. De optimale tumor-achtergrond ratio werd verkregen op 
dag 3 na de injectie van de tracer. In 5 van de 12 patiënten konden 11 van de 18 op basis van CT 
bekende lesies met 111In-mapatumumab worden weergegeven. Er was echter een grote mate van 
heterogeniteit in 111In-mapatumumab opname in deze 5 patiënten. Twee melanoompatiënten 
lieten een opmerkelijk sterke tracer opname zien. In drie van de 5 patiënten, konden alle 
lesies met 111In-mapatumumab SPECT worden gevisualiseerd. De SPECT resultaten in de 
derde cyclus kwamen overeen met die in de eerste cyclus. De gekwantifi  ceerde mediane 111In-
mapatumumab tumor opname was 3.5 (range, 2.2-8.0) ten opzichte van spierweefsel.
Evaluatie van de CT beelden na de tweede scan, liet geen verschil in grootte van de 
tumorlesies zien in de 5 patiënten met 111In-mapatumumab tumor opname ten opzichte van 
de uitgangsituatie.
Van 4 patiënten met een 111In-mapatumumab tumoropname was tumorweefsel beschikbaar. 
Drie van deze patiënten lieten tenminste lage cytoplasmatische TRAIL-R1 expressie zien. De 
intensiteit van de TRAIL-R1 kleuring kwam niet overeen met een positieve 111In-mapatumumab 
scan of respons van de tumor op de gegeven therapie. 
De  111In-mapatumumab opname was variabel in een subgroep van patiënten. De waarde 
van het vooraf uitvoeren van tumor-beeldvorming bij patiënten die worden behandeld met 
mapatumumab, dient daarom verder te worden onderzocht.
Alle tot nu toe gebruikte eiwitten waren of commercieel verkrijgbaar voor humane toepassing 
of reeds eerder geproduceerd. In hoofdstuk 7 wordt beschreven hoe het genetisch gefuseerde 
eiwit scFv425:TRAIL opgeschaald kan worden. De productie vond plaats in een ‘solid-
support cell growth matrix system’. Aan de hand van scFv425:TRAIL werd gekeken naar de 
mogelijkheid om met behulp van dit systeem de productie van potentiële anti-kankereiwitten 
te vergemakkelijken. ScFv425:TRAIL is een genetisch gefuseerde eiwit, bestaande uit single-
chain fragmenten van een anti-EGFR monoklonaal antilichaam en TRAIL.
Momenteel worden verscheidene nieuwe eiwitten in de academie ontwikkeld, die interessant 
kunnen zijn om ook klinisch te testen. Hiervoor is het belangrijk om deze eiwitten in voldoende 
grote hoeveelheden te produceren voor preklinische en de eerste klinische studies. Een solid-
support cell growth matrix system kan hierbij wellicht helpen door dat eenvoudiger grote 
hoeveelheden eiwit geproduceerd kunnen worden. De productie werd getoetst aan de huidige 
Europese regelgeving met betrekking tot de productie van eiwitten voor humane toepassing.
In een Fibrastage wegwerpfl  acon – een voorbeeld van een solid-support cell growth matrix 
system - werden CHO-K1 cellen gekweekt. Het door deze cellen geproduceerde scFv425:TRAIL 
werd gezuiverd en de kwaliteit van het scFv425:TRAIL werd geëvalueerd. De gemiddelde 
scFv425:TRAIL concentratie was 13,8 ± 3,7 mg/L en in totaal werd meer dan 55 mg ongezuiverd 
eiwit geproduceerd. De effi   ciëntie van de meerstaps-zuivering was 15,4%. Een vergelijking 9  NEDERLANDSTALIGE SAMENVATTING 139
met de huidige Europese regelgeving liet zien dat een nog uitgebreidere karakterisering en 
validering van het scFv425:TRAIL (productieproces) nodig is voordat het geneesmiddel 
klinisch toegepast kan worden.
Samenvattend kan gesteld worden dat een solid-support cell growth matrix system, zoals de 
Fibrastage, gebruikt kan worden om grotere hoeveelheden eiwit (zoals scFv425:TRAIL) te 
produceren.
Uiteindelijk zijn in dit proefschrift   drie nieuwe radiofarmaca tegen 2 verschillende receptoren 
ontwikkeld en geëvalueerd in dieren. 89Zr-trastuzumab en 111In-mapatumumab zijn bovendien 
ook klinisch toegepast. In patiënten bleek beeldvorming van tumoren met deze radiofarmaca 
mogelijk.140
DANKWOORD
Prof. Dr. E.G.E. de Vries, beste Liesbeth. Je bent zonder twijfel een grote motor achter mijn 
promotie geweest. Met zeer veel enthousiasme heb je vanaf het begin op het promotietraject 
gestort. Ik herinner me nog goed de eerste vergadering met Jos en Marjolijn, waarbij je - ruim 
6 jaar geleden – onmiddellijk vroeg hoe lang ik de tijd had en direct enthousiast was over het 
feit dat dat 6 jaar was. Dat bood duidelijk mogelijkheden!
In het nakijken van de stukken was je veeleisend, maar ook bijzonder snel. Als het er toe deed 
kon ik het – bij wijze van spreken – om 2 uur ’s nachts naar je toe sturen en een uur later al een 
zeer gedegen commentaar verwachten. Bedankt voor alles wat ik in deze periode heb geleerd!
Prof. Dr. R.A. Dierckx, beste Rudi. Vanaf het begin af aan ben je zeer geïnteresseerd in het 
promotieonderzoek. Ondanks dat het type onderzoek met antilichamen en langlevende PET-
isotopen onbekend was op de afdeling, heb jij je er hard voor gemaakt. De goede faciliteiten 
op de afdeling nucleaire geneeskunde en moleculaire beeldvorming hebben in een belangrijke 
mate bijgedragen aan het succes van dit en andere promotieonderzoeken.
Prof. dr. J.G.W. Kosterink, beste Jos. Jij had tijdens mijn ZAPIKO traject een bijzondere positie. 
Doordat je zowel (co)promotor als opleider was, kwam bij jou alles samen. Je hebt mij altijd 
gestimuleerd in het goed voltooien van zowel mijn opleiding als het promotieonderzoek. 
Daarnaast was je bedreven in het oplossen van knelpunten die ontstonden doordat 
promotieonderzoek en opleiding gecombineerd moesten worden in een beperkte tijd. Dank 
daarvoor!
Dr. M.N. Lub-de Hooge, beste Marjolijn. Van jou heb ik de fi  jne kneepjes van het vak geleerd. 
Je hebt me laten zien wat er bij komt kijken om – farmaceutisch verantwoord – eiwitten te 
labelen. Je was ook altijd bereid om – ook al had je het zelf nog zo druk – in het lab te komen 
kijken. Inmiddels zijn we een aantal jaar verder en is het mooi om te zien dat je trotse moeder 
bent van twee kinderen en een nog veel grotere schare aan promovendi.DANKWOORD 141
Prof. Dr. G.A.M.S. van Dongen, beste Guus. Direct vanaf het moment dat we voor het eerst de 
koppen bij elkaar staken, is een prettige en vruchtbare samenwerking ontstaan. Jij hebt daar, 
samen met je groep, onder andere bestaande uit Lars Perk, Maria Vosjan en Marijke Stigter van 
Walsum een belangrijke rol bij gespeeld. De deur stond direct wijd open en jullie deelden graag 
de kennis die jullie hadden verworven. Het was een plezier om met jullie samen te werken en 
het is schitterend om te zien dat de samenwerking tot op de dag van vandaag mooie resultaten 
oplevert.
Dr. T.H. Oude Munnink, beste Th  ijs. Dank voor de prettige samenwerking. We hebben in 
goede harmonie geschreven aan het klinische 89Zr-trastuzumab artikel en gelukkig is het – 
na wat omzwervingen – in een mooi blad terecht gekomen. De publicatie van de letter to the 
editor in de Journal of Clinical Oncology laat zien dat ons onderzoek zeker ‘nieuwswaarde’ 
had.
Drs. C.N.A.M. Oldenhuis, beste Corina. Dank voor de fi  jne samenwerking. Het onderzoek aan 
TRAIL bleek zowel preklinisch als klinisch voorbehouden aan mensen met een lange adem. 
Gelukkig werden we aan de fi  nish niet teleurgesteld. Succes met het afronden van je eigen 
proefschrift   en je opleiding interne geneeskunde.
Dr. A.H. Brouwers, beste Adrienne. Het was altijd weer prettig om samen met jou de scans te 
bekijken; je niet afl  atend enthousiasme voor het vak werkte aanstekelijk. Bedankt voor de tijd 
die je in het project hebt gestoken.
Dr. J.R. de Jong, beste Johan. Het was pionieren, daar in de kelder van het PET centrum, maar 
de beelden die uit de microPET kwamen bleken boven verwachting. Dank ook voor de klinisch 
fysische ondersteuning tijdens de vele studies. 
 
Prof. dr. P.L. Jager, beste Piet. Het is spijtig dat ik niet langer van je expertise gebruik heb 
kunnen maken, dank voor de prettige samenwerking en je grote enthousiasme voor HER2 
imaging.
Marieke, Anton en Frank-Jan, het is mooi om te zien dat mijn eerste inspanningen voor de 
ontwikkeling van de 89Zr labelingen in Groningen voortgang krijgen. Dit gaat – na Wouter en 
Th   ijs – zeker leiden tot nog meer interessante proefschrift  en. Succes daarmee!
Alle andere (oud) collega’s van de afdeling nucleaire geneeskunde en moleculaire beeldvorming 
wil ik graag bedanken. In het bijzonder Hugo, Hans en Chris. In het begin was het niet altijd 
gemakkelijk, aangezien de afdeling toen nog niet erg was ingesteld op het doen van onderzoek. 
Vaak heb ik dan ook moeten wijken voor ‘patiëntenzorg’. Gelukkig ging dit doorgaans in goede 
harmonie en waren jullie een vrolijke noot in de dag.142
Roel en Sergiy, bedankt voor de inspanningen die zijn verricht op de microPET en voor de 
ondersteuning bij de lastigere fysische vraagstukken.
Uiteraard wil ook iedereen van het moleculair oncologisch laboratorium bedanken, meer in 
het bijzonder degenen waarmee ik het nauwst heb samengewerkt. 
Evelien, gezamenlijk hebben we behoorlijk wat werk verzet ten aanzien van de preklinische 
rhTRAIL/mapatumumab studie. Lange dagen in het CDL. Dank voor de prettige samenwerking.
Beste Dr. S. de Jong, Steven, dank voor kritisch commentaar en het meedenken op tal van 
momenten tijdens mijn promotie.
Beste Dr. H. Timmer-Bosscha en Dr. J. Meijer, Hetty en Coby. Voor praktische en inhoudelijke 
informatie en hulp kon ik tijdens mijn promotieonderzoek altijd bij jullie terecht. Een 
oncologisch baken in de nacht.
Gert-Jan, dank voor de nodige hand- en spandiensten; jammer dat ik je nooit heb kunnen 
inhuren als analist.
Beste Dr. B. Pennarun, Bodvaël, helaas hebben onze gezamenlijke inspanningen aan het begin 
van ons beider promotieonderzoek niet tot concreet resultaat kunnen leiden. Aan de prettige 
samenwerking heeft   het in ieder geval niet gelegen!
Alle medewerkers van het CDL en Dr. C. Th   uring, Dr. M. van der Meulen, bedankt voor de 
ondersteuning bij de praktische werkzaamheden en het meedenken over de uitvoering van de 
experimenten. 
Beste Dr. J. van Zanten, Ir. M.A. de Jong, Dr. E. Bremer, Dr. W. Helfrich, Coba, Marian, Edwin 
en Wijnand, zeer bedankt voor de praktische ondersteuning bij het uitvoeren van een groot 
deel van de ScFv425:sTRAIL experimenten en het altijd mee willen denken met de resultaten 
en hoe nu het beste verder te gaan. 
Beste Dr. R. Cool, Dr. R.J. Kok en Dr. K. Temming, Robbert, Robbert Jan en Kai, dank voor 
de vruchtbare en prettige samenwerking die we gedurende de jaren van het werken aan mijn 
proefschrift   hebben gehad. 
Beste Dr. J. Proost, Hans, mijn dank ik groot voor jouw niet afl  atende enthousiasme om mij in 
te wijden in de hogere populatiekinetiek.
Beste Anouk, Annemieke, Anita, Jan-Willem, Mariët en Astrid. Een hele ‘schare’ 
farmaciestudenten heeft   in de loop der jaren zijn bijvak bij mij gelopen. Hoewel ik me af en toe 
– als het onderzoek weer eens tegenzat – afvroeg of ik jullie wel genoeg kon bijbrengen en of het 
niet frustrerend voor jullie moest zijn om vaak negatieve resultaten te hebben, vond ik het heel 
prettig om ondersteuning te krijgen bij het onderzoek. Niet alleen vanuit praktisch opzicht, 
maar vooral ook om samen te kunnen werken aan een gemeenschappelijk doel. Allemaal 
bijzonder bedankt voor jullie inzet. Ik heb het erg gezellig gevonden met jullie! Ik denk dat 
jullie allemaal wel een stukje van jullie werk in het proefschrift   terug kunnen vinden en succes 
met jullie eigen (wetenschappelijke) carrières.DANKWOORD 143
Zoals al eerder genoemd heb ik mijn promotieonderzoek en opleiding gecombineerd. Voor mij 
is het dan ook niet anders dan vanzelfsprekend dat ik op deze plek ook spreek over mijn tijd 
in opleiding tot ziekenhuisapotheker. De combinatie is niet altijd gemakkelijk geweest, zowel 
de promotie als de opleiding stonden altijd onder (tijds)druk. Het geheel moest immers in 6 
in plaats van 8 jaar afgerond worden. Desalniettemin heb ik de combinatie als erg plezierig 
ervaren. Zowel de duik in de diepte voor het promotieonderzoek als de directe bijdrage die ik 
tijdens dagdiensten kon leveren aan de patiëntenzorg waren beide waardevol.
Omdat je als ziekenhuisapotheker in opleiding alle afdelingen doorloopt, leer je iedereen goed 
kennen en werk je met zeer veel verschillende mensen samen. Ik kan niet anders zeggen dan 
dat er in de ziekenhuisapotheek van het UMCG fantastische mensen werken met een groot 
hart voor de zaak. Ik kan hier onmogelijk iedereen persoonlijk bedanken, maar een paar 
mensen wil ik er toch uitlichten.
Allereerst mijn (oud) collega (ziekenhuis)apothekers: Aileen, Barbara, Donald, Esther2, 
Folkert, Frank, Gea, Hans, Hèlen, Hendrikus, Jan, Jan Willem, Jasperien, Jos, Kim, Marian, 
Marieke, Marina, Marjolijn2, Nicolette, Prashant, Reinout, Rosalie en Sigrid. Bedankt voor alle 
gezelligheid tussen het harde werken door!
Ik wil ook mijn opleiders in het bijzonder bedanken: 
Prof. Dr. D.R.A. Uges, beste Donald, de manier waarop jij het lab leidt is ongelofelijk inspirerend. 
Het is voor elke ziekenhuisapotheker in opleiding geweldig dat je overal bij betrokken wordt. 
Dank. 
Dr. R.A. Schellekens, beste Reinout, ik ben getest en goedbevonden. Je hebt enorm veel 
aandacht voor de persoon in opleiding, tot ’s avonds laat als het moet. Tijdens de ontwikkeling 
van een geneesmiddel of mijn eigen onderzoek ben je zeer betrokken en leergierig. Ga zo door!
Drs. M. Laseur, beste Marian, je bent een bijzondere begeleidster. Met evenveel enthousiasme 
kun je vertellen over het vak, als over muziek of het roeien. Ik heb je nooit een overdracht zien 
missen en ’s ochtends zat je altijd vol verhalen over wat er de vorige dag was gebeurd. De METc 
was een gedeelde passie, dank voor wat je me daarover bijgebracht hebt.
Annemiek, Jessica en Wianda, dank voor de secretariële ondersteuning waar ik altijd op kon 
rekenen!
Agatha, Anneke, Jolanda en Remco. Met jullie heb ik ‘grotere’ projecten uitgevoerd tijdens 
mijn opleiding. Bedankt voor het goede teamwork!
Graag bedank ik de stichting OZG voor haar genereuze bijdrage in de drukkosten.
Tot slot: mijn ‘familie’. Lieve papa en mama, bedankt voor jullie niet afl  atende steun. Jullie 
hebben me geleerd om altijd door te zetten. Dat kwam bij tijden erg goed van pas. Ferre, het 
is een eer om jou als paranimf te hebben. Nu weet ik zeker dat het een goed ‘feestje’ wordt! 144
Tjeerd, jouw gastvrijheid is ongekend. Als ik bij jullie ben pas ik naadloos in het gezin en heb 
ik even ook drie prachtige dochters. Super dat je mijn paranimf wilt zijn! Arend en Tanya, na 
twee jaar Zuid-Korea en 2 jaar Japan wordt het hoog tijd om weer lekker naar Nederland terug 
te keren. We missen je hier!
Lieve Hermien, jij bent zondermeer de grootste ontdekking die ik tijdens mijn onderzoek heb 
gedaan!! Ik geniet dagelijks van ons leven samen in Rotterdam.